Synthesis of Novel Substrates to Probe the Specificities of Mupirocin Enzymes by Mountford, Abigail M C
                          
This electronic thesis or dissertation has been
downloaded from Explore Bristol Research,
http://research-information.bristol.ac.uk
Author:
Mountford, Abigail M C
Title:
Synthesis of Novel Substrates to Probe the Specificities of Mupirocin Enzymes
General rights
Access to the thesis is subject to the Creative Commons Attribution - NonCommercial-No Derivatives 4.0 International Public License.   A
copy of this may be found at https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode  This license sets out your rights and the
restrictions that apply to your access to the thesis so it is important you read this before proceeding.
Take down policy
Some pages of this thesis may have been removed for copyright restrictions prior to having it been deposited in Explore Bristol Research.
However, if you have discovered material within the thesis that you consider to be unlawful e.g. breaches of copyright (either yours or that of
a third party) or any other law, including but not limited to those relating to patent, trademark, confidentiality, data protection, obscenity,
defamation, libel, then please contact collections-metadata@bristol.ac.uk and include the following information in your message:
•	Your contact details
•	Bibliographic details for the item, including a URL
•	An outline nature of the complaint
Your claim will be investigated and, where appropriate, the item in question will be removed from public view as soon as possible.
 
 
Synthesis of Novel Substrates to Probe the 
Specificities of Mupirocin Enzymes 
  
Abigail Miranda Clare Mountford 
A thesis submitted to the University of Bristol as part of the 
requirements for award of the degree of Doctor of Philosophy in the 
Faculty of Science 
 
University of Bristol 
School of Chemistry 
Cantock’s Close 
Bristol, BS8 1TS February 2020 



































Mupirocin, produced by Pseudomonas fluorescens, displays antibiotic activity against a wide 
range of Gram positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA). It 
is a mixture of pseudomonic acids A, B and C as described in chapter one. Biosynthetic studies 
have provided an insight into the assembly of the polyketide backbone and post assembly 
modifications. However, some features of the biosynthetic pathway remain unknown including 




Chapter two describes investigations into the gene responsible for 6-hydroxylation, tentatively 
assigned as mupA in mupirocin biosynthesis. Thioester 28 was prepared in 11 steps via a key cross 
metathesis step to install the 10,11-alkene (pseudomonic acid numbering), followed by an aldol 
reaction to install the stereocentre at C-7. The synthesis of pantetheinic substrate 29 utilised a 
hydroboration to install the stereocentre at C-8, followed by a Suzuki cross coupling to establish 
the E alkene. Enzyme assays of these substrates were carried out with MupA, the results of which 
are discussed herein.  
 
Chapter three describes the synthesis of linear substrates 161 and 187, and studies towards the 
preparation of amine 196, to probe the specificities of MupW and MupZ, the enzymes responsible 
for the formation of the THP ring. The synthetic route to thioester 29 was adapted to introduce 
the fatty acid side chain of substrates 161 and 187 via a Mukaiyama aldol reaction. Bioassays of 
substrates 161 and 187 were carried out to provide insight into both the mechanism of the ring 
closure and the specificities of MupW and MupZ.  
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CHAPTER 1: Introduction 





1.1 Antimicrobial Resistance 
 
Antimicrobial resistance (AMR) is established as one of the greatest threats to the global 
population in the 21st century. A review in 2016 stated that then the current mortality rate 
from antibiotic resistant diseases was 700,000 cases per year, and was projected to increase 




This rise in AMR is due to several factors, some natural, and some of humanity’s own making. 
Bacteria have evolved to efficiently share genetic material offering a selective advantage, 
enabling them to quickly overcome new selection pressures,3-4 though this innate ability has 
been boosted by several human factors. Over-prescription of antibiotics, lack of awareness 
as to the correct uses of them, and their wasteful application in agriculture as a preventive 
rather than a treatment, has stretched the current supply of antibiotics to breaking point. 
The World Health Organisation (WHO) is backing changes in legislation to improve 
vaccination rates, provide more funding for research, reduce antibiotic use in agriculture and 
introduce global surveillance of antibiotic use.1 
Since the ‘golden era’ of antibiotic discovery from 1940 to 1960, only a handful of new classes 
of antibiotics have been discovered,5 and since 1962 only two new classes of antibiotics have 
been marketed.6 In 2017 the BMJ reported that only eight of the 51 antibiotics in clinical 
trials belonged to novel classes,7 and most antibiotics currently in development are 
analogues of existing ones, bearing the same mechanism of action as their parent antibiotic. 
This is a potentially fatal flaw as it does nothing to combat resistance which has already 
developed in the bacterial population. Between 1981-2011, 18 of the 26 drugs approved 
were based on natural products, which is why there has been a drive to develop new drug 
scaffolds which take inspiration from nature.8 
“Antimicrobial resistance (AMR) threatens the effective prevention and 
treatment of an ever-increasing range of infections caused by bacteria, 
parasites, viruses and fungi.” – WHO (2018).2 




Accessing the active components from a natural source can be challenging, especially if only 
very small amounts are being produced by the bacteria, plants or fungi. In these cases, it may 
be necessary to synthesise these molecules, which can be laborious and costly. Although 
published total syntheses often showcase impressive new methodologies, some might argue 
that it is simpler, more resource friendly, and quicker to re-engineer biosynthetic pathways 
to either increase the yield of the natural product or enhance its therapeutic properties. 
Therefore, an understanding of how a natural product is assembled and the genes 
responsible for each transformation is essential to enabling modification of pre-existing 
scaffolds in order to produce novel antibiotics based on natural products.  
1.2 Polyketides 
 
All living systems rely on a pool of simple organic molecules which they produce via complex 
metabolic pathways. These metabolites are divided into two key classes; primary 
metabolites, which are required for the survival of the organism; and secondary metabolites, 
which confer a selective advantage to the organism.9 
Polyketides are a large class of secondary metabolites produced by bacteria, fungi and plants 
which are structurally diverse, ranging from simple polyphenols to complex macrolides.10 
Owing to their structural complexity, polyketides exhibit a wide range of activities including 
antifungal, antibiotic, anti-parasitic and anti-cancer properties (figure 1). Due to their 
diversity and utility they are the subject of significant research interest, and make up 20% of 
all drugs sold worldwide per year.11 





Figure 1. Selected polyketides.  
The first polyketide reported was orcinol, which was synthesised by Collie in 1893.12 He went 
on to propose a repeating -CH2CO- ‘ketide’ unit as the biosynthetic basis of polyphenols in 
1907, however it was not until the late 1950s that experimental evidence was provided to 
support this hypothesis.13  Through the use of 14C labelling studies, Birch proved that 
6-methyl-salicylic acid was produced from a polyketone undergoing cyclisation.14 
 
Scheme 1. Isotope labelling studies showing the incorporation of labelled acetate into polyketide 
6-methyl-salicylic acid.14 
Since the seminal work of Collie and Birch,15 advances in the fields of genetics and genome 
sequencing have led to a greater understanding of biosynthetic gene clusters and the way in 
which they function to produce diverse structures. 
 




1.3 Polyketide biosynthesis 
 
In fatty acid biosynthesis the starter unit is transferred onto an acyl carrier protein (ACP) by 
an acyl transferase (AT), from which it is transferred onto a ketosynthase (KS) domain. A 
malonyl CoA unit is loaded onto an ACP via a malonyl acetyl transferase (MAT) domain;16-17 
these two units then undergo a decarboxylative Claisen condensation catalysed by the KS. 
The resulting ACP bound β-ketothioester can be further modified in what is termed β-
processing by the action of keto reductase (KR), dehydratase (DH), or enoyl reductase (ER) 
domains generating the fully reduced carbon chain.18 Further homologation cycles can take 
place in order to extend the chain length before the mature fatty acid chain is cleaved from 
the ACP by a thioesterase (TE) to be released as a free acid.19  
Polyketide biosynthesis is very similar to fatty acid biosynthesis; however, the reductive 
processing steps are optional. A typical module selects an extender unit based on the 
specificity of its acyl AT domain and condenses it with the growing chain using a KS domain. 
At any time during the β-processing steps, the partially saturated growing chain can undergo 
further homologation as shown in scheme 2.20-21 Following hydrolysis, tailoring enzymes can 
introduce further diversity by carrying out a variety of other useful modifications such as 
epoxidations, methylations and esterifications. 
 
Scheme 2. Biosynthesis of fatty acids and polyketides. 




In polyketide biosynthesis the starter unit is often acetate or propionate, though it may be 
more structurally complex for example benzoate as in the soraphen biosynthesis.22 This 
starter unit undergoes a series of two-carbon chain extensions with an extender unit. The 
most common and simplest extender unit is malonyl CoA, with all others being derived from 
this structure, for example methyl malonyl CoA which would generate a methyl branch at 
the α-position in the growing polyketide chain. 
 
Scheme 3. Methyl malonyl CoA as the extender unit introduces a methyl group at the α-position.  
Further modification of the growing polyketide backbone can be achieved by 
functionalisation at the α-carbons, for example the introduction of methyl groups by the 
action of S-adenosylmethionine (SAM) (scheme 4). Functionalisation can be also be achieved 
at the β-position and will be discussed in section 1.6. 
 
Scheme 4. SAM mediated methyl addition.  
Unlike fatty acid biosynthesis which only produces fully reduced fatty acid chains, polyketide 
biosynthesis creates much greater diversity. Depending on how many β-processing steps are 
carried out, polyketides are classified as highly reduced, partially reduced or non-reduced 
(scheme 5). Following the Claisen condensation between the starter and extender units, any 
amount of reductive processing can take place after each chain extension, leading to a vast 
array of structures with varying levels of oxidation from simple starter units.  





Scheme 5. The diversity of structures produced in polyketide synthesis.  
There are three distinct classes of PKSs, types I-III. In type I polyketide synthases the domains 
are arranged linearly23 and can be subdivided into two categories; iterative, where the 
domains are covalently linked and can act in multiple cycles; and modular, which are 
comprised of multi-functional enzymes in which the domains are not repeated and are used 
only once.24 Modular PKSs can be further divided into two categories; cis-AT in which all the 
AT domains are contained within the module; and trans-AT where catalytic domains are 
recruited from outside of the module.25 
1.4 Natural products containing a tetrahydropyran ring 
 
Most drugs on the market today contain at least one heterocyclic system, with Lewell et al. 
reporting that, in 2001, 96% of the 10,000 drugs in development at a major global 
pharmaceutical company contained a ring system.26 The importance of these systems has 
been widely reported, and they have been shown to play a key role in scaffold rigidity, 
lipophilicity and metabolic stability.27 Taylor et al. reported that in 2014 there were 32 
examples of tetrahydropyran (THP) ring containing natural products currently being 
marketed as small molecule drugs,27 a selection of which are shown in figure 2.  





Figure 2. A selection of natural products containing THP rings. 
The mechanism of THP formation in natural products often proceeds via an oxa-Michael 
addition of an alcohol to an unsaturated carboxyl derivative such as in the biosynthesis of 
the antifungal polyketide ambruticin (scheme 6).28 The timing and mechanism of this 
transformation has been elucidated by analysis of the gene cluster and characterisation of 
metabolites produced by gene knockout experiments (scheme 6).28 An oxa-1,4-conjugate 
addition catalysed by the DH domain gives rise to the desired THP, while late stage 
modification converts this tetrahydropyran to the dihydropyran in ambruticin J 1.28-29 
Interestingly, the THP ring is formed by a different mechanism, and one that is rarely seen in 
the biosynthesis of polyketide natural products. Following release of ambruticin J from the 
PKS, AmbJ, an epoxidase, catalyses the epoxidation of the 6,7-alkene to give 2, which 
spontaneously undergoes attack by the hydroxyl at C-3 forming the THP of ambruticin F 3. 
This mechanism of THP formation will be discussed further in chapter three.  





Scheme 6. An example of two different mechanisms for the formation of THP rings in natural 




Mupirocin is a polyketide derived secondary metabolite produced by Pseudomonas 
fluorescens, a rod shaped bacterium commonly found in the rhizosphere30 of plant roots, 
and was first isolated by Ernst Chain’s laboratory in 1971 from soil samples taken from 
Hampstead Heath, London.31-32 Mupirocin displays biological activity against a wide range of 
Gram positive bacteria33 including methicillin-resistant Staphylococcus aureus (MRSA)34 and 
vancomycin–resistant Staphylococcus aureus (VSRA).35 It comprises a mixture of 
pseudomonic acids, which are produced by a trans-AT type I polyketide synthase and was 
one of the first antibiotics to be discovered that fell into this category of modular polyketide 
synthases (PKSs).36 Trans-AT PKSs differ from classic PKSs in that they are not covalently 
linked to any AT domains. This means that instead, AT activity is provided at each elongation 
in trans by one or more free proteins that are usually encoded in the biosynthetic gene 
cluster;20 these act iteratively to introduce a single extender unit in each module.  
The major component of mupirocin is pseudomonic acid A (PA-A) 4, which accounts for over 
90% of the mixture (figure 3); Pseudomonic acid B (PA-B) 5 comprises 8% and pseudomonic 
acid C (PA-C) 6 makes up ca. 1%.37 The general structure of a pseudomonic acid consists of a 




monic acid moiety featuring a tetrahydropyran (THP) core bearing a cis-diol, which is 
esterified by 9-hydroxynonanoic acid (9-HN).38-39  
 
Figure 3. Structures of the pseudomonic acids A-C and percentages found in mupirocin. 
In comparison to PA-A, PA-B has an additional hydroxyl group at C-8, whereas PA-C retains 
the unsubstituted C-8 position but has a 10,11-alkene instead of an epoxide. Mupirocin has 
been shown to be an effective antibiotic as it inhibits bacterial isoleucyl-transfer RNA 
synthetase (IleRS), thereby preventing the incorporation of isoleucine into newly synthesised 
proteins, leaving bacterial cells unable to produce vital cell proteins or assemble their cell 
walls.40 Mupirocin was one of the first antibiotics to be discovered with this mechanism of 
action, and since its discovery only a few isolated cases of bacterial resistance have been 
reported.41-42  
The crystal structure of mupirocin binding to its target enzyme IleRS from Staphylococcus 
aureus has been solved (figure 4).40 The monic acid portion of mupirocin mimics the side 
chain of isoleucine and so interacts with the isoleucine specific binding pocket of IleRS. The 
THP ring and the C-1 to C-3 portion43 mimics adenine and ribose and binds to the ATP binding 
site.44 The 9-hydroxynonanoic acid side chain stabilises the complex by binding to a 
hydrophobic groove in the IleRs, whilst also contributing to the biological properties of 
mupirocin, as without it the corresponding monic acid is biologically inactive.44-45 





Figure 4. Binding of mupirocin to IleRS from Staphylococcus aureus.30 
Mupirocin is marketed under the trade name Bactroban® by GlaxoSmithKline and is used for 
the treatment of minor skin infections such as impetigo,46 as well as in hospitals to prevent 
the spread of non-symptomatic MRSA via nasal sprays.47 Treatment is limited to topical uses, 
rather than oral or parenteral administration, due hydrolytic instability of the C-1 ester 
linkage in blood serum, which gives rise to the inactive monic acid A 7 (scheme 7).48 
 
Scheme 7. Hydrolysis of PA-A to monic acid.  
If used intravenously, the bioavailability is greatly reduced due to its strong binding 
interactions with blood serum and its activity is limited outside a narrow pH range (pH 5-8) 
due to the instability of the 10,11-epoxide. In mildly acidic conditions intramolecular attack 




of the 7-hydroxyl into the epoxide occurs giving rise to two inactive bicyclic heterocycles 8 
and 9.49 
 
Scheme 8. A: Intramolecular attack of 7-OH gives rise to two inactive bicyclic compounds.49 B: 
inhibition zone test showing the activity of the PA-A, PA-B and PA-C. 
PA-A and PA-C show similar activity against both Gram positive and Gram negative bacteria 
(scheme 8 B), and it is proposed that PA-C could be used intravenously due to the lack of the 
unstable 10,11-epoxide. However, PA-C is produced in such low titres that at present its use 
as a pharmaceutical agent is precluded; it is hoped that a greater understanding of the 
biosynthetic pathway would allow for genetic modifications offering improved titres. 
1.6 Isotopic labelling studies 
 
Since the pioneering work of Birch, isotopic labelling has proved to be a valuable technique 
to elucidate the biosynthesis of natural products.50-51 A relevant precursor is prepared 
incorporating an isotopic label such as carbon-13, oxygen-18 or deuterium, which is then fed 
to the living organism prior to the production of secondary metabolites. Following 
incorporation of the labelled substrate, the metabolites of interest are extracted and 
analysed to determine where the labels have been incorporated in the natural product, 
providing information about the origin of each of the atoms.    
Such labelling studies have been carried out on the pseudomonic acids.52-53 [1-14C]-, [1-13C]- , 
[2-13C]-, and [1,2-13C2]-acetates all showed incorporation into pseudomonic acid A, 
accounting for the carbon backbone (scheme 9).50 These studies also gave interesting 
insights into the formation of the ester linkage. Labelling of C-1 and C-9’ by [1-13C]-acetate 




suggested that the 9-hydroxynonanoic acid chain and monic acid are joined by a 
condensation reaction, and discounted the possibility of the ester being formed through a 
Baeyer-Villiger type oxidation from a single long chain ketone intermediate.51  
Scheme 9. Isotopic labelling pattern of pseudomonic acid A.53  
These labelling studies also showed that [1-13C]-propionate was incorporated at C-7’, while 
the 8’,9’-acetate unit was not incorporated in the usual ‘head to tail’ fashion common in 
polyketides. This suggested that the 9-hydroxynonanoic side chain was formed from two 
separate biosynthetic units.  
Labelling experiments carried out by Martin and Simpson53 showed that when [1-13C, 18O2]-
acetate was incorporated, the oxygen atoms on C-1, C-5, C-7 and C-9’ were all derived from 
labelled acetate. This is consistent with the proposed mechanism of THP formation in which 
the C-5 hydroxyl group attacks the least hindered carbon (C-16) of epoxide 10 (derived from 
a methyl group) forming the desired THP (scheme 10). The oxygen atoms attached to C-6 
and C-8 were presumed to be derived from atmospheric oxygen, with the hydroxyl group at 
C-8 being removed later in the tailoring steps by MupP, a dehydratase. 36 It is thought that 
MupA is responsible for the 6-hydroxylation which is discussed in detail in chapter two. 
 
Scheme 10. The origins of the oxygen atoms in the pseudomonic acids.51 
P. fluorescens 




Labelling studies using L-[Me-13C]-methionine showed that the single carbon branches at 
C-16 and C-17 are derived from S-adenosyl methionine mediated processes as opposed to 
being derived from methylmalonyl extender units, consistent with the results obtained from 
the labelled acetate studies.30, 33, 53 The β-methyl group at C-15 (unlike the α-methyl groups 
at C-15 and C-17 which are incorporated using an electrophilic methyl source), requires the 
attack of an ‘alkyl’ nucleophile at the electrophilic β-position to the ester. Incorporation of 
[2-13C]-acetate showed that this methyl group was derived from a cleaved acetate unit.52 
Gene cluster analysis identified a cassette of enzymes responsible for this transformation, 
termed 3-hydroxy-3-methylglutaryl CoA-synthase (HCS). The β-branch arises from the 
interaction of the HCS cassette with the β-ketothioester bound to an acceptor ACP, the 
mechanism of which is shown in scheme 11. The cassette consists of a free standing donor 
ACP (macpC), a mutant KS lacking the conserved cysteine required for condensation (mupG), 
a 3-hydroxy-3-methylglutaryl synthase (HMGS, mupH) and two enoyl CoA hydratase (ECH) 
domains (mupK and mupJ).30, 36 
Scheme 11. The proposed mechanism for the introduction of the 15-methyl group.36, 54 




Mupirocin is not the only polyketide to undergo this type of β-branching, and work carried 
out in the group has identified several polyketides possessing an HCS cassette including 
kalimantacin A and thiomarinol A. (figure 5).54-55 
 
Figure 5. Thiomarinol A and kalimantacin A both contain β-methyl branches.54-55 
β-methyl branching can be subdivided into two classes: endo-β-methyl branching and exo-
β-methyl branching, depending on the mechanism for reprotonation following 
decarboxylation.56 Mupirocin contains an endo-β-methyl (α,β-unsaturated β-branch), which 
is the most common isomer produced by an HCS cassette. This substitution pattern arises 
from reprotonation of C-4 by the second enoyl coA hydratase domain, which in the case of 
mupirocin is MupK (scheme 11).57 If however reprotonation were to occur at C-2, an exo-β-
methyl (β,γ-unsaturated β-branch) would be formed instead (scheme 12). Kalimanticin is a 
particularly interesting example of β-branching as it contains both endo and exo-β-methyl 
branches which requires high PKS selectivity to ensure the correct β-methyl branch is 
installed.55 
 
Scheme 12. The mechanism of reprotonation to give endo or exo-β-methyl branches. 
 
 




1.7 Biosynthesis of the pseudomonic acids 
 
As research into genome sequencing and genetic engineering has become more advanced, 
gene knockout experiments have enabled the function of genes to be determined more 
readily.39, 57 The 74 kb mupirocin gene cluster encodes six modular multifunctional proteins 
(mmps). The first half of the cluster contains type 1 modular polyketide synthases (PKSs) 
including multifunctional genes mmpA and mmpD, the associated trans-acyltransferase 
mmpC, mmpB, which is a fatty acid synthase, and three single open reading frames (ORFs) 
mupZ, mupA and mupB.57 
 
Figure 6. Mupirocin gene cluster organisation.33 
MmpD and mmpA contain four and three modules respectively; each with a ketosynthase 
domain and an acyl carrier protein domain, and are both responsible for the production of 
the monic acid portion of mupirocin.33 The biosynthesis begins with the loading of a malonyl 
extender unit onto the first ACP of module one catalysed by the AT domain provided in trans 
by mmpC (figure 7). There are four condensations carried out by mmpD before the growing 
chain 6 is loaded onto mmpA. The isolation of mupiric acid (figure 8) as a result of mutation 
of the ketoreductase domain in the final module of mmpD provides evidence that links 
mmpD to the early stages of monic acid production.30 The first KS domain of mmpA is thought 
to be a KS0, an inactive domain, as only six condensations are needed in order to produce 
the C14 backbone.30 It is used to move the growing chain from mmpD on to mmpA before 
two further condensations are carried out to give the monic acid precursor 14. Deletion of 
this KS0 halted the biosynthetic pathway which proves it is essential in the biosynthesis of 
the pseudomonic acids.57 The final module of mmpA contains twin acyl carrier proteins, each 
with a unique recognition site for association with the HCS cassette.30 
An unusual feature of the mupirocin PKS is the absence of any ER domains, which is 
surprising due to the fact that the 8,9-alkene is reduced in all known pseudomonic acid 
analogues and has never been observed.33 Subsequent gene knockout experiments 
indicated that mupC, which encodes a putative dienoyl thioester reductase, acts in trans in 
module 3 to reduce this alkene.33 This was particularly interesting as it had also been shown 




that MupC is involved with the final tailoring steps of the pathway (scheme 13), and these 
results suggested that MupC could possess the ability to manifest activity on different 
substrates.33 
 
Figure 7. Early stages of the proposed biosynthesis of pseudomonic acids.30 
The iterative FAS mmpB encodes ketosynthase, ketoreductase and dehydrogenase domains 
and has been shown to be responsible for the biosynthesis of the 9-hydroxynonanoic acid 
side chain.58 The starter unit for this for this is proposed to be 3-hydroxypropionate which 
undergoes three malonate condensations in order to extend the chain. MmpB also encodes 
the only TE in the gene cluster and is therefore likely to control the final steps of the pathway 
and the release of products.59 MmpB lacks both an AT and ER domain; which are thought to 
be provided in trans by mmpC and MupE respectively; and unusually contains three ACP 
domains.57 Studies on these ACPs have shown that in-frame deletion of each of the ACPs in 
turn had no effect on the production of the pseudomonic acids, while deletion of all three 
abolished production. This shows that the ACP triplet provides a function in parallel but not 
all are essential.60 The mechanism of formation of the ester linkage between the thioester 
of the monic acid portion and 9-HN is still unclear. It has been hypothesised that an 
esterification takes place between monic acid and 3-hydroxypropionate, with the 
homologations of the fatty acid chain taking place subsequently, however a three carbon 
chain on monic acid has never been isolated, which suggests the AcpD which carries this 




proposed intermediate cannot recognise the esterase. Recent work undertaken in our group 
has shown that mmpF can extend this three-carbon chain to five carbons, however the 
mechanism for the full chain extension and esterification is still unclear.61 It has also been 
suggested that the two portions are produced separately and then esterified, however no 
accumulation of monic acid or 9-HN has been observed by any gene knockout experiment.  
The remaining 27 ORFs are in the second half of the cluster along with smaller PKS-like genes 
mmpE and mmpF. Some of these show similarity to type II PKS modules and are known to 
be tailoring genes, the proposed functions of which are summarised in table 1.62  
ORF Deduced functions of the encoded 
protein. 
ORF Deduced functions of the encoded 
protein. 
mupA Reduced flavin mononucleotide 
(FMNH2) oxygenase 
mupL Hydrolase 
mmpA PKS (KS, ACP and KR) mupM Isoleucyl-tRNA synthase 
mupB 3-Oxo-ACP reductase mupN Phosphopantetheinyl 
transferase 
mmpB PKS (FR, DH, KR, ACP, TE) mupO Cytochrome P450 
mmpC Acyltransferase and ER mupP DH47 
mmpD PKS (KR, DH, ACP, TE) mupQ Acyl CoA synthase 
mupC Dienoyl reductase mupS 3-Oxo-acyl carrier protein 
 reductase 
macpA ACP macpD ACP 
mupD 3-Oxo-ACP reductase mmpF PKS (KS) 
mupE ER macpE ACP 
macpB ACP mupT Ferredoxin dioxygenase 
mupF KR mupU Acyl CoA synthase 
macpC ACP mupV Oxidoreductase 
mupG 3-Oxo-ACP reductase mupW Rieske type oxygenase 
mupH β-hydroxyl-β-methyl glutarate 
CoA synthase 
mupR Transcriptional activator 
mupJ Enoyl CoA hydratase mupX Amidase 
mupK Enoyl CoA hydratase mupI N-Acyl homoserine lactone  
synthase 
mmpE PKS and oxidoreductase mupZ Epoxide hydrolase 
Table 1. The proposed functions of the encoded proteins.30 




These tailoring enzymes control various processes including the 10,11-epoxidation, as well 
as 6-hydroxylation and tetrahydropyran ring formation, which will be discussed in detail in 
this thesis.19,62 Extensive studies into the late stage modifications in pseudomonic acid 
biosynthesis have been carried out and have shown that two parallel pathways exist (scheme 
13).36 Classical biosynthetic logic would suggest that PA-C is the precursor to PA-A through 
epoxidation while PA-B is the downstream product, however this is not the case. Deletion of 
mupV, mupO, mupU, and macpE resulted in the formation of only PA-B with no PA-A 
detected.60 When mupC was also deleted in addition to one of the four genes mentioned 
above, the same result was seen, suggesting mupV, mupO, mupU, and macpE all act before 
mupC, and therefore that PA-B is the precursor to PA-A as previously suggested but not 
proven by Mantle et al.63  
 
Scheme 13. Simplified later stages of the biosynthesis of the pseudomonic acids.30 




PA-C was shown to be produced via a minor pathway in which mmpEOR, an oxidoreductase, 
does not act and so the epoxide is not installed. However, the following biosynthetic steps 
are analogous to PA-A in the major pathway: MupP (dehydratase), MupC (dienoyl reductase) 
and MupF (ketoreductase), which have all been identified and their functions assigned 
through gene knockout experiments.36 
Not all of the catalytic functions of the tailoring genes have been so easily assigned due to 
the so-called ‘leaky hosepipe’ mechanism.33 A number of gene knockout and mutation 
experiments have been shown to produce the same two shunt products: mupiric acid 15 and 
mupirocin H 16 (figure 8). These are hypothesised to be produced when a mutation occurs 
that interferes with the formation of 9-HN and/or its esterification onto monic acid. A point 
mutation of the first ACP in the triplet in mmpB (responsible for 9-HN biosynthesis) abolished 
the production of PA-A, while also producing 15 and 16.60 It has been reported that mupS 
and mupQ are responsible for the synthesis of the 3-hydroxypropionate precursor to 9-HN, 
while mupL is a potential candidate for attachment of 9-HN to monic acid or its precursor. 
When these genes were knocked out, again the shunt products 15 and 16 were produced.33 
The conveniently located mupB, found between mmpA and mmpB could allow loading of 3-
HN onto the KS of mmpB or the monic acid from mmpA-ACP-4 to mmpB. These results 
suggest that halting the biosynthesis of 9-HN means that the final product produced by the 
PKS is not removed from mmpA and therefore not esterified with 9-HN or its precursor. 
Mutations of the HCS cassette also produced 15 and 16, which is in accord with the proposal 
that mutation of the individual functionalities in the cassette impairs the flux of metabolites 
along the biosynthetic pathway, increasing the dwell time of intermediates at points on the 
synthase resulting in shunt products being produced.33 It is likely that these two compounds 
15 and 16 are released at chemically labile points as a result of impeding metabolic flux along 
the pathway, much like the analogy of stepping on a hosepipe. Only when the main flow is 
blocked do the leaks elsewhere become apparent.  
 
Figure 8. The structures of mupiric acid and mupirocin H. 




1.8 Introduction to the 6-hydroxylation in mupirocin biosynthesis 
 
The work in this thesis focuses on two transformations which have yet to be fully elucidated. 
The first that will be discussed involves investigations into the gene responsible for 
6-hydroxylation and the timing of this process in mupirocin biosynthesis. 
 
Figure 9. Proposed modules where 6-hydroxylation could occur (red circle).  
The introduction of a hydroxyl group is an α-modification which suggests this is being carried 
out by a tailoring enzyme, the prime candidate for which is MupA, which has no currently 
confirmed function. We hypothesise that this transformation takes place in the final module 
of mmpD or in the first module of mmpA (figure 9). 
1.8.1 α-Hydroxylases in polyketide biosynthesis 
 
In polyketide biosynthesis, α-hydroxylation has been shown to proceed in a variety of ways, 
both as part of the PKS machinery and during late stage modification. Incorporation of 
hydroxy-malonyl ACP bound extender unit is a simple way to functionalise the α-position as 
demonstrated in the biosynthesis of zwittermicin A, a broad spectrum antibiotic produced 
by the bacterium Bacillus cereus UW85.64 It is reported that this extender unit is formed from 
1,3-bisphosphoglyceric acid (1,3-bPG) (scheme 14), although a number of other mechanisms 
of formation have been proposed.64  





Scheme 14. Zwittermicin A and the hydroxyl-malonyl extender unit formed from 1,3-bPG.64 
Cytochrome P450 oxygenases are ubiquitous in nature, and are responsible for catalysing 
the installation of α-hydroxy groups in the biosynthesis of erythromycin,65 ossamycin66 and 
stambomycin.67 The biosynthesis of erythromycin has been extensively studied65, 68-70 and 
the enzyme responsible for the hydroxylation at the 6-position of the macrolide framework 
has been determined to be the P450 EryF, the structure of which was resolved by x-ray 
crystallography (scheme 15).65 As with other P450s, EryF is comprised of a haem prosthetic 
group embedded between helices, a helical domain and a mixture of β-pleated sheets and 
coils arranged randomly.65 
 
Scheme 15. 6-hydroxylation of 6-deoxyerythronolide B and the enzyme EryF.65 
EncM is the enzyme responsible for the catalysis of an α-hydroxylation in the enterocin 
biosynthetic pathway. This process was previously thought to occur via a standard flavin 
catalysed oxidation, however, studies undertaken by Miyanaga et al. proved that the 
α-hydroxylation was occurring via a novel mechanism utilising a flavin N5-oxide oxygenating 
species (scheme 16).71 





Scheme 16. The novel α-hydroxylation in the enterocin biosynthetic pathway catalysed by EncM via 
a flavin N5-oxide oxygenating species.71 
The C-7 hydroxyl group present in pederin and closely related antitumor agents, is known to 
be installed by α-hydroxylation catalysed by flavin-dependent oxygenases at an early stage 
in their respective biosyntheses.20, 72-73 It has been shown that PedJ, the enzyme responsible 
for this transformation in pederin biosynthesis, is a homologue of OnnC and NspB found in 
the onnamide and nosperin gene clusters respectively (Figure 10 A).73 
 
Figure 10. A: Gene cluster analysis of nosperin, pederin and onnamide. B: α-Hydroxylation 
catalysed by PedJ in the biosynthesis of pederin.20, 72-73 
The biosynthesis of the polyketide antibiotic β-rhodomycin involves an esoteric 
α-hydroxylation catalysed by the S-adenosyl-L-methionine-dependent methyltransferase 
homologue, RdmB. The crystal structure of aclacinomycin-10-hydroxylase (RdmB) revealed 




that the enzyme subunit has a fold similar to methyltransferases and binds 
S-adenosyl-L-methionine in an identical manner. RdmB catalyses both hydroxylation and 
decarboxylation of 15-demethoxy-ε-rhodomycin simultaneously (scheme 17).74-75 
 
Scheme 17. α-Hydroxylation catalysed by RdmB.74-75 
Thiomarinol A, produced by a marine bacterium of the genus Pseudoalteromonas is closely 
related in structure to pseudomonic acid A, however, thiomarinol A possesses a hydroxyl 
group at C-4, which again arises from α-hydroxylation (figure 11). The enzyme responsible 
for this transformation has been identified as TmuB which is a member of the non-haem-
iron(II)/α-ketoglutarate-dependent dioxygenase superfamily.76 
 
Figure 11. Thiomarinol A and PA-A.76 
Finally, but not exhaustively, oxygen functionality can be installed at the α-position by 
luciferase-type monooxygenases. In the biosynthesis of bacterially derived aromatic 
polyketide rishirilide A, an oxygen atom is inserted into the 4a-4 bond of 17 in a Baeyer-
Villiger-type rearrangement.77 Analysis of the gene cluster showed RslO1 to encode proteins 
homologous to other luciferase-type oxygenases78-80 and RslO2 to be a flavin monoreductase 
which is utilised by RslO1 as a co-factor. The mechanism of oxidations catalysed by luciferase-
type monooxygenases will be discussed further in section 1.8.2.   





Scheme 18. The installation of an oxygen atom catalysed by RslO1, a luciferase-type oxygenase.77 
1.8.2 Studies to identify the 6-hydroxylase and the structure of MupA 
 
Previous work in our group involved investigation into the gene responsible for 6-
hydroxylation in mupirocin biosynthesis.33 When gene knockout experiments were carried 
out with the P. fluorescens ΔmupH mutant, mupirocin H was isolated as discussed in section 
1.7.33 The production of this truncated -lactone was proposed to be formed via the 
mechanism shown in scheme 19.  
 
Scheme 19. The proposed mechanism of mupirocin H formation.33 
It was proposed that a ‘6-hydroxylase’ was acting on thioester 19, which allowed for 
intramolecular attack of this 6-OH onto the 3-ketone giving hemiketal 21, which, following a 
retro Claisen reaction gives mupirocin H 16. Previous literature reports have shown that it is 
possible for enzymes to exhibit dual functionality, for example MupC (section 1.7).33 
Hadatsch et al. have reported that if an accumulation of unnatural products from 
biosynthetic derailment occurs, it is possible for enzymes to act promiscuously,81 which in 
the case of ΔmupH could have resulted in 6-hydroxylation. 




More recent work carried out in our group by Dr Zhongshu Song (unpublished results) 
showed that when gene knockout experiments were carried out with the P. fluorescens 
ΔmupA mutant, a number of fermentation products lacking the 6-hydroxyl group were 
isolated, a selection of which are shown in figure 12. 
 
Figure 12. Metabolites isolated from gene knockout experiments with the ΔmupA mutant.  
Analysis of the mupirocin gene cluster showed MupA to be a monooxygenase which, coupled 
with the results from the mutant cultures, suggested that MupA was involved with 
6-hydroxylation. By comparing the structure of MupA to other known oxygenases, Dr Ash 
Winter (unpublished results) has shown that MupA is most likely to be a luciferase type 
monooxygenase. Figure 13 shows the similarity in structure between a flavin dependent 
monooxygenase, a cytochrome P450, a luciferase and MupA. The smaller the RMSD (root 
mean square deviation), the closer the structure of the oxygenase is to MupA. 
 
Figure 13. The structures of three different types of oxygenase and the structure of MupA 
superimposed onto 1LUC a known luciferase type monooxygenase. 
By mining the protein database (PDB), it was discovered that a known monooxygenase, 6KET 
(figure 14 C) had a 47% identity to the structure of MupA and belongs to the luciferase type 
II family of monooxygenases. Type I luciferase monooxygenases bind the co-factors NADPH 
and FAD, while type II bind flavin mononucleotide (FMN) as a co-factor and use NADPH as 




an electron donor.82 Type II luciferases contain a triose-phosphate isomerase (TIM) barrel 
consisting of eight α-helices and eight parallel β-strands that alternate along the peptide 
backbone.83 By comparing the structure of MupA to these known luciferase 
monooxygenases (figure 14) there is a good correlation between the three structures. 
Figure 14. The structure of RSlO1 (A), MupA (B) and 6KET (C). 
From this data, it is proposed that MupA is a luciferase type II monooxgenase, which would 
be unusual as luciferase-type monooxygenases usually act to install oxygen via Baeyer-
Villiger-type rearrangements or epoxidations,84-85 not hydroxylations as in the case of MupA. 
It is therefore hypothesised that the 6-hydroxylation proceeds via the mechanism shown in 
scheme 20.  
 
Scheme 20. The proposed mechanism of 6-hydroxylation catalysed by MupA. 
The key feature of this mechanism is the reaction of reduced flavin FMNH2 with molecular 
oxygen to generate the stable flavin-peroxide intermediate (Criegee intermediate). 




Following hydroxylation of the substrate, a hydroxy-flavin adduct is produced which is 
dehydrated to regenerate FMN. 
1.9 Previous synthetic strategies to pseudomonic acid based structures 
 
When planning the syntheses discussed in chapter two and three, inspiration was taken from 
a number of previous total syntheses. The synthesis of mupiric acid 15 was reported by Willis 
et al. in 2008 in six steps (longest linear sequence) utilising a key cross metathesis as shown 
in scheme 21.86 Elements of this total synthesis were applied to the syntheses discussed in 
chapter two. 
 
Scheme 21. The synthesis of mupiric acid by Willis et al. 86  
The total synthesis of mupirocin H 16 was first reported in 2011 by Chakraborty et al. in 19 
longest linear steps and 4.96% overall yield utilising a key Julia-Kocienski reaction.87 In 2012, 
Willis et al. reported an alternative synthesis in 20 steps (longest linear sequence) and 6.2% 
overall yield, employing ring closing metathesis methodology and a key alkylation step. This 
was improved upon by Zhao et al. in 2013 who reported a total synthesis in seven longest 
linear steps and 39% overall yield, that utilised a key Suzuki disconnection as shown in 
scheme 22.88 The stereoselective hydroboration and subsequent Suzuki reaction were 
applied to the synthetic route discussed in chapter two.  





Scheme 22. Total synthesis of mupirocin H by Zhou et al. 88  
An adaption of the synthetic strategy reported by Zhao et al. was utilised by Dr Bakar in the 
total synthesis of desepoxymupirocin W4-OH 27, which was completed in 14 longest linear 
steps and in 2.8% overall yield (scheme 23).89 This synthesis involved a key Mukaiyama aldol 
reaction to install the fatty acid side chain and will be discussed further in chapter three.   
 





















CHAPTER 2: MupA – the 6-
hydroxylase? 




2. Chapter 2 
2.1 Project aim 
 
The aim of the first part of the project was to prepare novel substrates (S)-28 and 29 (figure 
15) and conduct bioassays with the proposed 6-hydroxylase MupA in order to investigate 
whether MupA is indeed responsible for this biotransformation. The numbering of carbons 
in this thesis refers to pseudomonic acid numbering unless otherwise stated. This chapter 
focuses on structures lacking a 6-hydroxyl group and bearing a side chain which mimics the 
terminus of an ACP as it is hypothesised this transformation takes place prior to the 
installation of the fatty acid side chain. The longer the side-chain, the more similar it is to the 
native ACP and the more likely it is to be recognised and turned over by the enzyme than the 
analogous carboxylic acid. It was unknown whether MupA would recognise these substrates, 
and if so, what the phenotypic outcome of these transformations would be.  
 
Figure 15. Synthetic targets (S)-28 and 29. 
With this in mind, a retrosynthesis of (S)-28 was proposed whereby aldehyde 30 and acylated 
chiral auxiliary 31 are coupled under aldol conditions introducing the stereocentre at C-7 and 
providing a handle for thioesterification (scheme 24). In the next step a cross metathesis 
would couple alkenes 32 and 33, creating the E-alkene in 34. In the final step, a 
thioesterification would introduce the SNAC side chain, which is easily synthesised from the 
commercially available N-cysteamine hydrochloride.90 





Scheme 24. Retrosynthetic analysis of (S)-28. 
Thioester (S)-28 would then be used in biotransformation studies in E. coli expressing MupA 
to determine whether this enzyme is responsible for the installation of the hydroxyl group 
at C-6.  
2.1.1 Literature research into the key cross metathesis of alkene 32 and 33 
 
Olefin cross metathesis (CM) is a convenient way to take two relatively simple olefins and 
produce a more complex molecule. Cross metatheses have gained popularity in the last 20 
years, due to the development of Grubbs’ first-generation 36 and second generation 37 
catalysts. 
 
Figure 16. Grubbs’ first 36 and second generation 37 catalysts.91-92 
The replacement of a PCy3 ligand in 36 by an N‐heterocyclic carbene (NHC) in 37 leads to a 
more stable and reactive catalyst due to an enhanced preference for olefin coordination 
relative to phosphine coordination.93-95 NHCs are particularly strong σ‐donors which show 
little tendency to dissociate from the metal centre. The substitution of bulky mesityl groups 
on nitrogen atoms make them able to stabilise the catalytically relevant intermediates 
against attack by electronic and steric means.94 




The mechanism of this reaction has been thoroughly studied and has been shown to proceed 
by initial dissociation of a phosphine ligand to form a 14-electron intermediate I shown in 
scheme 25.96 A [2+2] cycloaddition between an olefin II and this metal carbene intermediate 
I takes place giving a metallacyclobutane intermediate III. This metallacycle breaks down in 
a productive way to form a new olefin and a new alkylidene complex IV, or in an 
unproductive way to regenerate the starting compounds. The alkylidene  then reacts with a 
different olefin V to give another metallacyclobutane intermediate VI which collapses to give 
the required cross product VII and regenerates the catalyst as shown in scheme 25.97 
 
Scheme 25. Catalytic cycle for a cross metathesis.97 
The selectivity of cross metatheses has been investigated using several different types of 
alkenes, for example substituted styrenes, 2o and 3o allylic alcohols, and olefins with an 
α‑quaternary centre.98  Alkenes have been categorised into four types: I, II, III and IV 
according to Grubbs et al.98 These will not be discussed in detail as the proposed coupling 
partners in the cross metathesis of alkenes 32 and 33 shown in scheme 24 are terminal 
olefins and therefore fall into the type I category as defined by Grubbs et al.  
Type I alkenes can rapidly homodimerise and participate in secondary metathesis reactions 
with type II or III alkenes.98 Olefin reactivity decreases from type I to type IV as a response to 
the increase in steric bulk and/or the electron deficiency of their double bonds. Therefore, 




careful consideration is needed when coupling any two olefins in the same category, as the 
kinetic rate towards the homodimer is very similar to that of the heterodimer, which is why 
usually one olefin is used in excess.98 Theoretically, up to 20 equivalents of one olefin would 
provide 95% of the desired product, however, in reality this would be impractical.  
 
Scheme 26. Statistical distribution of products on variation of starting material ratio.98 
Marko et al. reported in the total synthesis of pseudomonic acid C 6 that terminal olefins 38 
and 39 were coupled to give the desired E- alkene 40 in 56% yield using the Grubbs’ second 
generation catalyst (GII) shown in scheme 27.99 It was proposed that these conditions could 
be applied to unsaturated alcohol 32 and alkene 33 to achieve a successful coupling. 
 
Scheme 27. Coupling of terminal olefins by Marko et al.99  
Both alkene 38 and tetrahydropyran 39 are terminal olefins and so are type I alkenes. Marko 
et al. reported using four equivalents of alkene 38 with one equivalent of 39 in the synthesis 
shown in scheme 27, so this was considered when planning the synthesis of thioester (S)-28.  
2.2 Results and discussion 
 
To begin the proposed synthesis of thioester (S)-28, aldehyde 30 was prepared requiring the 
installation of the methyl group at C-8 with the correct stereochemistry. The use of a chiral 
auxiliary was investigated, and although there are many different chiral auxiliaries to choose 
from,100 in this case Evans’ auxiliary 41 was chosen due to its commercial availability and low 
cost. Preparation of 42 from auxiliary 41 was investigated using two different methods 
(scheme 28). The first approach involved the preparation of 4-pentenoyl chloride from the 
commercially available 4-pentenoic acid which was reacted with Evans’ auxiliary 41 in the 
presence of DMAP and Et3N as shown in scheme 28. Although this method is reported in the 




literature to be high yielding,101  the best achieved in this study was 24% yield. An alternative 
method involved formation of mixed anhydride 43 in situ before the addition of the Evans’ 
auxiliary 41102 which gave 42 in 81% yield.  
 
Scheme 28. The two different methods for the synthesis of 42. 
The next step was introduction of the methyl group using methyl iodide and the base 
NaHMDS. The sodium coordinates to both oxygen atoms to give the (Z)-enolate 44 
exclusively,103 holding the transition state rigid while the methyl group is directed to attack 
from the Re face, as the benzyl group is blocking the Si face (scheme 29). This reaction gave 
45 in 88% yield as a single diastereomer as observed by 1H NMR spectroscopy.  
 
Scheme 29. Coordination of the sodium ion giving the (Z)-enolate. 
Next the auxiliary was reductively cleaved using LiBH4 to give alcohol 46, which was oxidised 
under Swern conditions104 to give aldehyde 30 in four steps and 32% overall yield as shown 
in scheme 30. 
 
Scheme 30. Synthesis of aldehyde 30. 




2.2.1 Model studies of the aldol reaction between aldehyde 30 and 47 
 
Acylated chiral auxiliaries have been widely used in aldol reactions105-106 and to begin with 
acylated Evans’ auxiliary was used. Acylation of 41 under the conditions shown in scheme 31 
was straightforward and high yielding, requiring no purification of the product 47.  
 
Scheme 31. Acylation of Evans’ auxiliary.  
It has been reported that different Lewis acids give different stereochemical outcomes in 
aldol reactions with 47.107-110 The change in facial selectivity in aldol additions is proposed to 
be a result of switching mechanistic pathways between chelated and nonchelated transition 
states due to changes in the metal centre or auxiliary substituent.105, 107-110 
 
Scheme 32. Chelated vs non-chelated transition states107 and the ‘non-chelated’ transition state 
that occurs when using Bu2BOTf (right).  
To begin, the use of Bu2BOTf was investigated. This Lewis acid, when used in combination 
with a chiral auxiliary, to give stereocontrol in a 1,3 fashion with respect to the enolate.111 
Lewis acids containing boron can give a different transition state to those containing 
titanium. This is because boron cannot expand its octet in order to interact with the lone pair 
of the carbonyl oxygen in the oxazolidinone. There is also a steric interaction between the 
auxiliary substituent group (in this case a benzyl group) and the carbon backbone of the 
aldehyde.105 
Although the transition state shown in scheme 32 would give rise to a product with opposite 
stereochemistry to that required for the total synthesis of thioester (S)-28, the aim of this 
investigation was to determine whether these conditions could be utilised to give a product 




with high de. If successful, the opposite enantiomer of the Evans auxiliary could then be used 
in order to produce the product with the desired stereochemistry. Investigations into this 
reaction were carried out with the model aldehyde 48, due to its availability in one step from 
oxidation of 4-pentenol using pyridinium chlorochromate (PCC). 
When aldehyde 48 was reacted with acylated auxiliary 47 using the conditions shown in table 






Table 2. The different conditions used to carry out this aldol reaction. 
NMR analysis of the crude reaction mixtures showed none of the desired product to have 
formed, even though the characteristic aldehyde peak had disappeared. After purification 
neither acylated auxiliary 47 or aldehyde 48 was recovered.  
An alternative for stereoselective aldol reactions is the use of N-acyl thiazolidinethiones.107, 
112 These acylated auxiliaries have been shown to give products with the desired 
stereochemistry in high de, 99 while also being easily cleaved and thioesterified in one step, 
something that cannot be achieved with the corresponding oxazolidinone auxiliary.  
 
Scheme 33. Examples of a thiazolidinethione auxiliary being used in aldol reactions.105 
Auxiliary 52 was synthesised in a three-step procedure shown in scheme 34. Reduction of D-
valine to D-valinol has been reported using various reagents including LiAlH4 or BH3-THF.113 
Alternatively an excellent reducing agent for amino acids can be prepared using NaBH4 and 
Lewis Acid L.A Equivalents Time/ h Yield/% 
TiCl4 2 1.5 0 
TiCl4 2 4 0 
Ti(i-OPr)4/TiCl4 0.2/0.8 2 0 
Bu2BOTf 2 1.5 0 




I2 as first reported by Meyers and co-workers in 1993.113-114 These reduction conditions have 
the advantage of being safe and inexpensive, with no racemisation of the product being 
reported.  
 
Scheme 34. Synthesis of acylated thiazolidinethione auxiliary 52. 
Following reduction of D-valine 50 to D-valinol, the product was refluxed with CS2 to give 
thiazolidithione 51 in 68% yield over two steps. Acylation of auxiliary 51 was achieved in 91% 
yield using acetyl chloride and pyridine in DCM, giving the required substrate 52 to 
investigate conditions for the aldol reaction with aldehyde 48.  
 
Scheme 35.  Aldol reaction using aldehyde 48. 
Two aldol reactions were carried out using neat TiCl4 added dropwise to a stirring solution of 
auxiliary 52 in DCM. The base (either DIPEA or (-)-sparteine) was then added dropwise and 
stirred before addition of aldehyde 48 in DCM. TiCl4 was used as literature examples showed 
the desired stereochemical outcome could be achieved using this Lewis acid.107 Both 
reactions were successful, however it was seen that the yield was greatly improved (51% 
versus 30%) when using (-)-sparteine instead of DIPEA. This effect could be due to the fact 
that (-)-sparteine is a diamine and so could coordinate to the metal centre in a bidentate 
manner. Fewer equivalents of the aldehyde would be needed as the base binds to the vacant 
orbitals on titanium, however this is speculative.112 (-)-Sparteine has also been shown to 
dramatically increase the rate of these reactions, although why this happens is still 
unclear.115 The asymmetric induction provided by both (-)-sparteine and (+)-sparteine is 
minimal and (-)-sparteine gives similar diastereoselectivities when either enantiomer of the 
thiazolidinethione auxiliary is used.116 The thiocarbonyl of thiazolidinethiones is more 
nucleophilic than that of the previously used oxazolidinone 47 due to sulfur being larger than 




oxygen. The lone pairs on sulfur are more accessible to the Lewis acid leading to a stronger 
interaction and therefore a more rigid transition state. When thiazolidinethiones are used 
with chlorotitanium enolates, the reactions are known to proceed via the more rigid 
‘chelated’ transition state as shown in scheme 36.115 
Using the conditions that had been successful in trial reactions (scheme 35), aldehyde 30 and 
acylated auxiliary 52 were successfully coupled giving alcohol 54 in 51% yield, as a single 
diastereomer determined by 1H and 13C NMR (scheme 36). The stereochemistry of this 
product was confirmed by comparison of the spectroscopic data with the literature.117  
 
Scheme 36. Aldol reaction of aldehyde 30 and auxiliary 52 giving alcohol 54 as a single 
diastereomer. 
2.2.2 Synthesis of alkene 60 and cross metathesis with 54 
 
The next stage of the synthetic route to (S)-28 required the preparation of alkene 60, 
achieved in six steps, for use in cross metathesis chemistry (scheme 37). 
 
Scheme 37. Synthesis of alkene 60. 
In the first step, ester 55 was methylated to give the anti-product using LDA and 
iodomethane. This stereochemistry can be rationalised by the transition state model shown 




in figure 17.118 The lithium cation coordinates to the oxygen of the ester and hydroxyl group 
forming a 6-membered transition state. The methyl group is then added to the least hindered 
(Re) face, giving the desired anti configuration between the methyl and hydroxy groups.118 
 
Figure 17. Transition state model for the methylation of 55.118 
Reduction of this ester with LiAlH4 gave diol 56 which was PMB protected using para-
methoxybenzene dimethyl acetal to give 57 in 92% yield. Selective reduction of 57 using 
DIBAL-H gave primary alcohol 58. The aluminium selectively binds to the least hindered 
oxygen, which in this case is the primary alcohol (scheme 38). This gives rise to oxocarbenium 
ion 61, which is attacked by the hydride, producing the protected secondary alcohol 58. 
Work up was simplified by addition of Rochelle’s salt which removes the aluminium complex 
by acting as a ligand, binding to the aluminium and removing it from the product.  
 
Scheme 38. Proposed mechanism of DIBAL-H reduction of 57. 
Alcohol 58 was oxidised to aldehyde 59 using TEMPO/BAIB119 in 85% yield. A Wittig 
methylenation of aldehyde 59 gave the desired terminal olefin 60 which was the coupling 
partner for the next stage in the synthesis. Purification of aldehyde 59 by column 
chromatography was necessary after the oxidation to remove any iodobenzene from the 
crude reaction mixture as this was inseparable from alkene 60. 
The cross metathesis of 60 and 54 was investigated using conditions previously reported by 
Marko et al. (scheme 27) and used in our group by Mazzetti (scheme 39). 





Scheme 39. The cross metathesis carried out by Mazzetti.120 
Mazzetti reported that when alkene 63 was used, alkene 65 was formed in 50% yield as a 6:1 
ratio of E/Z isomers, however when alkene 62 bearing a free alcohol was used, alkene 66 
was formed as the E isomer exclusively. Using these reaction conditions, the coupling of 
alkenes 60 and 54 was unsuccessful and starting materials were recovered (scheme 40). It 
was hypothesised that this coupling was unsuccessful due to the presence of sulfur in the 
auxiliary, which has been reported to poison ruthenium catalysts.121 It is known that 
heteroatoms in close proximity to an olefin can form a chelating ligand on ruthenium, which 
slows catalyst turnover.122 To overcome this, the thiazolidithione auxiliary was cleaved using 
LiOH and H2O2 to give acid 67 (scheme 40). Treatment of acid 67 and alkene 60 with GII in 
toluene again returned starting materials.  
 
Scheme 40. Unsuccessful cross metathesis of terminal olefins 60 and 54.  
Interestingly, the terminal alkene of 60 had partially isomerised to give the more substituted 
internal alkene, which is a widely reported undesired side reaction that occurs during 
ruthenium catalysed cross metatheses.123-127 Nolan et al. reported that when GII was used in 
toluene, the efficiency of the cross coupling was impaired by the tendency of the active 
species to isomerise the double bonds of the substrate, leading to more highly substituted 
alkenes which are stabilised by hyperconjugation.128-129 This isomerisation can also be the 




result of decomposition of the ruthenium catalyst due to reaction times of over 24 h,130 
hence the cross metathesis of alkenes 60 and 54 was repeated for a shorter reaction time (8 
h) and in a different solvent (DCM), however isomerised starting material was still observed 
by 1H NMR and none of the required coupled product 68 was detected (scheme 41). 
 
Scheme 41. Attempted cross metathesis in DCM with a shorter reaction time.  
2.3 Revised Synthetic Approach to (S)-28  
 
Based on the results to date a new synthetic approach was designed which still incorporated 
the two key disconnections a stereoselective aldol and cross metathesis, however in reverse 
order (scheme 42). As thiazolidithione auxiliary based alkene 54 had been an unsuitable 
coupling partner for cross metathesis, it was decided to change the protecting group strategy 
and to prepare alkenes 70 and 64 for the key cross metatheses step.  
Scheme 42. Revised retrosynthesis of (S)-28.  
Synthesis of alkene 70 began from commercially available methyl 3-(S)-hydroxybutyrate 55 
(scheme 43). Following a stereoselective methylation of 55 using LDA and MeI, ester 74 was 
protected using TBSCl, imidazole and DMAP. Ester 75 was reduced using DIBAL-H to alcohol 
76 and Dess Martin periodinane (DMP)53 used as the oxidant due to the simple purification 
procedure required.131 Purification of the crude material by trituration with Et2O gave the 




required product in 96% yield, which was then methylenated under Wittig conditions to give 
alkene 70.  
 
Scheme 43. Synthesis of 70 in five steps from 55.  
Alkene 64 was synthesised by reaction of commercially available auxiliary 78 with anhydride 
79 in the presence of LiCl and Et3N to give propionylated oxazolidinone 80 (scheme 44). 
Allylation of 80 with LDA and allyl bromide gave alkene 64 in 73% yield as a single 
diastereomer as determined by 1H NMR spectroscopy.  
 
Scheme 44. Synthesis of 64 from 78.  
With both alkenes 70 and 64 in hand, the cross metathesis was investigated. By using the 
statistical distribution of products model (scheme 26, page 33), four equivalents of alkene 
70 and one equivalent of 64 were used as these provided a compromise between material 
value of the substrates and metathesis selectivity (scheme 45). Grubbs et al. reported that 
with this ratio, up to 80% selectivity for the cross coupled product could be achieved (scheme 
26).98 
Both alkenes 70 and 64 were dissolved in toluene at a concentration of 5 M followed by 
catalyst addition and the mixture refluxed for 16 h to give the required alkene 71 in 40% 
yield as a 5:1 mixture of E/Z isomers (scheme 45). The product of self-metathesis, alkene 81, 
was observed by 1H NMR, however as type I alkene 70 was in excess this side-product was 




unsurprising. This side-product 81 was isolated and used as a coupling partner in further 
cross metatheses, with no detriment to the yield.  
 
Scheme 45. Cross metathesis of 70 and 64.  
As this reaction had only given a 40% yield of the required alkene 71, a series of different 
experiments were carried out in order to optimise conditions for this cross metathesis. 
Careful attention was paid to the concentration of the reaction mixture as the intermolecular 
reactions needed to be favoured. Most CM reactions are thermoneutral which makes 
it possible to run reactions neat or very concentrated. In this case, the best yield (53%) was 
achieved when the reaction was run at a concentration of 10 M. 
Changes in the order of addition were also explored. It was found that when the alkene in 
excess (in this case 70) was premixed with the catalyst and 64 added to the mixture, very 
low yields of the desired product 71 were obtained. Isolation of the starting materials 
showed 64 was untouched, however isomerisation of the double bond in 70 had occurred, 
as well as the product of self-metathesis 81 (scheme 45). The best yields were achieved when 
alkenes 70 and 64 were premixed and added dropwise to a stirring solution of catalyst in 
toluene at RT. 
Copper iodide has been shown not only to improve the yield of cross metatheses but also to 
increase the rate, possibly due to the iodide ion acting as a stabilising ligand on ruthenium.132 
Copper (I) acts as a phosphine scavenger which assists in the formation of ruthenium-alkene 
complexes as the phosphine ligand cannot re-associate with ruthenium in the first step of 
the catalytic cycle (scheme 25). In addition, Grubbs et al. have shown that free phosphine 
ligands quench the catalyst after a few turnover cycles, so the addition of CuI can increase 
the longevity of the ruthenium catalyst.132 However, in the reaction of 70 and 64, no 
improvement in yield or rate was observed after the addition of CuI.  
The required product alkene 71 was found to coordinate readily with the ruthenium catalyst, 
which is common in cross metatheses.133 There are many literature examples of techniques 




to circumvent this problem such as adding a water soluble phosphine ligand that coordinates 
to the ruthenium metal centre allowing the desired product to be isolated cleanly by simple 
work up procedures, or the addition of lead tetraacetate which binds strongly to the 
catalyst.134-136  In this case, flushing the column with neat ethyl acetate after collection of the 
product containing fractions was found to recover over 10% more product. 
By changing the concentration of the reaction and optimising the order of addition of the 
reagents and catalyst, alkene 71 was isolated in 53% yield with predominantly E geometry 
(scheme 46). 
 
Scheme 46. Cross metathesis of alkenes 70 and 64 following optimisation.  
In the 1H NMR spectrum of 71, the signal assigned to 10-H appeared as a double doublet of 
triplets (ddt) with coupling constants of 15.5, 8.0 and 1.0 Hz, in accordance with the main 
product of this CM having E geometry (figure 18).  
 
Figure 18. Region of 1H NMR spectrum (CDCl3, 400 MHz) showing signal assigned to 10-H.  
It was envisaged that the ruthenium benzylidene catalyst reacts with the terminal olefin of 
64 giving alkylidene 82. Alkene 70 forms a ruthenacyclobutane 83 in the anti-arrangement 
leading to the more thermodynamically stable E-alkene product 71 (scheme 47). 





Scheme 47. Proposed geometry of ruthenacyclobutane 83. 
Until relatively recently, there were not many reported methods for ensuring high trans 
selectivity in olefin metatheses. Selectivity can be achieved by long reaction times, ensuring 
that the thermodynamically favoured product (the trans olefin) is present in high 
concentrations.137-139 Grubbs and co-workers later published further work on how the 
stereochemical relationships in the ruthenacyclobutane intermediate can affect the 
resulting alkene geometry.140-141 There is experimental evidence supporting olefin binding 
trans to the NHC,140-141 causing the metallocycle to lie trans to the NHC95 favouring the trans 
olefin product on cycloreversion.  
Pleasingly, the reaction of 70 and 64 proceeded with good E/Z selectivity of approximately 
20:1. In comparison to the cross metathesis carried out by Mazzetti (scheme 39), the 
enhanced E selectivity of this reaction could be due to the bulky TBS group providing a steric 
effect. To investigate the effect of the protecting group, PMB protected alkene 60, was 
coupled with alkene 64, giving 84 in 40% yield and a 5:2 ratio of E/Z isomers (scheme 48). 
This reduction in selectivity could be due to the PMB group being less bulky than the 
corresponding TBS protected olefin 70, leading to alkene 60 being more able to bind in such 
a way that the ruthenium metallocycle lies cis to the NHC, giving rise to the cis (Z) product 
on cycloreversion.  
 
Scheme 48. Cross metathesis of 60 with 64. 
 




2.3.1 Completing the total synthesis of thioester 28 
 
Following the successful cross metathesis to form 71, the final steps of the proposed 
synthetic route (scheme 49) were carried out. The oxazolidinone auxiliary of 71 was 
reductively cleaved using LiBH4 in EtOH142 to give alcohol 85 in 88% yield (scheme 49). 
Oxidation of alcohol 85 by DMP gave aldehyde 72 in 89% yield. 
 
Scheme 49. Cleavage of the auxiliary of 71 to alcohol 85 followed by oxidation and coupling of 
aldehyde 72 and acylated auxiliary 52.  
An aldol reaction was carried out between aldehyde 72 and acylated thiazolidithione 
auxiliary 52 using TiCl4 and (-)-sparteine which gave alcohol 73 in 66% yield and as a 1:1 
mixture of diastereomers epimeric at C-7. The characteristic signals of the two diastereomers 
are shown in the 1H NMR spectrum (figure 19). 
 
Figure 19. 1H NMR showing the mixture of diastereomers of 73. The different coloured labels 
indicate the different diastereomers to which these protons belong. 
It is interesting to compare the diastereoselectivity of the two aldol reactions as shown in 












longer chain on aldehyde 72 compared with aldehyde 30 making the aldehyde too large to 
be held reliably in the rigid transition state as shown in scheme 36. The aldol reaction 
between aldehyde 30 and acylated auxiliary 52 as previously discussed (scheme 36) used 
neat TiCl4, however this reagent has since been discontinued so TiCl4 in DCM was used 
instead, which could account for the difference in selectivity.   
Using the non-chelated Felkin-Ahn model to predict the stereochemical outcome shows that 
without selectivity and chelation influencing the outcome of this reaction, the major product 
would have both methyl and hydroxyl groups on the same face, which is another factor that 
complicates achieving selectivity in this reaction. 
Due to the lack of stereoselectivity in this aldol reaction (scheme 49), and as cross metathesis 
conditions to couple alkenes 70 and 64 had been optimised (scheme 46), it was decided to 
re-investigate the original cross coupling between alkene 70 and unsaturated alcohol 54 as 
shown in scheme 50, to determine whether this reaction had failed due to incorrect 
conditions or an incompatibility of the catalyst and the substrates. 
Using the optimised conditions that had been developed in the coupling of alkenes 70 and 
64, (scheme 46), did not give rise to the required product (S)-73 as shown in scheme 50, 
which suggests this reaction failed due to the incompatibility of the substrates and the 
catalyst, rather than the conditions (solvent, concentration and temperature). 
 
Scheme 50.  The attempted cross metathesis of alkenes 70 and 54 using the optimised conditions. 
It was decided to continue the synthesis with alcohol 73 as a mixture of diastereomers as it 
was hoped that the two diastereomers epimeric at C-7 could be separated later in the 
synthesis by HPLC. Furthermore, both diastereomers would be of interest in exploring the 
substrate specificities in biotransformations. 
It was envisaged that the thiazolidithione 73 could be directly converted to the required 
substrate 28 for the biotransformations in two steps. First, the required thiol HSNAC 35 was 




synthesised in 97% yield from N-cysteamine hydrochloride 86 by reaction with Ac2O, KOH, 
NaHCO3 following a literature procedure.143 Treatment of thiazolidithione 73 with imidazole 
and thiol 35 at room temperature gave the desired thioester 87 in 62% yield after 5 h.144 The 
final step required a silyl deprotection, and while there is no literature precedence for the 
use of TBAF in the presence of an SNAC group, the use of HF.pyridine has been reported.145 
Hence, silyl ether 87 was treated with HF.pyridine at room temperature to give thioester 28 
in 77% yield (scheme 51) as a 1:1 mixture of diastereomers epimeric at C-7.  
 
Scheme 51. Final steps to give 28 as a 1:1 mixture of diastereomers. 
Analysis of 13C NMR showed the characteristic thioester and amide carbons at 199.9 and 
170.7 ppm respectively, the carbons alpha to oxygen: C-13 at 72.4 ppm and two signals for 
C-7 at 71.5 and 71.3 ppm, and the alkene carbons at 134.4 and 130.2 ppm. As mentioned 
previously, this substrate was isolated as a 1:1 mixture of diastereomers epimeric at C-7 
although this is not immediately obvious as the majority of signals in the 13C NMR overlapped 
perfectly with the corresponding carbon in the opposite diastereomer, apart from C-7. 
 





Figure 20. Region of the 13C NMR spectrum (101 MHz, CDCl3) of thioester 28.  
In summary, thioester 28 was synthesised in 11 steps (longest linear sequence) in 4.8% 
overall yield albeit as a mixture of diastereomers epimeric at C-7. Although separation of 
these diastereomers was attempted by both chiral HPLC and standard reverse phase HPLC 
conditions, the retention times proved too similar to achieve separation. It was decided to 
carry out the biotransformation studies with the hope that the diastereomer with the 
‘natural’ stereochemistry at C-7 would be recognised and turned over by MupA.  
2.4 Biotransformation studies of thioester 28 with MupA 
 
With thioester 28 in hand, investigations into the putative function of MupA as the 6-
hydroxylase could be carried out using in vivo biotransformations in E. coli. Two identical 
feeding studies and a negative control experiment (denatured enzyme boiled at 95 oC for 10 
mins) were carried out. The biotransformation mixtures (1 mL) contained 0.2 g E. coli cells 
which had been modified to contain a plasmid for MupA expression by Dr Luoyi Wang. Each 
reaction contained 100 mM potassium phosphate buffer pH 7.3, 20 mM glucose and 
thioester 28 dissolved in MeOH (100 µL) as shown in scheme 52. These were incubated at 30 
oC and shaken at 200 rpm for 24 h. After this time, the reactions were quenched by the 
addition of acetonitrile, vortexed and centrifuged. The organic layer was analysed by HPLC-
MS. 
Whole cells were used in these initial experiments as it was thought they would contain the 
relevant co-factors that MupA requires to carry out the biotransformation. After 24 h, HR-MS 
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revealed that the ester had been hydrolysed to give carboxylic acid 88 as shown in scheme 









Scheme 52. HPLC trace showing hydrolysis of thioester 28 to acid 88. 
These results showed that substrate 28 was not recognised by the system possibly due to 
the SNAC side chain not being similar enough to the native ACP and so with this in mind, 
work was started on the synthesis of 29 bearing the pantetheine side chain.  
2.5 Synthetic efforts towards substrate 29 
 
Whilst feeding studies with SNAC derivatives have been successful in investigations of 
polyketide biosynthesis,146 greater success may be achieved using the longer pantetheine 
side-chain, thus, the next goal was to prepare thioester 29.  
A new approach to the synthesis of thioester 29 was devised due to the difficulties 
experienced in achieving stereoselectivity at C-7 in the synthesis of 28.   
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Scheme 53. The proposed synthesis of 29 from 89.  
This new route involved two key disconnections, a one-pot hydroboration followed by Suzuki 
cross coupling, which introduced the stereocentre at C-8, and a thioesterification to install 
the pantetheine side-chain. This synthesis used key elements Zhao et al. described in the 
total synthesis of mupirocin H (scheme 22, page 28). 
2.5.1 Synthesis of protected unsaturated diol 99 
 
This new approach started by converting commercially available D-methionine 89 into D-
homoserine 93 using H2O and MeI followed by KHCO3 and MeOH/H2O (scheme 54). 
Treatment of D-homoserine 93 with acetic acid followed by NaNO2 forms a metastable 
diazonium intermediate, which on addition of water, releases nitrogen gas and 
dihydroxybutanoic acid is formed. Although this is a literature reaction, in my hands hydroxy 
lactone 90 was not observed by 1H NMR spectoscopy.147 
 
Scheme 54. Synthesis of hydroxy lactone 90 from D-methionine 89. 
Another approach to hydroxy lactone 90 started from commercially available L-malic acid 94 
which was protected to give acid 95 (scheme 54).147 Selective reduction of acid 95 with 
BH3.THF gave alcohol 96, which was treated with PTSA in situ. It was reported acetonide 
deprotection and spontaneous cyclisation should occur,148 however in my hands none of the 




required hydroxy lactone 90 was isolated. When alcohol 96 was treated with Dowex the 
product 90 was isolated in 5% yield.  
 
Scheme 55. The synthesis of hydroxy lactone 90 from L-malic acid 94.  
Monitoring the reaction by both 1H NMR and IR showed that reduction of acid 95 to alcohol 
96 was taking place, however after the isolation of alcohol 96, further analysis showed that 
the acetonide protecting group had been lost prior to the addition of the acid catalyst.  
Hydroxy lactone 90 is commercially available, so it was purchased, and the synthesis 
continued by protection of the hydroxyl group as the TBS ether using standard protection 
conditions (scheme 56). Addition of MeLi to hydroxy lactone 97 gave lactol 98 in 81% yield. 
Wittig conditions were used in the subsequent methylenation, however only a modest yield 
(34%) of unsaturated alcohol 99 was obtained.  
 
Scheme 56. Synthesis of alkene 99 from hydroxy lactone 90.  
Analysis of lactol 98 by 1H NMR showed that it existed exclusively as the lactol tautomer, and 
not as the ring opened methyl ketone which is the required substrate for methylenation. 
This could explain why no consumption of starting material was observed when the reaction 
was carried out at RT, as heating to reflux for 24 hours was required for this ring opening to 
take place and therefore methylenation to occur.  
Wittig reactions are also known to be sensitive to steric bulk surrounding the carbonyl group 
undergoing the reaction 149-150 and so to investigate this hydroxy lactone 90 was protected 
with the less bulky PMB protecting group using PMBTCA to give PMB ether 100 as shown in 
scheme 57. Addition of MeLi gave protected lactol 101, which was methylenated under 
Wittig conditions to give alkene 102 in 28% yield.   





Scheme 57. Synthesis of alkene 102.  
The basic character of the ylide in the Wittig reaction is known to be incompatible with some 
sensitive carbonyl-containing compounds, especially readily enolisable ketones. Many of the 
classic, widely used Wittig reagents can act to remove the acidic proton α to the carbonyl 
group making proton abstraction the dominant reaction.138 
Due to the low yields achieved using Wittig conditions (scheme 56 and 57) it was decided to 
explore other methylenation conditions. Methylenations carried out using organotitanium 
or organozirconium reagents have proven particularly useful for transformations on 
hindered or base sensitive carbonyls.151 The basicities of these species are comparatively 
weaker than Wittig salts, which enables easily enolisable substrates to be used and gives the 
desired olefins in high yields and short reaction times, while also reducing the risk of 
epimerisation taking place at enolisable asymmetric centres.152 
In 1989 Tour reported the use of a zirconium complex as a methylenating agent. Treatment 
of zirconocene dichloride with dibromomethane and zinc affords an organometallic 
intermediate 103 (scheme 58) which rapidly methylenates aldehydes, ketones, and enones 
at room temperature.152 It is seen as a milder alternative to organotitanium reagents as 
zirconium is less Lewis acidic than titanium.152 Treatment of lactol 76 with the conditions 
specified by Tour et al. gave ca. 1% yield of the desired product.152  
 
Scheme 58. The proposed mechanism for methylenation under Tour’s conditions.152  
Petasis reagent 104 (scheme 59) has been reported to be an effective methylenating agent 
for hindered carbonyls, with the active species being Schrock carbene 105 (scheme 59).153 
Once this carbene 105 has been formed, it reacts with the oxygen of carbonyl compound to 
give a hypothesised oxatitanacyclobutane intermediate 106. In the final step of the 




mechanism, this oxatitanacyclobutane 106 breaks down to give the desired olefin 107, the 
driving force of which is the high oxophilicity of Ti(IV).151  
 
Scheme 59. The proposed mechanism of methylenation using Petasis reagent.151  
Refluxing protected lactol 98 in a solution of Petasis reagent in toluene for 16 h gave 99 in 
48% yield (scheme 60), however a difficult acidic work-up procedure precluded this reaction 
being carried out on a large scale. Addition of ethanol to the reaction mixture after full 
consumption of starting material, and heating for 6 hours at 60 C followed by a simple 
filtration proved effective in removing any titanium by-products,154 and enabled this reaction 
to be scaled up effectively, giving the required alkene in 58% yield.  
 
Scheme 60. Optimised methylenation of lactol 98 to give alkene 99. 
Alcohol 99 was protected as a PMB ether 91 using PMBTCA and PPTS as shown in scheme 
61, as this was orthogonal to the other protecting group strategies used in the synthesis of 
thioester 29.  
 
Scheme 61. Synthesis of alkene 91. 




To summarise, core fragment 91 was synthesised in four steps from the commercially 
available hydroxy lactone 90 in 18% overall yield (scheme 61). Initially, Wittig conditions 
were used in the methylenation of lactol 98, however modest yields (34%) were obtained 
even when a less bulky protecting group was used. After subjecting protected lactol 98 to a 
number of different methylenation conditions, the best yield (58%) of alkene 99 was 
achieved when using Petasis reagent.  
2.5.1 Synthesis of trans vinyl iodide 108 
 
With an effective synthetic route to alkene 91 established, the next steps in this synthetic 
route involved the synthesis of trans vinyl iodide 108 required for the key Suzuki cross 
coupling. Using the synthetic route established to terminal alkene 70 in the synthesis of 
thioester 28 (scheme 43, page 42), modifications were made in order to synthesise trans 
vinyl iodide 108 from aldehyde 77 using Takai’s conditions as shown in scheme 62.155 
 
Scheme 62. Synthesis of trans vinyl iodide 108 from aldehyde 77. 
Transformation of aldehyde 77 to trans vinyl iodide 108 utilised Takai’s methodology which 
is highly selective for the formation of (E)-alkenes.155 Hodgson et al. and Takai et al. have 
proposed very similar mechanisms which explain the (E)-stereoselectivity observed in this 
reaction (scheme 63).156-157 It is proposed that iodoform is converted to a nucleophilic 
geminal dichromium complex 109 by reaction with CrCl2.  
 
Scheme 63. The proposed intermediates in the formation of trans vinyl iodides. 




The oxygen of the aldehyde coordinates to the chromium centre forming a six-membered 
pseudo-chair transition state 110 containing two chromium atoms bridged by iodine as 
shown in scheme 63. The aldehyde side-chain and the iodide occupy the sterically favoured 
equatorial positions, such that the chromium adduct 111 exists in the anti-conformation. It 
is proposed that C-C bond rotation takes place at the same time as syn elimination to give 
the trans vinyl iodide 112 as the major product. Alkenyl halides with trans geometry are 
produced almost exclusively when iodoform is used, the ratio decreasing with bromoform 
and more so with chloroform.155 The reaction of aldehyde 77 with CHI3 and CrCl2 proved to 
be very sensitive to concentration, temperature and scale. The best yield (49%) was achieved 
when the reaction was run at 0 C and 1 M concentration. Pleasingly, total control of the 
geometry was achieved (figure 21) and 1H NMR analysis of the 11-H proton (PA numbering) 
showed the coupling constant of this proton to the 10-H proton to be 14.5 Hz, which is in 
accord with a trans relationship.  
 
 
Figure 21. An excerpt from the 1H NMR spectrum of 108, showing the trans relationship between 
11-H and 10-H.  
2.5.2 Hydroboration of alkene 91 and Suzuki reaction with vinyl iodide 108 
 
With trans vinyl iodide 108 in hand, the hydroboration of alkene 91 was undertaken prior to 
the Suzuki cross coupling. Terminal alkene 91 was stirred for 16 hours with the hindered 
organoborane 9-borabicyclo[3.3.1]nonane (9-BBN), followed by the addition of water, which 
was degassed in order to eliminate any risk of catalyst poisoning in the subsequent Suzuki 




reaction. The resulting organoborane was not isolated and was used in situ with trans vinyl 
iodide 108 (scheme 64). 
Scheme 64. The hydroboration of 91 and subsequent Suzuki coupling with 108. 
Hydroborations usually proceed to give the anti-Markovnikov product with syn 
stereochemistry.158 The borane is added to the least hindered carbon, allowing the partial 
positive charge to form on the more substituted carbon as proposed by the anti-
Markovnikov rule. Houk et al. showed from computational studies using the 3-21G basis set 
that a methyl substituent at the alkene terminus away from boron lowers the activation 
energy of this transition state which is consistent with the idea that this is an electrophilic 
process, and further confirms the hypothesis that the borane attacks at the least hindered 
carbon.159 
Calculations by Houk et al. assessed the steric requirements of each group attached to a 
central carbon. They found that the largest groups had to be antiperiplanar to the forming 
bond which is clearly the least sterically hindered position. The next largest group should be 
away from the double bond “outside” the transition state, with the smallest group “inside” 
the transition state, however this does not take into account electronic effects.159 
 
Figure 22. The relative energies (kcal/mol) of the different transition state models.159 
Houk et al. went on to investigate the electronic effect of an allylic alcohol on the proposed 
transition state.159 The transition state with the lowest activation energy showed the alcohol 
“inside” the transition state, the proposed reason for this being that when the allylic CO bond 
is nearly in the plane of the alkene, it withdraws less electron density from the bond 




(compared to if it was perpendicular). If it were perpendicular, then the overlap of the  * 
with the alkene  orbital would destabilise the electrophilic transition state.  
Evans et al. explored the difference between electronic effects and steric effects on the 
different transition states. He noted that when a small boron reagent was used, transition 
state S1 was much more favoured than S2 and so the opposite facial selectivity of 
hydroboration is achieved than when using a bulky boron reagent (figure 23).160 
 
Figure 23. The difference in facial selectivity when a small (left) and a large (right) boron reagent is 
used.160 
In the case of alkene 91, the allylic alcohol is protected with a large silyl protecting group and 
a bulky organoboron reagent is used, so it is assumed that steric effects play a bigger role in 
the transition state formation than electronic effects. All of these factors rationalise the 
formation of a single diastereomer at C-8 (scheme 65). 
 
Scheme 65. The proposed transition states in hydroboration of alkene 91 to give organoborane 
114.  
With both trans vinyl iodide 108 and organoborane 114 synthesised, the Suzuki coupling was 
carried out using Pd(ddpf)Cl2 as the catalyst, to give alkene 113 with E geometry as a single 
diastereomer in 56% yield over two steps.  





Scheme 66. The Suzuki reaction between trans vinyl iodide 108 and organoborane 114. 
Since the advent of cross coupling chemistry, the Suzuki reaction has been a popular way of 
bringing together complex units. The proposed catalytic cycle proceeds as shown in scheme 
67. Oxidative addition of the vinyl iodide to the Pd(0) complex in the first step yields a stable 
trans-palladium (II) complex 115.161 
 
Scheme 67. The catalytic cycle of the Suzuki cross coupling. 
Transmetallation takes place in the next step of the catalytic cycle in the presence of a 
suitable base and ligand, in this case Cs2CO3 and AsPh3, producing a Pd (II) complex. Halogen 
exchange to the more reactive organopalladium hydroxide 116 accelerates this step. In the 
final step, reductive elimination gives 113 and regenerates the Pd(0) catalyst.161 




There are a wide range of air stable palladium catalysts that can be used in the Suzuki 
reaction such as Pd(OAc)2 and Pd(PPh3)4 which can be readily reduced to Pd(0). In this case 
Pd(dppf)2Cl2 was used as it had been used successfully in similar reactions within in the 
group.162 
In order to determine whether the protecting group on the primary alcohol of organoborane 
114 was influencing both the efficacy of the coupling and the stereochemistry of the methyl 
group at C-8, model studies were carried out using trans vinyl iodide 108 and alkenes 99 and 
119 (schemes 68 and 69). When unsaturated alcohol 99 was hydroborated using 9-BBN, and 
the resulting organoborane reacted with trans vinyl iodide 108 under the conditions shown 
in scheme 68, no reaction was observed, and vinyl iodide 108 and the organoborane were 
isolated by column chromatography. Limited studies carried out in this area have proposed 
that hydroxyl groups can form hydrogen bonds with Pd(II), reducing them to Pd(0) and 
therefore rendering the catalyst inactive.163 
 
Scheme 68.  The unsuccessful coupling of 99 and 108. 
Alkene 119 was synthesised in one step from core fragment 99 in 94% yield (scheme 69). 
When bis-TBS protected alkene 119 and trans vinyl iodide 108 were subjected to the same 
conditions as shown in scheme 66, the reaction proceeded with 89% yield and the product 
120 was isolated as single diastereomer at C-8 with the E-alkene (J 15.0 Hz) as determined 
by 1H NMR.  
 
Scheme 69. Synthesis of 120.  




The product 120 was recrystallised from petrol and although some single crystals were 
produced, the needle-like crystals were deemed to be too thin to diffract the light and so 
were unsuitable for X-ray crystallography to confirm the stereochemistry of the methyl 
group. It was decided to continue with the synthesis and compare the data of the final 
product to data from isolated natural products, which would provide confirmation of the 
stereochemistry at this position.  
2.5.3 Completion of the total synthesis of 29 
 
With both protected triols 113 and 120 in hand, the next challenge was to selectively remove 
the protecting groups on the primary alcohols to generate 92 (scheme 70).   
 
Scheme 70. The two deprotection strategies to give 92.  
First, PMB ether 113 was stirred with DDQ for 5 h at RT to give the required alcohol 92 in 
20% yield. As this was a relatively low yield, conditions were investigated to selectively 
remove the primary silyl ether of 120 in the presence of the secondary silyl ethers.164 
 
 
                   Products 
    Conditions 
                       








0.05 eq. Py.Br3, MeOH 







0.1 eq. PyBr3, MeOH 







0.005 eq. NaAuCl4.H2O 







Table 3. Different conditions used in the selective deprotection of 120.  




The best yield of required alcohol 92 was achieved when 0.05 equivalents of Py.Br3 were 
used. Jennings et al. first used these conditions when trying to recreate the work of Patel et 
al. who noted that when tetrabutylammonium tribromide (TBATB) was used in silyl 
deprotections, a primary TBS ether could be removed in a matter of minutes as opposed to 
hours for a secondary TBS ether.165 
The working hypothesis for this reaction suggests that pyridinium tribromide goes through 
the same catalytic cycle as TBATB (scheme 71). Catalytic amounts of HBr are formed in the 
first step, which protonates the TBS ether forming oxonium cation II which undergoes 
nucleophilic displacement by MeOH to give cation III, releasing the desired primary alcohol. 
In the final step the acid catalyst is reformed so the cycle can continue as shown in scheme 
71.165 
 
Scheme 71. The proposed catalytic cycle generating HBr used in silyl deprotections.165 
Although Jennings et al. specifies these conditions will selectively remove a primary TBS 
ether in the presence of a secondary TBS ether,165 achieving reproducible results in the 
deprotection of protected triol 120 proved challenging. When 0.1 equivalents of the catalyst 
were used under literature conditions as shown in scheme 72, monoprotected triol 122 was 
isolated as the major product (75% yield). Using 0.05 equivalents of the catalyst gave 
exclusively the desired product in 40% yield, however this proved to be irreproducible. 





Scheme 72. Deprotection of TBS ether 120 to monoprotected alcohol 122. 
As it was proving difficult to achieve selectivity for the mono-deprotected alcohol 92 from 
silyl ether 120, optimisation of the deprotection of PMB ether 113 using DDQ was carried 
out as shown in scheme 73. It was found that when by adding 5% pH 7 buffer to the solvent 
mixture, the yield of alcohol 92 increased to 50%.166 
 
Scheme 73. The optimised deprotection of PMB ether 113 to alcohol 92. 
To complete the total synthesis of 29, oxidation of alcohol 92 with TEMPO/BAIB in 
MeCN/H2O was carried out which gave aldehyde 123 in 62% yield (scheme 74). Aldehyde 
123 was then oxidised with Oxone which not only converted aldehyde 123 to a carboxylic 
acid, but also removed one of the silyl protecting groups to give 124, which was not 
surprising as Oxone is a known silyl deprotecting agent.167 
 
Scheme 74. Oxidation of alcohol 92 to acid 124 via aldehyde 123.  
Protected pantetheine 127 was synthesised in two steps by first treating commercially 
available calcium D-pantothenate 125 with PTSA in acetone to give protected pantothenic 
acid 126, which was coupled to N-cysteamine hydrochloride 35 in the presence of 
carbonyldiimidazole (CDI) to give the desired product 127 in 75% yield (scheme 75). Coupling 
of acid 124 with protected pantetheine 127 in the presence of EDCI/DMAP proceeded 
cleanly, and following silyl deprotection, gave the required product 29 in 92% yield. 





Scheme 75. Coupling and final deprotection to give thioester 29.  
The second substrate for biotransformation studies, thioester 29, was synthesised in 12 
longest linear steps and 3.3% overall yield. Pleasingly, all four stereocentres were set with 
total stereocontrol. 
2.6 Biotransformation studies of pantetheine linked substrate 29 with MupA 
 
Biotransformation studies with substrate 29 and MupA were carried out using the same 
methodology as discussed in section 2.4 (page 49). Substrate 29 was incubated with E. coli 
whole cells expressing MupA at 30 C and shaken at 200 rpm for 24 hours. After this time, 
the reaction was quenched by addition of acetonitrile, vortexed and centrifuged. LCMS-MS 
analysis of the organic extract revealed that thioester hydrolysis had occurred to produce 
acid 66 (scheme 76).  
 
Scheme 76. Hydrolysis of thioester 29 to give acid 88.  




2.6.1 Upgrade of substrate 29 onto mmpD-ACP-4 
 
As both substrates, thioester 28 and pantetheine 29, had not been turned over by MupA, it 
was decided to carry out work to install the full ACP side chain onto thioester 28. It was 
hypothesised that this transformation takes place on the final ACP in mmpD (mmpD-ACP-4) 
as shown in figure 24 and therefore thioester 29 was upgraded onto this ACP as shown in 
scheme 77. This work was undertaken by Dr Ash Winter of the Crump group in Bristol.  
 
Figure 24. The final ACP in mmpD and the proposed site of 6-hydroxylation (red circle). 
This process was carried out by adding an excess of thioester 29 to the desired ACP (mmpD-
ACP-4). Magnesium was added in the form of hydrated MgSO4 as a stock solution in water 
as this is required by MupN – a phosphopantetheinyl transferase. Co-enzymes A, D and E 
were added, which upgraded the substrate onto CoA. This chain extended substrate was 
then loaded onto the ACP by MupN using ATP (scheme 77).  
 
Scheme 77. Upgrade of substrate 29 onto mmpD-ACP-4.  




The mechanism of the 6-hydroxylation, catalysed by MupA, is proposed to proceed as shown 
in scheme 78. Reduced flavin FMNH2, reacts with molecular oxygen to generate the stable 
flavin-peroxide intermediate (Criegee intermediate). Following hydroxylation of the 
substrate, a hydroxy-flavin adduct is produced which is dehydrated to regenerate FMN. 
 
Scheme 78. The proposed mechanism for 6-hydroxylation of substrate 104.  
When substrate 12 was incubated with MupA, FMNH2 and NADPH in the presence of O2, 
none of the expected 6-hydroxylated material 128 was observed. An NMR assay, carried out 
by Dr Winter, showed no apparent interaction of MupA with mmpD-ACP-4, indicating that 
MupA was not acting on that ACP, as the interaction between the two proteins (MupA and 
mmpD-ACP-4) should be visible by NMR (figure 25). 





Figure 25. NMR assays of mmpD-ACP-4 (left) and after the addition of MupA (right). 
This type of NMR assay is designed to show protein-protein interactions. If there was 
interaction between the two proteins, the signals in the spectra would be expected to shift 
or disappear on addition of one to the other. If there is no interaction, then there is no 
change in the position or number of signals. Although this is not a quantitative indication of 
how much two proteins interact, it is indicative of an interaction. From these NMR spectra 
(figure 25), it was clear that no significant changes are seen upon the addition of MupA to 
mmpD-ACP-4, which indicates there is not an interaction between these two proteins and 
that the transformation was not taking place on mmpD-ACP-4. 
As 6-hydroxylation was not taking place on mmpD-ACP-4, the timing of this transformation 
was reconsidered. Another potential location for the 6-hydroxylation was the first ACP of 
mmpA (mmpA-ACP-1) as shown in figure 26. 





Figure 26. The final modules of mmpD and the first module of mmpA, with the two ACPs used in 
the experiments highlighted. 
Before the upgrade of substrate 29 onto this ACP, an NMR assay of MupA with mmpA-ACP-1 
was carried out by Dr Winter (figure 27). The spectrum in blue shows mmpA-ACP-1, while 
the spectrum in red was recorded after the addition of MupA. It can be seen that there are 
significant differences between the two spectra which is indicative of an interaction between 
mmpA-ACP-1 and MupA.  
 
Figure 27. NMR assays of mmpA-ACP-1 (left) and after the addition of MupA (right) carried out by 
Dr Winter. 




Encouraged by this positive interaction, substrate 29 was loaded onto this ACP by Dr Winter 
using the same conditions as discussed previously as shown in scheme 79.   
 
Scheme 79. The upgrade of substrate 29 to mmpA-ACP-1.  
When bioassays were carried out by Dr Winter of substrate 13 with MupA, again no turnover 
by the enzyme was seen. Work is currently ongoing to determine exactly the conditions 
needed for this biotransformation.  
2.7 Conclusion 
 
The total synthesis of thioester 28 was achieved in 11 longest linear steps and 4.9% overall 
yield albeit as a mixture of diastereomers epimeric at C-7. The key steps involved a cross 
metathesis of terminal olefins 70 and 64 to introduce the alkene bond with excellent control 
of the (E) double bond geometry. An aldol reaction installed the alcohol at C-7 and provided 
a handle for thioesterification.  
 
Scheme 80. The completed synthesis of 28.  




Model studies of the aldol reaction between aldehyde 30 and thiazolidithione auxiliary 52 
were shown to proceed with complete stereocontrol (scheme 81), however when these 
conditions were applied to aldehyde 72, a 1:1 mixture of diastereomers of unsaturated 
alcohol 73 was achieved. Although this was disappointing, the Felkin-Ahn transition state 
model, predicted selectivity for the opposite diastereomer to the one that was required and 
so perfect diastereoselectivity would be very difficult to achieve in this reaction.  
 
Scheme 81. Aldol reaction giving unsaturated alcohol 54 as a single diastereomer. 
This synthetic route included a key cross metathesis step between terminal alkenes 70 and 
64, which was optimised and pleasingly gave the desired olefin in 58% yield. This cross 
metathesis did not take place in the presence of the thiazolidithione auxiliary, even under 
optimised conditions as shown in scheme 82. 
 
Scheme 82. The cross metathesis of 70 and 54 under optimised conditions.  
Following the completion of the synthesis, bioassays of this substrate in E. coli expressing 
MupA were carried out, however the desired 6-hydroxylated material was not seen by HPLC 
and instead hydrolysis occurred to give acid 88.  
 
Scheme 83. Hydrolysis of thioester 28 to give carboxylic acid 88.  




The total synthesis of 29 was completed in 11 longest linear steps with 3.3% overall yield. 
The key disconnections included: a hydroboration which installed the stereocentre at C-8, a 
Suzuki cross coupling which installed the E-alkene, and a thioesterification which installed 
the pantetheine side-chain.  
 
Scheme 84. Total synthesis of 29. 
After the initial difficulty in synthesising hydroxylactone 90, it was purchased enabling the 
stereocentre at C-7 to be set from the starting material. The low yielding methylenation step 
was optimised by the use of Petasis reagent which gave alkene 99 in 58% yield as shown in 
scheme 85. 
 
Scheme 85. The optimised methylenation to give 99. 
The hydroboration of unsaturated alcohol 91 gave a single diastereomer at the C-8 position, 
which was rationalised by applying Houk’s modelling studies (page 57) to the two possible 
transition states as shown in scheme 86.   





Scheme 86. Transition state models for the stereoselective hydroboration. 
Following the final steps in the synthesis, substrate 29 was used in enzyme assays in E. coli 
expressing MupA however none of the required 6-hydroxylated material 129 was isolated as 
shown in scheme 87.  
 
Scheme 87. The expected product 129 from bioassays with MupA. 
Again, thioester 29 was hydrolysed to give carboxylic acid 88. Due to the substrate not being 
turned over, it was decided to upgrade the substrate onto mmpD-ACP-4 as shown in scheme 
77. Biotransformation studies were carried out by Dr Winter, however none of the desired 
product was observed by MS. An NMR assay of mmpD-ACP-4 and MupA showed no 
interaction, which led to the re-evaluation of the timing of 6-hydroxylation in the 
biosynthetic pathway. A similar NMR assay of MupA and mmpA-ACP-1 showed there to be 
an interaction between these two proteins and so substrate 29 was upgraded onto this ACP 
to give 13. Biotransformation studies of substrate 13 with MupA showed none of the desired 
6-hydroxylated to be present.  




It is known that luciferase type monooxygenases have a low affinity for FMN and instead 
interact with the reduced form FMNH2, which is why the presence of this species is crucial 
for the desired transformation. In order to achieve this reduced state, it is believed a co-
reductase is acting, however at present this has not been identified in the mupirocin gene 
cluster. The reductase used in the experiments described in this chapter has been isolated 
from E. coli, however there is concern that this reductase is not working on this specific 
system. In order to probe this reductase further, work is ongoing to determine its activity 
level on NADH with different levels of aeration.  
Work is currently being undertaken to determine whether oxygen concentration is inhibiting 
the process. In the presence of atmospheric levels of O2, it is thought that the reduced 
FMNH2 is being oxidised to FMN which is known to not interact with MupA, however O2 is 
needed in order to form the Criegee intermediate and so work is currently being undertaken 
to carry out these bioassays in a carefully controlled atmosphere.  
Another avenue of interest is the oligomeric state of MupA. Previous purification of MupA 
showed it to exist as a dimer, which is in agreement with other luciferase monooxygenases, 
however it has now been determined that this depends on concentration. At higher 
concentrations it has been noted that MupA exists as a tetramer, which is thought to 
inactivate MupA by making its active site inaccessible. Further work is needed to determine 
whether the concentration of MupA plays a role in the efficacy of the 6-hydroxylation. A 
crystal structure of MupA as a monomer or dimer would be highly valuable and to that end 
initial crystallography studies have commenced. By mapping the active site of MupA, more 



















CHAPTER 3: Investigating the 
specificities of MupW and MupZ 




3. Chapter 3 
3.1 Introduction 
One of the most interesting transformations that takes place in the late stage biosynthesis 
of the pseudomonic acids is the formation of the tetrahydropyran (THP) ring from an 
unactivated methyl group, which would be very challenging to achieve synthetically. This 
transformation will be discussed in detail in this chapter. 
 
Scheme 88. The proposed transformation of linear substrate 130 to desepoxy PA-B 11. 
3.1.1 Gene knockout experiments with the ΔmupW mutant 
 
It was initially proposed that MupW, a Rieske non-haem oxygenase and its ferredoxin 
partner MupT, were responsible for the formation of the THP ring in the biosynthetic 
pathway.36 ΔmupW gene knockout experiments in P. fluorescens gave mupirocins W1 133 
and W2 134 as shown in scheme 89 B. It was hypothesised that these products arise from 
spontaneous intramolecular attack of the 7-hydroxyl group onto C-10, opening the epoxide 
and forming inactive bicyclic compounds as shown in scheme 89.36 
 
Scheme 89. A: The structure of PA-A and HPLC trace of ΔmupW gene knockout experiments. B: 
Mupirocin W1 133 and W2 134 produced from the spontaneous cyclisation of expected products 
131 and 132.36 




A fifth multifunctional modular protein mmpEOR, which acts to install the 10,11-epoxide, 
was subsequently identified.19 It was hypothesised that gene knockout experiments with the 
mmpEΔOR mutant would produce metabolites lacking this epoxide and so would prevent 
the formation of the shunt products mupirocins W1 133 and W2 134 (scheme 89 B), while 
giving a more accurate insight into the function of MupW and MupT. Indeed, mmpEΔOR gene 
knockout experiments in P. fluorescens gave PA-C 6 rather than PA-A 4 as evident from the 
HPLC trace (scheme 90 A).168 
The double mmpEΔOR/ΔmupW mutant produced desepoxy mupirocin W4 130 and W5 136 
in very low titres as shown in scheme 90 A, which supported the proposal that MupW was 
involved in the formation of the THP ring.36 Desepoxy mupirocin W4 isolated from the 
mmpEΔOR/ΔmupW gene knockout experiment was incubated with E. coli expressing MupW, 
which led to the isolation of a product with the expected mass of the THP product desepoxy 
PA-B 11, however structural elucidation by 1D and 2D NMR revealed that the product 
contained a five-membered ring, mupirocin Z1 137 (scheme 90 B).36 
 
Scheme 90. A: HPLC trace of mmpEΔOR gene knockout experiments producing PA-C 6 and 
mmpEΔOR/ΔmupW gene knockout experiments producing desepoxy mupirocin W4 130 and W5 
136. B: Isolation of THF mupirocin Z1 137 from desepoxy mupirocin W4 130. 
To gain further insight into the unexpected formation of this THF product 137, Dr Bakar 
prepared alkene 138 for use in model studies (scheme 91).168 When this alkene was reacted 
with mCPBA, no epoxide 139 was detected as it was rapidly transformed to the five 




membered tetrahydrofurans 140 and 141 (scheme 91). Therefore, it was proposed that 
mupirocin Z1 137 was being formed from spontaneous cyclisation of an 8,16-epoxide.89, 168 
Scheme 91. Model studies gave two tetrahydrofurans 140 and 141.89, 168 
To investigate whether mupirocin Z1 137 was an intermediate in the biosynthesis of the 
pseudomonic acids, it was fed to cultures of the mmpEΔOR/ΔmupW mutant of P. 
fluorescens, however only starting material was observed. In contrast, when desepoxy PA-B 
11 was fed to cultures of this mutant it was transformed to PA-C 6 (scheme 92), which led to 
the conclusion that substrates bearing the THF ring are not intermediates in the pathway, 
but arise from spontaneous cyclisation of a proposed epoxide intermediate.168 
Scheme 92. Transformation of desepoxy PA-B 11 to PA-C 6 in cultures of mmpEΔOR/ΔmupW 
mutant of P. fluorescens. 
It was therefore proposed that an epoxide is formed from the 8-methyl group of 130 
catalysed by MupW, and that a second enzyme is required to effect 6-endo cyclisation to 
give THP 11. It is important to note that there is much discussion over the use of ‘endo’ in 
these types of cyclisation, as the bond breaking is outside of the newly formed ring. Another 
way of describing this is the use of ‘fused’ when describing the transition state, however 
both terms are used in the literature interchangeably.169 From sequencing the mupirocin 
gene cluster, MupZ had not been assigned a function and so was proposed to have a role in 
this transformation as a possible epoxide hydrolase. Biotransformation studies were carried 
out with desepoxy mupirocin W4 130 in E. coli expressing both MupW and MupZ, to 
determine whether MupZ was the missing epoxide hydrolase (scheme 93). 





Scheme 93. Transformation of desepoxy mupirocin W4 130 to desepoxy PA-B 11 catalysed by 
MupW and MupZ.168 
Pleasingly this substrate 130 was turned over and desepoxy PA-B 11 was isolated by 
preparative HPLC and the structure confirmed by 1D and 2D NMR (scheme 93). These results 
demonstrated that MupW catalyses the oxidation of the unactivated 8-methyl group of 130, 
while MupZ is an epoxide hydrolase which catalyses a 6-endo-tet cyclisation of a putative 
8,16-epoxide 142 (scheme 94).168 
 
Scheme 94. Proposed epoxide intermediate 142 undergoing spontaneous cyclisation to give THF 
137 in the absence of MupZ, which catalyses the formation of the THP product 11. 
X-ray crystallographic studies were undertaken of MupZ, revealing that it is a symmetric 
homodimer (figure 28, A). The structure comprises five antiparallel β-pleated sheets 




Figure 28. X-ray structure of MupZ (A) and a model of the active site of MupZ binding epoxide 142 
(B).168  
A B 




Molecular modelling studies were also undertaken on MupZ with docking of the proposed 
epoxide intermediate 142. Two key amino acid residues in the active site, Tyr41 and Glu54 
were identified. It was hypothesised that these are involved in an acid-base mechanism 
whereby Glu54 deprotonates the 5-OH, while Tyr41 protonates the epoxide oxygen, 
subsequently stabilising the developing transition state. In this way the desired THP ring 
product is produced as shown in scheme 11.168 A model of this interaction is shown in figure 
28 (B). 
 
Scheme 95. The interaction of the acid base pair Tyr41 and Glu54 in the active site of MupZ.168 
Mutagenesis experiments gave the point mutants MupZ-Y41F and Mupz-E54Q. 
Co-expression of MupW with either of the point mutants in E. coli, followed by incubation 
with desepoxy mupirocin W4 130 led to the formation of the five-membered ring product 
137 (scheme 96), in contrast to the THP product produced by WT-MupW/Z.168 These results 
are in accordance with the proposed catalytic dyad involved in a 6-endo cyclisation of 
epoxide 142. 
 
Scheme 96. Incubation of mupirocin W4 130 with MupW and the point mutant MupZ-Y41F.168 
Further studies are currently being undertaken to prove the existence of an epoxide 
intermediate and its mechanism of formation catalysed by MupW.  
 




3.1.2 Previous substrate specificity studies on MupW and MupZ 
 
To probe the substrate specificity of both MupW and MupZ, a number of substrates were 
used in whole cell bioassays with E. coli expressing MupW and MupZ, the products of which 
were analysed by LCMS and their structures elucidated by NMR.89 It has been shown that 
unknown enzymes contained within the blank E. coli cells are responsible for the selective 
oxidation of the primary alcohol to the corresponding acid (scheme 97); this was fortuitous 
as it obviated the need to carry out this selective transformation chemically. 
 
Scheme 97. Oxidation of desepoxy mupirocin W4-OH 27 by blank E. coli cells.89 
Desepoxy mupirocin W4-OH 27, synthesised by Dr Bakar, was incubated with E. coli co-
expressing MupW and MupZ and was shown to be fully converted to desepoxy PA-B 11 and 
desepoxy mupirocin W4 130 in a 3:1 ratio after 16 hours, which strengthened the working 
hypothesis that 130 is the precursor to desepoxy PA-B 11 (scheme 98).  
 
Scheme 98. Formation of THP 11 and acid 130 from incubation of desepoxy mupirocin W4-OH 27 
with E.coli co-expressing MupW and MupZ. 
Further studies have been aimed at investigating the substrate specificities of enzymes 
involved in this cascade process. Substrates 143 and 144, synthesised by Dr Bakar, both bear 
a ketone at C-13 and 144 also has the unnatural (S) stereochemistry at C-12 (scheme 99). 
When these substrates were incubated in E. coli expressing MupW/Z, THP products were not 
observed by MS, although both substrates were oxidised to the corresponding acids 145 and 
146 by E. coli. 





Scheme 99. Incubation of ketones 143 and 144 with MupW/Z in E. coli carried out by Dr L Wang. 
When alkenes 147 and 148 with truncated side-chains, synthesised by Dr Bakar, were 
incubated with E. coli expressing MupW, both were oxidised to the corresponding carboxylic 
acids 149 and 150, but no ring formation was apparent (scheme 100).89 
 
Scheme 100. Incubation of alkenes 147 and 148 in E. coli expressing MupW/Z carried out by Dr L 
Wang.89 
The effect of changes to the structure of the core (C5-C9) of desepoxy mupirocin W4 130 
were also investigated. Ketone 151, isolated from the KR6 mutant,54 alcohol 153, isolated 
from the DH4 mutant,54,89 and alcohol 155 with unnatural stereochemistry at C-5, 
synthesised by Joe Barker, were incubated with E. coli expressing both MupW and MupZ, 
however only alcohol 155 was turned over to give the ring closed product 156. 
 
Scheme 101. Bioassays of ketone 151 and alcohols 153 and 155 with MupW/Z in E. coli carried out 
by Dr L Wang. 




In addition, analogues of desepoxy mupirocin W4 with varying chain lengths (n=4,6), isolated 
from gene knockout experiments with the mupW mutants, were also used in the 
biotransformations and pleasingly were all accepted and turned over by MupW and MupZ 
(scheme 102). 
Scheme 102. Formation of THP 159 and 160 from incubation of analogues of desepoxy mupirocin 
W4 157 and 158 with MupW and MupZ. 
From these experiments it is clear that the biocatalytic system is very particular as to what 
structural modifications will be tolerated. Substrates modified in the C9-C14 portion were 
oxidised (primary alcohols to carboxylic acids) but not cyclised, whilst changes to the fatty 
acid chain length had no effect on the efficacy of MupW or MupZ. From experiments with 
the C-7 ketone 151 (scheme 101), it is hypothesised that a hydroxyl group is required at that 
position for formation of the THP ring to occur. 
3.1.3 Project aim 
 
The aim of this project was to prepare tetraol 161, which retains all the structural features 
of desepoxy mupirocin W4-OH 27 except the 6-hydroxyl group. This was required to examine 
further the substrate specificities of MupW and MupZ as well as to give a new substrate with 
which to explore 6-hydroxylation.  
 
Figure 29. The structure of the target substrate 161. 
3.2 Retrosynthesis of tetraol 161 and vinylogous Mukaiyama aldol reactions 
 
Having developed an efficient route to thioester 29 in the investigations involving MupA 
(chapter two), it was decided to apply elements of this route to the synthesis of substrate 
161. By utilising the same key Suzuki disconnection that was used previously in the synthesis 
of 29, it was envisaged the route to substrate 161 could be modified to include a key 




Mukaiyama aldol to install the fatty acid side chain, whilst also controlling the stereocentre 
at C-5. 
 
Scheme 103. Proposed route for the synthesis of substrate 161 from protected triol 113.  
The synthesis of protected triol 113 will not be discussed in this chapter due to the detailed 
discussion of the synthetic approach to this key intermediate in chapter two.  
Vinylogous Mukaiyama aldol reactions (VMARs) are valuable transformations in the 
synthesis of polyketides and allow large portions of polyketide backbone to be added to 
substrates, whilst also introducing a new stereogenic centre.170-173 By reacting an aldehyde 
with an O-silylated ketene acetal in the presence of either a Lewis acid or a chiral ligand 
excellent stereoselectivity can be achieved. Scheme 104 shows an example of this carried 
out by Kalesse et al., utilising a boronate Lewis acid with excellent stereocontrol.170 
 
Scheme 104. A vinylogous Mukaiyama aldol reaction carried out by Kalesse et al.170 
The Lewis acid coordinates to the oxygen atom of the aldehyde making the carbon centre 
more susceptible to nucleophilic attack by the O-silylated ketene acetal. These species have 
been shown to be much more nucleophilic at the γ-position than the α-position, as opposed 
to metal dienolates, which are nucleophilic at the α-position (figure 30).170 
 





Figure 30. The electrophilic susceptibility of different positions in metal dienolates compared with 
O-silylated ketene acetals.170 
This was confirmed by using molecular orbital electron density calculations.174 The HOMO 
coefficient and the electrophilic susceptibility value at the γ-position in O-silylated ketene 
acetal 166 is higher than at the α-position; a kinetic preference for the γ-addition product is 
therefore predicted. On the other hand, metal dienolate 165 displays a larger HOMO 
coefficient and electrophilic susceptibility value at the α-position than at the γ-position, and 
so the product of α-addition is favoured.  
There is extensive literature precedent for selective 1,2-syn and anti VMARs through Felkin 
controlled addition of silyl ketene acetals to chiral α-substituted aldehydes.175-180 Aldehyde 
123 lacks an α-stereocentre, and so controlling the stereo-outcome of the Mukaiyama aldol 
reaction in the synthesis of tetraol 161 could prove to be challenging. There is limited 
literature precedence for the formation 1,3-anti products, however in the total synthesis of 
swinholide A, a polyketide derived antifungal agent, selectivity for the 1,3-anti product 
aldehyde 168 was achieved using BF3.OEt2 as the Lewis acid, with 72% de.181 
 
Scheme 105. The VMAR in the total synthesis of swinholide A.181 
In the total synthesis of desepoxy mupirocin W4-OH 27, Bakar reported that silyl dienol ether 
171 was successfully coupled to aldehyde 170 giving products 172 and 173 with high de 
under the conditions shown in scheme 106.89 





Scheme 106. The Mukaiyama aldol reaction carried out by Dr Bakar.89 
The conditions for this reaction were first reported by Zhao et al. in the total synthesis of 
mupirocin H.88 Zinc iodide is used as the Lewis acid as these conditions are mild enough to 
retain the acetonide protecting group and have been widely reported to give the desired 
stereochemical outcome in 1,2-directed vinylogous Mukaiyama aldol reactions.88, 182 The 
stereochemistry of 172 and 173 can be rationalised by the transition state model shown in 
scheme 106. It is proposed that the zinc coordinates to the carbonyl oxygen and the C-7 
oxygen in a 1,3- fashion. The Felkin-Ahn model shows that attack is then favoured at the Si 
face aldehyde 170, generating the desired stereochemistry at C-5.  These conditions could 
be applied to aldehyde 123 and silyl dienol ether 171 in the synthesis of substrate 161. 
3.3 Results and Discussion 
3.3.1 Synthesis and coupling of aldehyde 123 and silyl dienol ether 171 
 
First, syntheses of the required coupling partners aldehyde 123 and silyl dienol ether 171 
were carried out. Protected triol 113 was selectively deprotected using DDQ to give the 
primary alcohol, which was then oxidised with DMP to give aldehyde 123 (scheme 107). 
 
Scheme 107. Synthesis of aldehyde 123. 
The synthesis of silyl dienol ether 171 began with the mono-protection of 1,9-nonanediol 
with PMBCl, NaH and TBAI in a DMSO/THF mixture to give alcohol 174. This was coupled 




with commercially available 3,3-dimethylacrylic acid 175 via a Steglich esterification183 to 
give ester 176 in 84% yield (scheme 108). The synthesis of ester 176 was straightforward and 
high yielding, however formation of silyl dienol ether 171 proved challenging and 
irreproducible. Silyl dienol ether 171 was unstable on silica, and therefore with challenges 
associated with purification, it was vital to achieve full conversion of starting material 176 to 
product 171. After optimisation, it was found that an excess of TMSCl and LDA was needed 
in order to give pure silyl dienol ether 171 in 95% yield.  
 
Scheme 108. Synthesis of silyl dienol ether 171.  
With both aldehyde 123 and silyl dienol ether 171 in hand, the VMAR between these 
coupling partners was investigated using zinc iodide at both -10 °C and RT (scheme 109), 
however, the reaction was unsuccessful and unreacted aldehyde 123 and ester 176 were 
isolated following column chromatography. 
 
Scheme 109. Attempted Mukiayama aldol reaction of aldehyde 123 and silyl dienol ether 171.  
In the synthesis of desepoxy mupirocin W4-OH 27, the 6,7-diol of aldehyde 170 had been 
acetonide protected (scheme 106), whereas in aldehyde 123 there was a TBS ether at C-7, 
hence it was hypothesised that the reaction was unsuccessful due to the bulk of this silyl 
protecting group. Thus it was deemed necessary to remove the silyl protecting groups of 
aldehyde 123, however when this was attempted using HF.pyridine, degradation occurred 
(scheme 110).  
 
Scheme 110. The attempted deprotection of 123. 




A different deprotection strategy was investigated. Stirring alcohol 92 with 10 equivalents of 
TBAF for 24 h gave monoprotected triol 121. It was proposed that the primary alcohol could 
be selectively oxidised to aldehyde 178, which would then be used in a VMAR with silyl dienol 
ether 171 to give alcohol 179 and silyl ether 180 (scheme 111). 
 
Scheme 111. Selective deprotection of silyl ether 92 gave alcohol 121.  
There is literature precedence for the selective oxidation of a primary alcohol in the presence 
of a secondary alcohol using TEMPO/BAIB as the oxidants.184 When 121 was subjected to 
these conditions, a number of products were isolated as shown in scheme 112. The desired 
product aldehyde 178 was isolated in 5% yield, while the major product 181 was the result 
of oxidation of the secondary alcohol. In addition, an oxetane product 182 was also isolated, 
which is formed from attack of the primary alcohol into the ketone. 
 
Scheme 112. Attempted selective oxidation of diol 121. 
Owing to the difficulties in synthesising aldehyde 178, it was decided to return to the VMAR 
between aldehyde 123 and silyl dienol ether 171 using a different Lewis acid catalyst. 
Trispentafluorophenyl borane (TPPB) is a strong Lewis acid which has been shown to be 
compatible with silyl protecting groups, so this was used in the reaction as shown in scheme 
113.173  When aldehyde 123 and silyl dienol ether 171 were mixed with TPPB at -78 C for 1 
h, complete consumption of starting material was seen and a 1:1 mixture of C-5 epimers, 
183 and 184 were isolated, which were inseparable by chiral, reverse and normal phase 
HPLC. The formation of the unnatural diastereomer was not surprising due to the difficulty 




in controlling the stereochemistry as discussed in section 3.2 (page 83). However, its 
synthesis was fortuitous as feeding studies with the ‘unnatural’ epimer at C-5 had the 
potential to give greater insight into the specificities of MupW and MupZ, than feeding 
studies with tetraol 161 alone. To this end, the synthesis was continued with the hope that 
these diastereomers could be separated at a later stage.  
 
Scheme 113. Mukaiyama aldol conditions to give alcohol 183 and silyl ether 184, both as a 1:1 
mixture of diastereomers.  
3.3.2 Completing the total synthesis of substrates 161 and 187 
 
To complete the synthesis of the target tetraols 161 and 187, it was necessary to remove the 
silyl protecting groups. The mixture of esters 183 and 184 were treated with 2 M HCl in THF, 
however this resulted in low yields and poor mass recovery of the required triols 185 and 
186 as the expected mixture of diastereomers. Hence, 183 and 184 were treated with a 
catalytic amount of Py.Br3 (0.1 equivalents) in MeOH which gave a 1:1 mixture of 185 and 
186 in 85% yield as shown in scheme 114.  
 
Scheme 114. Silyl deprotection of 183 and 184 to give a 1:1 mixture of diastereomers 185 and 186.  
The two diastereomers 185 and 186 were separated by column chromatography and 
deprotected with DDQ at pH 7 in DCM to give both tetraols with natural 161 and unnatural 
187 stereochemistry at C-5 in 58% and 63% yield respectively (scheme 115). 









Scheme 115. Separation of 186 and 187 followed by deprotection to give 161 and 187.  
At this stage it was not possible to conclusively assign the stereochemistry of each epimer, 
so it was decided to continue with the biotransformation studies with the hope that the 
stereochemistry could be assigned retrospectively by comparison of the products of these 
bioassays, to those previously isolated from mupA knockout experiments (section 1.8.2). 
By comparing the NMR spectra (figure 31) of substrates 187 and 161, the significant 
difference in shift of the 5-H and 7-H protons is evident.  
 
 














3.4 Biotransformation studies of substrates 161 and 187 with MupW/Z in E. coli 
 
The use of (un)natural in a scheme in this section denotes the (un)natural stereochemistry 
at C-5 compared to the natural product. With the two substrates in hand, biotransformation 
studies were carried out to determine the specificities of MupW and MupZ in E. coli. 
Pleasingly the primary alcohol of 161 was oxidised to acid 188 by E. coli, and the 
corresponding acid turned over after 24 h to give expected THP product 24 (scheme 116).  
 
Scheme 116. Biotransformation of tetraol 161 to THPs 189 and 24 and acid 188. 
Interestingly, a small amount of THP 189 possessing the primary alcohol was isolated by 
preparative HPLC and the structure elucidated using 1D and 2D NMR. This result suggested 
that it is not necessarily a prerequisite for the primary alcohol to be oxidised before MupW 
and MupZ can act to form the THP ring. The expected THP 24 was also isolated by preparative 
HPLC and the structure elucidated by 1D and 2D NMR. Comparison of the 1H NMR spectra of 
alcohol 161 with acid 188 (figure 32 A) showed there to be a disappearance of the protons α 
to the primary alcohol (1’-H2) at δ 3.60 ppm and the appearance of a new triplet (2’-H2) at δ 
2.45 ppm consistent with an oxidation having occurred. To confirm the stereochemistry at 
C-5 and C-8 of substrate 161, the 1H and 13C NMR data of THP 24 were compared with data 
from the same compound isolated from gene knockout experiments with the ΔmupA mutant 
as discussed in chapter one (page 25). Pleasingly, the data from both the 1H (figure 32 A) and 
13C NMR (figure 32 B) for product 24 matched the spectra of the isolated metabolite, which 
validated our hypothesis that the hydroboration of alkene 91 (scheme 65, page 58) would 
give the (S)-stereochemistry at C-8 and that substrate 161 had the natural stereochemistry 
at C-5 (5S). 
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Figure 32. A: Comparison of isolated products 189 and 24 B: 13C NMR of 24 compared with 24 









16 h  484 
The natural substrate 161 (m/z 456) was also incubated with E. coli expressing MupW, and 
pleasingly, the primary alcohol was oxidised, and ring closure occurred to give the expected 
THF product 190 with m/z 484 after 16 h (scheme 117). This product was isolated by 






Scheme 117. HPLC trace of the incubation of tetraol 161 in E. coli expressing MupW to give THF 
190. 
Both the THF 190 and THP 24 products isolated from the biotransformations shown in 
scheme 118 have the same mass and so are difficult to differentiate between using mass 
spectrometry alone. In this way, NMR is the gold standard for identifying metabolites from 
biotransformations (figure 33). 
 
Scheme 118. Biotransformation of 161 to THF 190 and THP 24. 
The disappearance of the methyl group at 0.90 ppm (8-CH3) was the first indicator that a 
transformation had taken place (figure 33). Analysis of the HMBC and HSQC spectra of THP 
456 




24 showed there to be a correlation between 16-H2 and 5-H, which gave evidence for the 
proposed structure being correct. No such correlation was seen in the 2D spectra of THF 190.  
 
Figure 33. 1H NMR spectra (700 MHz CD3OD) of THF 190 and THP 24 isolated from the incubation of 
substrate 161 in E. coli expressing MupW or MupW/Z, compared with tetraol 161.  
Next the unnatural 5-epimer 187 was incubated with E. coli expressing MupW and MupZ 
(scheme 119). The major product after 24 hours was the product of oxidation, carboxylic acid 
192. Two further peaks were apparent by HPLC and each was isolated. The peak with a 
retention time of 12.4 mins had m/z 484 and was tentatively assigned as cyclic product 191, 
while the peak with a retention time of 12.9 mins gave mass 468 and was tentatively 
assigned as alkene 193, however there was insufficient material of both, for them to be 











               







Scheme 119. Biotransformation of 187 to 191 and HPLC trace of this transformation.  
It was proposed that alkene 193 may be an intermediate to epoxide 194 generated by 
MupW, whilst MupZ would catalyse the cyclisation of this intermediate to the THP. Hence a 
biotransformation was carried out in E. coli expressing MupW alone to support this proposal. 
Unnatural (5R) substrate 187 was incubated in E. coli expressing MupW and this 
biotransformation analysed by HPLC after 16 h (scheme 120). Interestingly, five compounds 
with different retention times were observed by HPLC, including the expected THF product 
195 (scheme 120). Again, a peak with mass of 468 was seen, which pleasingly was isolated 
by preparative HPLC and confirmed to be alkene 193 by 1D and 2D NMR. Initially, it wasn’t 
clear whether this isolated metabolite was the proposed 8,16-alkene due to the presence of 
only one new alkene proton in the 1H NMR spectrum. However, analysis of the 2D NMR data 
(scheme 120) showed there to be two new methylene protons. The missing proton in the 1H 
NMR spectrum was underneath the solvent peak at δ 4.85 ppm.  
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Scheme 120. HPLC trace of the biotransformation of 187 to 195. HSQC (presat CD3OD) showing the 
presence of two new methylene carbons.  
Another interesting result from this biotransformation (scheme 120) was the appearance of 
a peak with a mass of 484 and a retention time of 11.9 mins, which could correspond to 
epoxide 194, a putative intermediate in the formation of the THP ring. This epoxide is highly 
reactive and has never been observed or isolated by HPLC, and so confirming its existence 
by NMR would prove our proposed mechanism of THP formation to be correct. Work was 









undertaken to isolate this metabolite by preparative HPLC, however the amount of material 
isolated proved too little to elucidate the structure by 1D and 2D NMR spectroscopy. 
Alkene 193 isolated from the biotransformation shown in scheme 120 was re-fed to E. coli 
expressing MupW, with the expectation it would be transformed to THF 195, and pleasingly 
this was observed by HPLC. This lends evidence to our hypothesis that in mupirocin 
biosynthesis, the 8-methyl group is converted to an alkene which is then epoxidised prior to 
cyclisation to form the THP product. 
 
Scheme 121. Biotransformation of 8,16-alkene 193 to THF 195. 
The combination of these results proved that not only are substrates lacking the 6-hydroxyl 
group well tolerated by both MupW and MupZ, but also the unnatural stereochemistry at 
C-5 (187) is accepted. From feeding studies with unnatural (5R) substrate 187, it was possible 
to isolate a range of different metabolites including alkene 193, which we have proven is an 
intermediate in the formation of the THF ring 195.  
3.4.1 Biotransformation studies of thioester 29 with MupW and MupZ 
 
Pantetheinic substrate 29, synthesised in chapter two for the MupA project, was incubated 
in E. coli co-expressing MupW and MupZ, the purpose of which was to determine whether 
the MupW/Z system would recognise substrates with a different side chain from the fatty 
acids found in the pseudomonic acids.   
 
Scheme 122. Biotransformation of thioester 29 to acid 88. 
The only product observed arose from thioester hydrolysis giving the corresponding acid 88 
(scheme 122). It is known that this acid 88 is not a substrate for MupW.  




3.4.2 Biotransformation studies of substrates 188 and 24 with MupA 
 
Next, studies were undertaken with natural substrate 161 to probe whether the proposed 
6-hydroxylase, MupA (discussed in chapter two), would act on a substrate bearing the full 
fatty acid side chain. Tetraol 161 was incubated with blank E. coli cells in order to access the 
corresponding acid 188 for enzyme assays with MupA. This was necessary as these enzyme 
assays were not conducted in E. coli, and so substrate 161 would not otherwise have been 
oxidised. The 1H NMR of 161 showed a triplet at δ 3.60 ppm assigned to 1’-H2, whereas in 
acid 188, this signal had disappeared and a new signal was apparent at δ 2.25 ppm assigned 
to 2’-H2.   
 
 
Scheme 123. Oxidation of alcohol 161 to acid 188 by E. coli.  
Acid 188 was isolated by preparative HPLC and incubated with MupA to determine whether 
6-hydroxylation would occur, however analysis by HPLC showed no new peaks and the 










Scheme 124. Biotransformation studies carried out with substrates 188 and 24 with MupA. 
In addition, THP 24, isolated from the incubation of substrate 161 with E. coli co-expressing 
MupW and MupZ (scheme 124), was incubated with MupA. Analysis by HPLC showed no 
turnover had taken place, which lends further evidence to the hypothesis that 
6-hydroxylation takes place prior to cyclisation and installation of the fatty acid side chain, 
as discussed in chapter two.  
3.5 Synthetic efforts towards a mupirocin W4-OH analogue 196 
 
To probe the specificities of MupW and MupZ further, work was undertaken to synthesise 
amine 196, an analogue of desepoxy mupirocin W4-OH 27 bearing an amine group at C-5. If 
this substrate 196 was turned over by MupW/Z, a piperidine analogue of desepoxy PA-B 197 
would be produced. Piperidine scaffolds are found in many biologically active compounds, 
so it would be interesting and useful to compare the structure activity relationship (SAR) of 
the pseudomonic acids with a piperidine analogue 197, to determine its possible use as an 
antibiotic. 
 
Scheme 125. The structures of amine analogue 196 and the desired piperidine 197.  




Due to the similarity in structure of amine 196 to desepoxy mupirocin W4-OH 27, the 
beginning of the synthetic route utilised the chemistry developed by Dr Bakar in the 
synthesis of desepoxy mupirocin W4-OH 27 as shown in scheme 126.   
 
Scheme 126. Synthesis of mupirocin W4-OH 27 as carried out by Dr Bakar. 
With respect to amine instillation, literature research gave two potential routes to substrate 
196. The first was a Mukaiyama-Mannich type reaction would directly install the fatty acid 
side chain and the amine simultaneously. This is proven to be an efficient way to install an 
amine group with high yields and high diastereoselectivity.185-187  
 
Scheme 127. A proposed method of installing the amine group at C-5. 




Zhou et al. reported that with the development of a new BINOL derived chiral phosphoric 
acid catalyst 202, β-amino carbonyl compounds could be synthesised with high yields and 
high e.e.188  
 
Scheme 128. A novel catalyst developed by Zhou et al. for the use in Mukaiyama-Mannich 
reactions.188 
The second potential route would include the Mukaiyama aldol reaction between aldehyde 
170 and silyl dienol ether 171 as in the synthesis carried out by Dr Bakar (scheme 126), 
followed by an oxidation in order to enable the amine moiety to be installed via reductive 
amination as shown in scheme 127. Although this would likely give a mixture of 
diastereomers at the C-5 position, both substrates with natural and unnatural 
stereochemistry would be interesting to use in enzyme assays, especially as unnatural 
substrate 187 had been recognised and turned over by MupW and MupZ. 
 
Scheme 129. A proposed synthesis for the installation of the amine at C-5. 
 
 




3.5.1 Synthesis of core alkene 199 
 
As the chemistry to alcohol 172 is known, it was decided to carry out the Mukaiyama aldol 
reaction to give 172, followed by an oxidation to ketone 203 and reductive amination to give 
amine 204 as shown in scheme 129. With this in mind, the route to 172 began with the 
synthesis of the core fragment alkene 199, following the approach developed by Dr Bakar in 
the synthesis of desepoxy mupirocin W4-OH 27.  
D-Ribose 198 was protected as the acetonide using acetone and H2SO4 to give lactol 205 in 
85% yield (scheme 130). A one-pot reduction of 205 with NaBH4 and periodate cleavage gave 
lactol 206 in 42% yield over two steps.  
 
Scheme 130. Preparation of core fragment 199. 
Lactol 206 was then oxidised to lactone 207 using mild TEMPO/NCS conditions189 in the 
presence of TBACl, which acts as a phase transfer catalyst and allows the reaction to be 
carried out in a biphasic solvent system which in this case was CHCl3/H2O. Although the 
mechanism of TEMPO oxidation is the subject of debate, it is widely regarded to be a single 
electron transfer (SET) oxidant, while the NCS acts as the secondary oxidant.189 Addition of 
MeLi to lactone 207 gave lactol 208, which was then converted to alkene 209 in 29% yield 
via a Wittig reaction. Due to the incompatability of the free alcohol with the Suzuki 
conditions as discussed in chapter two (page 60) in the synthesis of thioester 29, primary 
alcohol 209 was protected using PMBCl to give 199 in 26% yield.  




The core fragment 199 was hydroborated using 9-BBN to give organoborane 210, which was 
then reacted with vinyl iodide 108 under Suzuki conditions (scheme 131), generating alkene 
200 in 42% yield as a single diastereomer with E alkene geometry. This was confirmed by 1H 




Scheme 131. Suzuki coupling of 210 and 108 to give 200 with E alkene geometry exclusively. 1H 
NMR spectrum showing the 11-H proton and its coupling constants.  
In order to complete the synthesis of aldehyde 170, PMB ether 200 was deprotected using 
DDQ to give alcohol 211, which was oxidised using DMP to aldehyde 170 in 40% yield over 
two steps (scheme 132).  
 
Scheme 132. Synthesis of aldehyde 170 from PMB ether 200. 
The Mukaiyama aldol reaction had to be approached differently than in the synthesis of 
substrate 161 (page 87, scheme 113), due to the sensitivity of the acetonide to strong Lewis 
acids. Kita et al. reported that high yields and stereoselectivity could be achieved when 




acetonide protected glyceraldehyde derivatives were reacted with O-silylated ketene acetals 
in the presence of zinc and zirconium based Lewis acids, with the products retaining the 
acetonide protecting group (scheme 133).182 When ZrCl4 and ZnI2 were used a dr of greater 
than 90% was observed, while ZnBr2 and ZnCl2 gave over 70% dr. Interestingly it was reported 
that with the widely used Lewis acids TiCl4, BF3.OEt2 and SnCl4, no satisfactory result was 
achieved.182 
 
Scheme 133. The reaction of an O-silylated ketene acetal with an acetonide protected 
glyceraldehyde derivative as carried out by Kita et al.190 
Dr Bakar achieved the best results when aldehyde 170 was reacted with TMS O-silylated 
ketene acetal 171 in the presence of ZnI2 at 0 C, which gave alcohol 172 with 90% dr. In my 
hands, none of the desired product 172 was isolated and due to time constraints, this 
reaction was not reattempted. 
 
Scheme 134. The successful Mukaiyama aldol reaction of aldehyde 170 with silyl dienol ether 171 
carried out by Dr Bakar. 
3.6 Conclusions and future work 
 
The total synthesis of substrates 161 and 187 was achieved in 12 longest linear steps and 
2.2% (natural) and 2.4% (unnatural) yield respectively. The key steps involved a Suzuki 
reaction which introduced the alkene with excellent control of E-geometry, a hydroboration 
which set the stereocentre at C-8. The synthetic route developed in the synthesis of thioester 
29 (chapter two) was adapted in order to install the alcohol at C-5, utilising a key Mukaiyama 
aldol reaction. 





Scheme 135. Synthesis of 161 and 187. 
After a series of failed attempts at the VMAR, B(C6F5)3 was used as the Lewis acid, which gave 
silyl ethers 183 and 184 as a mixture of diastereomers epimeric at C-5. This was serendipitous 
as the unnatural diastereomer proved to give interesting results in the biotransformation 
studies. 
 
Scheme 136. Mukaiyama aldol reaction between 123 and 171. 
Both substrates 161 and 187 were recognised and turned over by MupW and MupZ to give 
the 6-membered THP ring products (scheme 137). Interestingly, HPLC analysis of natural 
substrate 161 showed this substrate could be cyclised before oxidation, which suggests that 
oxidation is not a prerequisite for cyclisation to occur. THP 24 was isolated by preparative 
HPLC and the structure elucidated by 1D and 2D NMR (figure 32), however an insufficient 
amount of THP 191 was isolated for full characterisation by NMR spectroscopy. 





Scheme 137. THP products 24 and 191 produced by the incubation of alcohols 161 and 187 with 
MupW and MupZ. 
Bioassays with the unnatural substrate (5R) 187 were particularly interesting due to the 
intermediate compounds that were observed by HPLC. When this substrate 187 was 
incubated in E. coli expressing both MupW, a peak with a mass corresponding to 8,16-alkene 
193 was observed. This was isolated by preparative HPLC and the structure confirmed by 
NMR spectroscopy.  
 
Scheme 138. Incubation of unnatural substrate 187 with E. coli expressing MupW and MupZ and 
the observed metabolites. 
In addition, a novel peak in the HPLC trace with a mass that corresponds to the proposed 
epoxide intermediate 194 was observed. This bioassay was repeated on a larger scale and 
isolation of this peak attempted by HPLC, however this proposed intermediate was present 
in too small an amount to be able to determine its structure by NMR.  




Alkene 193 isolated from feeding studies of unnatural substrate 187 with MupW in E. coli 
(scheme 138) was re-fed to E. coli expressing MupW, and the expected THF 195 was 
observed by HPLC-MS, indicating that alkene 193 is a true intermediate in the formation of 
THF 195. From this result, we can infer that in PA-C biosynthesis the 8-methyl group is 
converted to the 8-16-alkene 212, before epoxidation catalysed by MupW. In the presence 
of MupZ, this proposed epoxide intermediate undergoes ring closure to give desepoxy PA-B 
11, a precursor to PA-C 6.  
 
Scheme 139. The proposed mechanism for the conversion of desepoxy mupirocin W4 130 to 
desepoxy PA-B 11. 
To probe the specificities of MupW and MupZ further, work was started towards the 
synthesis of amine 196, an analogue of desepoxy mupirocin W4-OH 27. By utilising the 
synthetic strategy employed by Dr Bakar in the total synthesis of desepoxy mupirocin W4-
OH,89 the synthesis of aldehyde 170 was achieved successfully, however in my hands the 
Mukaiyama aldol between aldehyde 170 and 171 was unsuccessful. Further work will be 
undertaken to complete this synthesis and install the amine moiety at C-5 by optimisation of 
the Mukaiyama aldol reaction between 170 and 171.  





Scheme 140. The starting steps of the synthesis of amine 196.  
Once conditions have been established for the synthesis of alcohol 172, work can be 
undertaken to install the amine as shown in scheme 141. 
 
Scheme 141. The final steps towards the synthesis of amine 196.  
Work is currently being undertaken to synthesise alkene 212 and alcohols 213 and 214 
(figure 34), which will be used in biotransformation studies with MupW to probe the 
biosynthetic origin of the proposed epoxide intermediate 142. In addition to this, work is 
ongoing to scale up the bioassay with tetraol 187 in E. coli expressing MupW to isolate the 
proposed epoxide 194 in order to verify our hypothesis.  






Figure 34. Alkene 212 and alcohols 213 and 214, currently being synthesised for use in 
biotransformation studies. 
In addition to amine 190, a further substrate scope will be carried out including the des-7-
hydroxy 215 and des-5-hydroxy 216 substrates. Tetraol 216 would be of particular interest 
as a non-turnover substrate due to the lack of hydroxyl group at C-5 preventing cyclisation. 
It is hoped that crystallisation studies of this compound could show the epoxide bound in 
the active site of MupW, giving further insight into this transformation.  
 
Figure 35. Tetraols 215 and 216 for use in a substrate scope of MupW and MupZ. 
A long term aim for the MupW/MupZ work would be to develop a novel biocatalyst that can 
form ring systems from acyclic precursors by point mutations of the enzymes active sites. 
From this it would be possible to build up complex functionality in a molecule that would be 




















CHAPTER 4: Experimental 




4. Experimental  
 
General Experimental 
Commercially available compounds were used without further purification. Experiments which were 
air sensitive were carried out in flame-dried glassware under a positive pressure of nitrogen using 
standard syringe techniques. Anhydrous solvents dichloromethane, diethyl ether, tetrahydrofuran, 
and toluene were obtained by passing through a modified Grubbs system of alumina columns, 
manufactured by Anhydrous Engineering. Petroleum ether is of the 40-60 C boiling point range. 
Phosphate buffer was purchased from Sigma Aldrich at pH 7.2 and 0.1 M concentration unless 
otherwise stated. Routine monitoring of reactions was performed using precoated Merck-Keiselgel 
60 F254 aluminium backed TLC plates. The spots were visualised by UV254 light, or potassium 
permanganate. Flash column chromatography was performed using silica gel (40-63 micron, 
obtained by Sigma Aldrich) as the adsorbent and carried out according to the procedure outlined by 
Still et al.191 Infrared (IR) spectra were recorded on a Perkin Elmer Spectrum One FT-IR spectrometer 
using either the neat compound or the compound dissolved in chloroform. Optical rotations were 
recorded using a Bellingham and Stanley ADP220 polarimeter, irradiating with the sodium D line ( 
= 589 nm), and [] values are quoted as in units 10-1 deg cm2 g-1. 1H and 13C NMR spectra were 
recorded in CDCl3 or CD3OD unless stated otherwise. The spectra were recorded on a Bruker 400 MHz 
spectrometer unless otherwise stated. The chemical shifts () are reported in parts per million (ppm) 
and the coupling constant (J) are in Hertz (Hz). HSQC NMR were routinely used to definitively assign 
the signals of 13C NMR spectra. Electron ionisation (EI) was recorded on a VG analytical Autospec 
mass spectrometer. Electrospray ionisation (ESI) was recorded on a Bruker Daltonics Apex 4e 7.0T 
FT-MS mass spectrometer. Methane was the ionised gas used for the chemical ionisation. Unless 












 (R)-4-Benzyl-3-(pent-4-enoyl)oxazolidin-2-one 42 
 
4-Pentenoic acid (1.00 mL, 10.2 mmol) in anhydrous THF (5 mL) was cooled to -78 C under 
N2. Triethylamine (1.81 mL, 13.2 mmol) was added and then pivaloyl chloride (1.25 mL, 10.2 
mmol) was added dropwise. The reaction mixture was stirred at -78 C for 30 mins, then 
warmed to RT for 2 h before being cooled again to -78 C. In a separate flask, Evans’ auxiliary 
41 (1.64 g, 10.2 mmol) in anhydrous THF (10 mL) was cooled to -78 C under N2. nBuLi (1.6 
M in hexanes, 6.45 mL, 10.2 mmol) was added slowly at -78 C and the mixture stirred for 30 
mins at RT. The anion was slowly transferred to the mixed anhydride and stirred at RT for 16 
h. The reaction mixture was quenched with NaHCO3 (20 mL), extracted with EtOAc (3 x 20 
mL) and the combined organic extracts dried (MgSO4). The solvent was removed in vacuo to 
give a pale yellow oil which was purified by column chromatography (10%-20% EtOAc in 
petrol) to give 42 as a colourless oil (2.10 g, 81%); H (400 MHz, CDCl3) 7.25 (3 H, m, Ar-H), 
7.15 (2 H, m, Ar-H), 5.81 (1 H, m, 4’-H), 5.00 (2 H, m, 5’-H2), 4.62 (1 H, m, 5-HH), 4.12 (1 H, m, 
5-HH), 4.05 (1 H, m, 4-H), 3.25 (1 H, dd, J 13.0, 3.0, 3’-HH), 2.97 (2 H, m, 6-H2), 2.71 (1 H, m, 
3’-HH), 2.40 (2 H, m, 2’-H2); C (100 MHz, CDCl3) 172.5 (C-2), 153.4 (C-1’), 136.7 (C-4’), 135.2 
(Ar-C), 129.4 (Ar-C), 129.0 (Ar-C), 127.3 (Ar-C), 115.7 (C-5’), 66.2 (C-5), 55.2 (C-4), 38.1 (C-3’), 




A solution of the alkene 42 (0.20 g, 1.18 mmol), in anhydrous THF (4 mL) under N2 was cooled 
to -78 C and NaHMDS (1 M in hexanes, 1.77 mL, 1.77 mmol) was added dropwise and stirred 
for 1 h, followed by the dropwise addition of MeI (0.21 mL, 4.72 mmol) at -78 C. After 




stirring for 1 h, the reaction was quenched with sat. aq. NH4Cl (10 mL) and extracted with 
EtOAc (3 x 15 mL). The combined organics were dried (MgSO4) and the solvent removed in 
vacuo to give a pale orange oil. This was purified by column chromatography (20% EtOAc in 
petrol) to give 45 as a colourless oil (0.23 g, 88%); []D
24 -2.0 (c 1, CHCl3); H (400 MHz, CDCl3) 
7.22 (3 H, m, Ar-H), 7.11 (2 H, m, Ar-H), 5.66 (1 H, m, 4’-H), 4.93 (2 H, m, 5’-H2), 4.53 (1 H, m, 
5-HH), 4.08 (1 H, m, 5-HH), 4.06 (1 H, m, 4-H), 3.71 (1 H, m, 2’-H), 3.15 (1 H, dd, J 13.0, 3.0, 
3’-HH), 2.66 (1 H, m, 3’-HH), 2.37 (1 H, m, 6-HH), 2.08 (1 H, m, 6-HH), 1.13 (3 H, d, J 7.0, 2’-
CH3); C (100 MHz, CDCl3) 136.3 (C-4’), 135.2 (Ar-C), 129.7 (Ar-C), 128.3 (Ar-C), 127.3 (Ar-C) 
117.5 (C-5’), 69.0 (C-4), 65.7 (C-5), 38.9 (C-2’), 38.6 (C-3’), 38.1 (C-6), 17.6 (2’-CH3). Data in 
accordance with the literature.192 No optical rotation recorded in literature.  
(R)-2-Methylpent-4-en-1-ol 46 
 
Alkene 45 (0.20 g, 0.73 mmol) was dissolved in anhydrous Et2O (5 mL) and cooled to 0 C 
under N2. To this solution was added EtOH (0.06 mL, 1.09 mmol) followed by the dropwise 
addition of LiBH4 (2 M in THF, 0.51 mL, 1.02 mmol). The solution was stirred for 1 h at 0 C 
and then 3 h at RT. The reaction was quenched with NaOH (1 M, 5 mL) and extracted with 
EtOAc (3 x 15 mL). The combined organic extracts were dried (MgSO4) and the solvent 
removed in vacuo to give a colourless oil, which was purified by column chromatography 
(40% EtOAc in petrol) to give alcohol 46 as a colourless oil (52 mg, 71%); H (400 MHz, CDCl3) 
5.74 (1 H, m, 4-H), 4.96 (2 H, m, 5-H2), 3.42 (2 H, m, 1-H2), 2.10 (1 H, m, 3-HH), 1.87 (1 H, m, 
3-HH), 1.68 (1 H, m, 2-H), 0.85 (3 H, d, J 7.0, 2-CH3); C (100 MHz, CDCl3) 137.5 (C-4), 116.7 











A solution of oxalyl chloride (0.12 mL, 1.43 mmol) in anhydrous DCM (5 mL) was cooled to -
78 C and DMSO (0.20 mL, 2.86 mmol) added under N2. After stirring for 15 mins a solution 
of alcohol 46 (130 mg, 1.31 mmol) in anhydrous DCM (5 mL) and Et3N (0.91 mL, 6.50 mmol) 
were added successively. The reaction was stirred at RT for 3 h before being quenched with 
H2O (10 mL) and extracted with DCM (3 x 15 mL). The combined organic extracts were dried 
(MgSO4) and the solvent removed in vacuo to give aldehyde 30 as an orange oil (80 mg, 63%); 
H (400 MHz, CDCl3) 9.51 (1 H, s, 1-H), 5.61 (1 H, m, 4-H), 4.97 (2 H, m, 5-H2), 2.31 (2 H, m, 3-
H2), 2.01 (1 H, m, 2-H), 0.97 (3 H, d, J 7.0, CH3); c (100 MHz, CDCl3) 134.9 (C-4), 117.3(C-5), 
46.2 (C-1), 41.0 (C-3), 34.7 (C-2), 11.5 (CH3). Data in accordance with the literature.194 
(R)-3-Acetyl-4-benzyloxazolidin-2-one 47 
 
To Evans’ auxiliary 41 (500 mg, 3.06 mmol) in anhydrous THF (10 mL) was added DMAP (7.3 
mg, 0.06 mmol) and Et3N (0.42 mL, 3.06 mmol) under N2. The reaction mixture was kept at 
between 0 C and 10 C while Ac2O (0.57 mL, 6.12 mmol) was added dropwise over 5 min. 
The reaction mixture was stirred at RT for 15 h. After this time, TLC analysis showed the 
reaction to have not reached completion so DMAP (7.3 mg, 0.06 mmol) and Ac2O (0.57 mL, 
6.12 mmol) were added. The reaction was stirred for 1.5 h before the volatiles were removed 
in vacuo and the resulting oil extracted with EtOAc (3 x 15 mL). The combined organic 
extracts were washed with water (10 mL), followed by brine (15 mL) and dried (MgSO4). The 
solvent was removed in vacuo to give 47 as a colourless solid (630 mg, 94%); H (400 MHz, 
CDCl3) 7.36 (3 H, m, Ar-H), 7.24 (2 H, m, Ar-H), 4.69 (1 H, m, 4-H), 4.20 (2 H, m, 6-H2), 3.32 (1 
H, dd, J 13.0, 3.0, 5-HH), 2.80 (1 H, dd, J 13.0, 10.0, 5-HH), 2.59 (3 H, s, 2’-CH3); c (100 MHz, 




CDCl3) 170.3 (C-1’), 153.6 (Ar-H), 135.2 (C-2), 129.4 (Ar-C), 129.0 (Ar-C), 127.4 (Ar-C), 66.0 (C-
6), 55.0 (C-4), 37.9 (C-5), 23.8 (C-2’). Data in accordance with the literature.195  
Pent-4-enal 48 
 
PCC (1.88 g, 8.71 mmol) was suspended in anhydrous DCM (13 mL) to which 4-penten-1-ol 
(0.59 mL, 5.81 mmol) was added under N2 and the reaction stirred for 3 h at RT. The reaction 
mixture was filtered through silica and celite (3:1) and the solvent removed in vacuo to give 
aldehyde 48 as a colourless oil (345 mg, 71%); H (400 MHz, CDCl3) 9.71 (1 H, s, CHO), 5.76 (1 
H, m, 4-H), 4.98 (2 H, m, 5-H2), 2.48 (2 H, m, 2-H2), 2.32 (2 H, m, 3-H2); C (100 MHz, CDCl3) 




To a solution of D-valine 50 (6.00 g, 51.1 mmol) in anhydrous THF (165 mL) at 0 C was added 
NaBH4 (4.54 g, 107 mmol) in one portion. The resulting mixture was stirred for 5 min before 
a solution of iodine (12.7 g, 51.1 mmol) in anhydrous THF (15 mL) was added slowly dropwise 
over 20 min. The reaction mixture was warmed to RT and stirred until no more effervescence 
was observed, then heated at reflux for 24 h. After this time the reaction was cooled to RT 
and MeOH (20 mL) was added dropwise until the reaction mixture became clear. Volatiles 
were removed in vacuo and the resultant white paste dissolved in an aqueous solution of 
KOH (3 M). The solution was stirred for 4 h before being extracted with DCM (3 x 40 mL). The 
combined organic extracts were washed with brine (10 mL) and dried (MgSO4). The solvent 
was removed in vacuo to give D-valinol; lit.[𝛼]𝐷
25=-17.0; [𝛼]𝐷
24=-17.0 (c 3, EtOH). To a solution 
of D-valinol (6.70 g, 64.9 mmol) in EtOH (20 mL) was added CS2 (10.2 mL, 169 mmol). A 
solution of KOH (2.25 M, 77.9 mL, 175 mmol) in a 1:1 mixture of EtOH (35 mL) and H2O (35 
mL) was added slowly over 20 mins. The reaction mixture was heated at reflux for 72 h. After 




this time, the reaction was cooled to RT and the volatiles removed in vacuo. The resulting 
suspension was acidified with HCl (0.5 M, ca. 300 mL) and extracted with DCM (3 x 150 mL). 
The combined organic extracts were dried (MgSO4) and the solvent removed in vacuo to give 
51 as a colourless solid (8.20 g, 78%); lit.[𝛼]𝐷
25=+32.7; [𝛼]𝐷
24=+32.2 (c 1, CHCl3); δH (400 MHz, 
CDCl3) 7.48 (1 H, br s, NH), 4.04 (1 H, td, J 8.0, 6.5, 4-H), 3.51 (1 H, dd, J 11.0, 8.0, 5-HH), 3.33 
(1 H, dd, J 8.0, 11.0, 5-HH), 2.00-1.90 (1 H, m, 6-H), 1.05 (3 H, d, J 6.5, CH3), 1.01 (3 H, d, J 6.5, 
CH3); δC (100 MHz, CDCl3) 201.2 (C-2), 69.7 (C-4), 36.1 (C-5), 32.0 (C-6), 18.7 (CH3), 18.2 (CH3). 
Data in accordance with the literature.198  
 (R)-1-(4-Isopropyl-2-thioxothiazolidin-3-yl)ethan-1-one 52 
 
Auxiliary 51 (8.20 g, 50.8 mmol) was dissolved in anhydrous DCM (200 mL) and AcCl (5.34 
mL, 76.3 mmol) added under N2 at RT. Pyridine (6.13 mL, 76.3 mmol) was added dropwise 
and the reaction mixture stirred at RT for 3 h, then concentrated in vacuo. The resulting 
residue was filtered and the solvent removed in vacuo to give an orange oil which was 
purified by column chromatography (30% EtOAc in hexanes) to give 52 as an orange oil (8.75 
g, 85%); lit.[𝛼]𝐷
25=-450; [𝛼]𝐷
24=-442 (c 1, CHCl3); δH (400 MHz, CDCl3) 5.15 (1 H, ddd, J 8.0, 6.0, 
1.0, 4-H), 3.50 (1 H, dd, J 11.5, 8.0, 5-HH), 3.02 (1 H, dd, J 11.5, 1.0, 5-HH), 2.77 (3 H, s, 2’-H3), 
2.36 (1 H, m, 6-H), 1.05 (3 H, d, J 7.0, CH3), 0.97 (3 H, d, J 7.0, CH3); δC (100 MHz, CDCl3) 203.6 
(C-2), 171.1 (C-1’), 71.7 (C-4), 31.2 (C-6), 30.9 (C-5), 27.4 (C-2’), 19.5 (CH3), 18.2 (CH3). Data 




Auxiliary 52 (3.10 g, 15.3 mmol) was dissolved in anhydrous DCM (75 mL) under N2 and TiCl4 
(3.35 mL, 30.6 mmol) was added dropwise at 0 C. The reaction mixture was stirred for 10 




mins, after which time the solution was cooled to – 40 C and (-)-sparteine (1.93 mL, 15.3 
mmol) was added. After stirring for 1 h, the reaction mixture was cooled to – 78 C and 
aldehyde 30 (0.50 g, 5.09 mmol) in anhydrous DCM (5 mL) was added. The reaction mixture 
was stirred for a further 1.5 h before being quenched pH 7 buffer (20 mL) and extracted with 
DCM (3 x 40 mL). The combined organic extracts were dried (MgSO4) and the solvent 
removed in vacuo to give an orange oil which was purified by column chromatography (15% 
EtOAc in petrol) to give 54 as an orange oil (750 mg, 51%); []D
24 -330 (c 0.4, CHCl3); H (400 
MHz, CDCl3) 5.81 (1 H, m, 6’-H), 5.16 (1 H, ddd, J  7.5, 6.0, 1.0, 3-H), 5.03 (2 H, m, 7’-H2), 3.99 
(1 H, ddd, J 10.0, 6.0, 2.0, 3’-H), 3.61 (1 H, dd, J 18.0, 2.0, 2’-HH), 3.53 (1 H, dd, J 11.5, 7.5, 4-
HH), 3.20 (1 H, m, 2’-HH), 3.05 (1 H, dd, J 11.5, 1.0, 4-HH), 2.36 (1 H, m, 5-H), 2.31 (1 H, m, 5’-
HH), 1.97 (1 H, m, 4’-H), 1.73 (1 H, m, 5’-HH), 1.08 (3 H, d,  J 7.0, 4’-CH3), 0.99 (3 H, d,  J 7.0, 
5-CH3), 0.91 (3 H, d,  J 7.0, 5-CH3); C (100 MHz, CDCl3) 203.1 (C-1’), 173.7 (C-1), 137.0 (C-6’), 
116.3 (C-7’), 71.5 (C-3), 71.4 (C-3’), 42.5 (C-2’), 38.0 (C-5’), 37.0 (C-5), 37.0 (C-4’), 30.6 (C-4), 
19.1 (4’-CH3), 17.8 (5-CH3), 15.2 (5-CH3). Data in accordance with the literature.117 Literature 
[]D
24 -330 (c 0.4, CHCl3).  
Methyl (2S,3S)-3-hydroxy-2-methylbutanoate 74 
 
DIPA (3.77 mL, 26.7 mmol) was dissolved in anhydrous THF (20 mL) and cooled to -78 C 
under N2. nBuLi (16.7 mL, 26.7 mmol, 1.61 M in hexanes) was added dropwise and the 
reaction mixture stirred for 1 h. A solution of ester 55 (1.40 mL, 12.8 mmol) in anhydrous 
THF (10 mL) was added dropwise. The reaction mixture was stirred at RT for 20 mins, after 
which time it was cooled to -78 C. MeI (0.96 mL, 15.4 mmol) was added dropwise and the 
reaction mixture stirred at 0 C for 3 h after which time the reaction was quenched with HCl 
(6 M, 10 mL). The reaction was extracted with Et2O (3 x 30 mL), the combined organic extracts 
were dried (MgSO4) and the solvent removed in vacuo to give an orange oil. This was purified 
by column chromatography (5% EtOAc in petrol) to give ester 74 as a colourless oil (1.20 g, 
82%); H (400 MHz, CDCl3) 3.87 (1 H, p, J 7.0, 3-H), 3.69 (3 H, s, OCH3), 2.44 (1 H, p, J 7.0, 2-
H), 1.20 (3 H, d, J 7.0, 4-H3), 1.15 (3-H, d, J 7.0, 2-CH3); C (100 MHz, CDCl3) 176.3 (C-1), 63.4 








LiAlH4 (302 mg, 7.94 mmol) was suspended in anhydrous Et2O (12 mL) and cooled to 0 C 
under N2. Ester 74 (500 mg, 3.78 mmol) in anhydrous Et2O (1 mL) was added dropwise and 
the reaction mixture stirred for 1 h. The reaction was quenched by addition of H2O (0.3 mL) 
followed by NaOH (1 M, 0.5 mL). The slurry was dried (MgSO4) and filtered through a plug of 
celite. The solvent was removed in vacuo to give diol 56 as a pale yellow oil (381 mg, 97%). 
H (400 MHz, CDCl3) 3.72 (2 H, m, 1-H2), 3.62 (1 H, m, 3-H), 1.67 (1 H, m, 2-H), 1.24 (3 H, d, J 
7.0, 2-CH3), 0.86 (3 H, d,  J 7.0, 4-H3); C (100 MHz, CDCl3) 73.7 (C-1), 68.2 (C-3), 41.8 (C-2), 
22.1 (2-CH3), 13.7 (C-4). Data in accordance with the literature.202 
(4S,5R)-2-(4-Methoxyphenyl)-4,5-dimethyl-1,3-dioxane 57 
 
To diol 56 (200 mg, 1.92 mmol) dissolved in anhydrous DCM (5 mL) was added p-
methoxybenzaldehyde dimethyl acetal (419 mg, 2.30 mmol) and PPTS (95 mg, 0.38 mmol) 
under N2. The reaction mixture was stirred at RT for 5 h, after which time the reaction was 
quenched with sat. aq. NaHCO3 (5 mL). The reaction mixture was extracted with DCM (3 x 10 
mL), the combined organic extracts dried (MgSO4) and the solvent removed in vacuo. The 
resulting orange oil was purified by column chromatography (5% EtOAc in petrol) to give 57 
as a colourless oil (392 mg, 92%); H (400 MHz, CDCl3) 7.36 (2 H, d, J 9.0, Ar-H), 6.80 (2 H, d, 
J 9.0, Ar-H), 5.38 (1 H, s, 1-H), 4.03 (1 H, m, 3-HH), 3.73 (3 H, s, OMe), 3.49 (1 H, m, 5-H), 3.41 
(1 H, m, 3-HH), 1.69 (1 H, m, 4-H), 1.23 (3 H, d, J 7.0, 4-CH3), 0.72 (3 H, d, J 7.0, 6-H3); C (100 
MHz, CDCl3) 159.9 (Ar-C), 131.3 (Ar-C), 127.5 (Ar-C), 113.6 (Ar-C), 102.0 (C-1), 79.5 (C-5), 72.9 








Acetal 57 (250 mg, 1.13 mmol) was dissolved in anhydrous DCM (6 mL) and cooled to – 50 
C under N2. DIBAL-H (1 M in DCM, 5.65 mL, 5.65 mmol) was added dropwise and the 
reaction mixture stirred for 1.5 h at 0 C, after which time the reaction was quenched by 
addition of MeOH (2 mL) and Rochelle’s salt (15 mL). The reaction mixture was stirred 
vigorously overnight before being extracted with Et2O (3 x 10 mL). The combined organic 
extracts were dried (MgSO4) and the solvent removed in vacuo to give a colourless oil. This 
was purified by column chromatography (1% EtOAc in petrol) to give 58 as a pale yellow oil 
(232 mg, 92%); H (400 MHz, CDCl3) 7.26 (2 H, d, J 8.0, Ar-H), 6.87 (2 H, d, J 8.0, Ar-H), 4.51- 
4.28 (2 H, m, OCH2), 3.73 (3 H, s, OMe), 3.57-3.49 (2 H, m, 1-H2), 3.39 (1 H, m, 3-H), 1.70 (1 
H, m, 2-H), 1.17 (3 H, d, J 8.0, 2-CH3), 0.82 (3 H, d, J 8.0, 4-H3); C (100 MHz, CDCl3) 159.3 (Ar-
C), 130.3 (Ar-C), 129.4 (Ar-C), 113.9 (Ar-C), 80.2 (C-3), 70.6 (OCH2), 67.2 (C-1), 55.3 (OMe), 
41.2 (C-2), 17.4 (2-CH3), 14.1 (C-4). Data in accordance with the literature.203 
(2S,3S)-3-((4-Methoxybenzyl)oxy)-2-methylbutanal 59 
 
To alcohol 58 (250 mg, 1.11 mmol) in anhydrous DCM (5 mL) was added TEMPO (70 mg, 0.45 
mmol) and BAIB (538 mg, 1.67 mmol) under N2. The reaction mixture was stirred for 3 h at 
RT, then quenched with sat. aq. Na2S2O3 (5 mL) and extracted with Et2O (3 x 10 mL). The 
combined organic extracts were dried (MgSO4) and the solvent removed in vacuo to give an 
orange oil. This was purified by column chromatography (3% EtOAc in petrol) to give 
aldehyde 59 as a colourless oil (221 mg, 90%); H (400 MHz, CDCl3) 9.64 (1 H, s, 1-H), 7.16 (2 
H, d, J 8.0, Ar-H), 6.81 (2 H, d, J 8.0, Ar-H), 4.47-4.32 (2 H, m, OCH2), 3.72 (3 H, s, OMe), 3.72 




(1 H, m, 3-H), 2.47 (1 H, m, 2-H), 1.17 (3 H, d, J 7.0, 2-CH3), 0.87 (3 H, d, J 7.0, 4-H3); C (100 
MHz, CDCl3) 204.6 (C-1), 159.3 (Ar-C), 130.3 (Ar-C), 129.3 (Ar-C), 113.9 (Ar-C), 75.0 (OMe), 




CH3PPh3Br (475 mg, 1.33 mmol) was suspended in anhydrous Et2O (5 mL) and cooled to -
78 C under N2. NaHMDS (1 M in Et2O, 1.3 mL, 1.30 mmol) was added and stirred for 1 h. 
Aldehyde 59 (1.11 mmol) in anhydrous Et2O (5 mL) was added dropwise and the reaction 
stirred for 16 h at RT. The reaction was quenched with sat. aq. NH4Cl (5 mL) and extracted 
with Et2O (3 x 10 mL). The combined organic extracts were dried (MgSO4) and the solvent 
removed in vacuo to give an orange oil. This was purified by column chromatography (1% 
EtOAc in petrol) to give 60 as a colourless oil (234 mg, 80%); H (400 MHz, CDCl3) 7.16 (2 H, 
d, J 8.0, Ar-H), 6.74 (2 H, d, J 8.0, Ar-H), 5.68 (1 H, m, 2-H), 4.91- 4.87 (2 H, m, 1-H2), 4.37- 
4.26 (2 H, m, OCH2), 3.66 (3 H, s, OMe), 3.29 (1 H, m, 4-H), 2.25 (1 H, m, 3-H), 0.97 (3 H, d, J 
7.0, 3-CH3), 0.87 (3 H, d, J 7.0, 5-H3); C (100 MHz, CDCl3) 159.1 (Ar-C), 141.2 (C-2), 131.2 (Ar-
C), 129.2 (Ar-C), 114.3 (Ar-C), 77.8 (OCH2), 70.3 (OMe), 65.9 (C-4), 55.3 (C-3) 42.5 (C-1), 16.1 
(C-5), 14.7 (3-CH3). Data in accordance with the literature.204-205 
 (3S,4R)-3-Hydroxy-4-methylhept-6-enoic acid 67 
 
To a stirred solution of 54 (200 mg, 0.66 mmol) in THF/H2O (6.5 mL/1.5 mL) was added H2O2 
(30% w:v, 1.8 mL, 5.31 mmol) and aq. LiOH (1 M, 2.7 mL) at 0 C. The reaction mixture was 
allowed to warm to RT and stirred for 24 h after which time sat. aq. Na2S2O4 (ca. 5 mL) was 
added and the reaction mixture extracted with Et2O (3 x 15 mL). The aqueous layer was then 
acidified to pH 5 by addition of HCl (1 M, 3 mL) and extracted with Et2O (3 x 15 mL). The 
combined organic extracts were dried (MgSO4) and the solvent removed in vacuo to give 67 




as a colourless oil (75 mg, 72%); H (400 MHz, CDCl3) 5.71 (1 H, m, 6-H), 4.98 (2 H, m, 7-H2), 
3.96 (1 H, m, 3-H), 2.45 (2 H, m, 2-H2), 2.18 (1 H, m, 5-HH), 1.88 (1 H, m, 5-HH), 1.59 (1 H, m, 
4-H) 0.86 (3 H, d, J 7.0, 4-Me); C (100 MHz, CDCl3) 176.8 (C-1), 136.7 (C-6), 116.5 (C-7), 70.5 
(C-3), 38.4 (C-2), 38.0 (C-4), 37.4 (C-5), 13.8 (CH3). Data in accordance with the literature. 
Methyl (2S,3S)-3-(tert-butyldimethylsilyloxy)-2-methylbutanoate 75 
 
Alcohol 74 (600 mg, 4.54 mmol), imidazole (463 mg, 6.91 mmol) and DMAP (55 mg, 0.45 
mmol) were dissolved in anhydrous DCM (15 mL) under N2. TBSCl (1.23 g, 8.17 mmol) was 
added and the reaction stirred for 16 h. The reaction was quenched with H2O (ca. 10 mL) and 
extracted with DCM (3 x 15 mL). The combined organic extracts were dried (MgSO4) and the 
solvent removed in vacuo to give an orange oil. This was purified by column chromatography 
(2% EtOAc in petrol) to give ester 75 as a colourless oil (1.08 g, 96%); [𝛼]𝐷
24 +35.4 (c 1.3, 
CHCl3), lit.55 [𝛼]𝐷
24 (c 1.25, CHCl3);  δH (400 MHz, CDCl3): 3.98 (1 H, dq, J 7.0, 6.0, 3-H), 3.63 (3 
H, s, OMe), 2.47 (1 H, pent, J 7.0, 2-H), 1.10 (3 H, d, J 6.0, 4-H3), 1.06 (3 H, d, J 7.0, 2-CH3), 
0.89 (9 H, s, C(CH3)3), 0.03 (3 H, s, SiCH3), 0.00 (3 H, s, SiCH3); δC (100 MHz, CDCl3): 70.2 (C-3), 
51.4 (OCH3), 48.1 (C-2), 25.7 (SiC(CH3)3), 20.6 (C-4), 17.9 (SiC(CH3)3), 12.7 (2-CH3), -4.3 
(Si(CH3)2), -5.1 (Si(CH3)2). Data in accordance with the literature.206  
(2R,3S)-3-(tert-butyldimethylsilyloxy)-2-methylbutan-1-ol 76 
 
Ester 75 (500 mg, 2.15 mmol) was dissolved in DCM (6 mL) and cooled to -78 °C and DIBAL-
H (1 M in DCM, 4.52 mL, 4.52 mmol) was added dropwise under N2. The reaction mixture 
was stirred for 2 h at RT. Rochelle’s salt (10 mL) was added and the reaction mixture was 
stirred vigorously overnight before being extracted with DCM (3 x 10 mL). The combined 
organic extracts were dried (MgSO4) and the solvent removed in vacuo to give 76 as a 
colourless oil (447 mg, 95%); [𝛼]𝐷
24 = +12.0 (c 1.0, CHCl3), lit.56 [𝛼]𝐷
24 = +18.0 (c 1.0, CHCl3); δH 
(400 MHz, CDCl3): 3.72 (1 H, m, 1-HH), 3.66 (1 H, m, 3-H), 2.73 (1 H, m, 1-HH), 1.52 (1 H, m, 
OH), 1.12 (3 H, d, J 7.0, 4-H3), 0.87 (3 H, d, J 7.0, 2-CH3), 0.80 (9 H, s, SiC(CH3)3), 0.00 (3 H, s, 




SiCH3), 0.00 (3 H, s, SiCH3); δC (400 MHz, CDCl3): 74.1 (C-3), 65.9 (C-1), 41.7 (C-2), 25.8 
(SiC(CH3)3), 22.2 (C-4), 17.9 (SiC(CH3)3), 14.7 (2-CH3), -4.2 (Si(CH3)2), -5.0 (Si(CH3)2). Data in 
accordance with the literature.207 
(2S,3S)-3-(tert-Butyldimethylsilyloxy)-2-methylbutanal 77 
 
Alcohol 76 (300 mg, 1.47 mmol) was dissolved in anhydrous DCM (5 mL) and TEMPO (459 
mg, 2.94 mmol) was added followed by BAIB (711 mg, 2.21 mmol) under N2. The reaction 
mixture was stirred at RT for 3 h before the reaction was quenched with sat. aq. Na2S2O3 (5 
mL) and extracted with DCM (3 x 10 mL). The combined organic extracts were dried (MgSO4) 
and the solvent removed in vacuo to give an orange oil. This was purified by column 
chromatography (0-5% EtOAc in petrol) to give aldehyde 77 as a pale yellow oil (250 mg, 
83%); [𝛼]𝐷
24 = +43 (c 1.0, CHCl3), lit.56 [𝛼]𝐷
24 = +47 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 9.69 (1 
H, d, J 2.5, 1-H), 3.96 (1 H, m, 3-H), 2.30 (1 H, app. pd, J 6.0, 2.5, 2-H), 1.15 (3 H, d, J 6.0, 4-
H3), 1.00 (3 H, d, J 6.0, 2-CH3), 0.80 (9 H, s, SiC(CH3)3), 0.00 (3 H, s, SiCH3), -0.01 (3 H, s, SiCH3); 
δC (100 MHz, CDCl3) 205.2 (C-1), 69.9 (C-3), 53.7 (C-2), 25.7 (SiC(CH3)3), 21.8 (C-4), 18.0 
(SiC(CH3)3), 10.6 (2-CH3), -4.2 (SiCH3), -5.0 (SiCH3). Data in accordance with the literature.208  
(3R,4S)-4-(tert Butyldimethylsilyloxy)-3-methylpent-1-ene 70 
 
CH3PPh3Br (1.16 g, 3.25 mmol) was suspended anhydrous Et2O (10 mL) and cooled to -78 °C 
under N2. NaHMDS (1 M in Et2O, 3.33 mL, 3.33 mmol) was added and stirred for 1 h at this 
temperature. Aldehyde 77 (600 mg, 2.78 mmol) was added dropwise and the reaction 
mixture stirred for 16 h at RT. The reaction mixture was quenched with sat. aq. NH4Cl (10 
mL), extracted with Et2O (3 x 10 mL) and the combined organic extracts were dried (MgSO4). 
The solvent was removed in vacuo to give a pale yellow oil which was purified by column 
chromatography (1% EtOAc in petrol) to give 70 as a colourless oil (446 mg, 64%); [𝛼]𝐷
23.6 = 
+7.5 (c 2.0, CHCl3), lit.54 [𝛼]𝐷
26.6 = +8.0 (c 2.3, CHCl3); δH (400 MHz, CDCl3) 5.75 (1 H, ddd, J 
17.0, 10.5, 7.5, 2-H), 4.96 (1 H, m, 1-HH), 4.92 (1 H, m, 1-HH), 3.67 (1 H, qd, J 6.0, 4.5, 4-H), 




2.13 (1 H, m, 3-H), 1.01 (3 H, d, J 6.5, 5-H3), 0.95 (3 H, d, J 6.5, 3-CH3), 0.85 (9 H, s, SiC(CH3)3), 
0.00 (3 H, s, SiCH3), 0.00 (3 H, s, SiCH3); δC (100 MHz, CDCl3) 141.2 (C-2), 114.2 (C-1), 71.7 (C-
4), 45.4 (C-3), 25.9 (SiC(CH3)3), 20.6 (C-5), 18.1 (SiC(CH3)3), 15.5 (3-CH3), -4.3 (SiCH3), -4.8 
(SiCH3). Data in accordance with the literature.209 
(S)-4-Isopropyl-3-propionyloxazolidin-2-one 80 
 
Auxiliary 78 (1.00 g, 7.74 mmol) was dissolved in anhydrous THF (25 mL) and cooled to 0 °C 
under N2. LiCl (0.36 g, 8.51 mmol) was added followed by Et3N (1.41 mL, 10.1 mmol) and the 
resulting mixture stirred for 30 min. Propionic anhydride (1.04 mL, 8.13 mmol) was added 
dropwise and the reaction was warmed slowly to RT before stirring for 1.5 h. After this time 
the reaction was quenched by addition of NaCl (1 M, 10 mL), extracted with EtOAc (3 x 15 
mL) and the combined extracts washed HCl (1 M, 10 mL) before being dried (MgSO4). The 
solvent was removed in vacuo to give a colourless oil which was purified by column 
chromatography (40% EtOAc in petrol) to give 80 as a colourless oil (1.33 g, 93%). δH (400 
MHz, CDCl3) 4.37 (1 H, dt, J 8.0, 3.5, 4-H), 4.20 (1 H, m, 5-HH), 4.14 (1 H, dd, J 9.0, 3.0. 5-HH), 
2.92 (1 H, dq, J 18.0, 7.5, 2’-HH), 2.83 (1 H, dq, J 18.0, 7.5, 2’-HH), 2.31 (1 H, ddq, J 11.0, 7.0, 
4.0, 3.5, 6-H), 1.10 (3 H, t, J 7.0, 3’-H3), 0.86 (3 H, d, J 7.0, 6-CH3), 0.82 (3 H, d, J 7.0, 6-CH3); 
δC (100 MHz, CDCl3) 174.1 (C-1’), 154.1 (C-2), 63.4 (C-5), 58.4 (C-4), 29.2 (C-2’), 28.4 (C-6), 
18.0 (6-CH3), 14.7 (6-CH3), 8.5 (C-3’). Data in accordance with the literature.210  
(S)-4-Isopropyl-3-((R)-2-methylpent-4-enoyl)oxazolidin-2-one 64 
 
DIPA (1.59 mL, 11.34 mmol) was dissolved in anhydrous THF (10 mL) and cooled to -78 °C. 
nBuLi (1.52 M in hexanes, 7.46 mL, 11.34 mmol) was added dropwise under N2 and the 
reaction stirred at this temperature for 30 mins. 80 (1.00 g, 5.40 mmol) in anhydrous THF (10 
mL) was added dropwise at -78 °C. After 30 mins allyl bromide (1.96 g, 16.20 mmol) was 




added and the reaction stirred at 0 °C for 4 h after which time sat. aq. NH4Cl (15 mL) was 
added and the reaction mixture extracted with DCM (3 x 15 mL). The combined organic 
extracts were dried (MgSO4) and the solvent removed in vacuo to give a yellow oil, which 
was purified by column chromatography (40% EtOAc in petrol) to give 64 as a colourless oil 
(0.89 g, 73%); [𝛼]𝐷
26 = +59 (c 1.0, CHCl3), lit.57 [𝛼]𝐷
20 = +62.3 (c 1.3, CHCl3); H (400 MHz, CDCl3) 
5.72 (1 H, ddt, J 17.0, 10.0, 7.0, 4’-H), 5.02 (1 H, m, 5’-H), 4.98 (1 H, m, 5’-H), 4.39 (1 H, dt, J 
9.0, 3.0, 4-H), 4.19 (1 H, m, 5-HH), 4.12 (1 H, dd, J 9.0, 3.0, 5-HH), 3.82 (1 H, app. sextet, J 7.0, 
2’-H), 2.44 (1 H, ddt, J 14.0, 7.0, 1.0, 3’-HH), 2.25 (1 H, ddq, J 10.0, 7.0, 3.0, 6-H), 2.13 (1 H, 
ddt, J 14.0, 7.0, 1.0, 3’-HH), 1.08 (3 H, d, J 7.0, 2’-CH3), 0.84 (3 H, d, J 7.0, 6-CH3), 0.80 (3 H, d, 
J 7.0, 6-CH3); C (100 MHz, CDCl3) 176.5 (C-1’), 153.7 (C-2), 135.3 (C-4’), 117.1 (C-5’), 63.1 (C-
5), 58.5 (C-4), 38.2 (C-3’), 37.2 (C-2’), 28.5 (C-6), 18.0 (6-CH3), 16.2 (2’-CH3), 14.7 (6-CH3). Data 




Terminal alkene 64 (52 mg, 0.23 mmol) and 70 (200 mg, 0.93 mmol) were added 
simultaneously via syringe to a stirring solution of G2 (19 mg, 0.02 mmol) in anhydrous 
toluene (2.5 mL) under N2 at RT. The reaction was stirred for 16 h at 80 °C after which time 
it was cooled to RT, filtered through silica and concentrated in vacuo to give a brown liquid 
which was purified by column chromatography (5-10% EtOAc in petrol) to give 71 as a 
colourless oil (52 mg, 53%); νmax (neat)/cm-1 3010, 2956, 2874, 1742 (C=O), 1635, 1451, 1427, 
1368, 1229; [𝛼]𝐷
24=+24 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 5.42 (1 H, dd, J 15.5, 7.5, 5’-H), 5.33 
(1 H, m, 4’-H), 4.43 (1 H, ddd, J 8.5, 4.0, 3.0, 4-H), 4.23 (1 H, app. t, J 8.5, 5-HH), 4.12 (1 H, dd, 
J 9.0, 3.0, 5-HH), 3.77 (1 H, m, 2’-H), 3.65 (1 H, qd, J 6.0, 4.0, 7’-H), 2.44 (1 H, m, 3’-HH), 2.31 
(1 H, m, 6-H), 2.30 (1 H, m, 6’-H) 2.08 (1 H, dt, J 14.0, 7.0, 3’-HH), 1.10 (3 H, d, J 7.0, 2’-CH3), 
0.99 (3 H, d, J 7.0, 8’-H3), 0.91 (3 H, d, J 7.0, 6’-CH3), 0.88 (3 H, d, J 7.0, 6-CH3), 0.86 (9 H, s, 
C(CH3)3), 0.83 (3 H, d, J 7.0, 6-CH3), 0.00 (3 H, s, SiCH3), 0.00 (3 H, s, SiCH3); δC (100 MHz, 
CDCl3) 176.6 (C-1’), 153.7 (C-2), 135.7 (C-5’), 126.7 (C-4’), 71.8 (C-7’), 63.1 (C-5), 58.4 (C-4), 




44.2 (C-6’), 37.8 (C-2’), 37.1 (C-3’), 28.5 (C-6), 25.9 (SiC(CH3)3), 20.4 (C-8’), 18.1 (SiC(CH3)3), 
18.0 (6-CH3), 16.0 (2’-CH3), 15.8 (6’-CH3), 14.7 (6-CH3), -4.4 (SiCH3), -4.8 (SiCH3); Found (ESI) 




Terminal alkene 64 (52 mg, 0.23 mmol) and 60 (200 mg, 0.91 mmol) were added 
simultaneously via syringe to a stirring solution of G2 (19 mg, 0.02 mmol) in anhydrous 
toluene (2.5 mL) under N2 at RT. The reaction was stirred for 16 h at 80 °C after which time 
it was cooled to RT, filtered through silica and concentrated in vacuo to give a brown liquid. 
This was purified by column chromatography (5-20% EtOAc in petrol) to give 84 as a 
colourless oil (38 mg, 40%); νmax (neat)/cm-1 3021, 2946, 2894, 1740 (C=O), 1632, 1459, 1424, 
1369, 1229; [𝛼]𝐷
24 = +25 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 7.19 (2 H, d, J 8.5, Ar-H), 6.80 (2 
H, d, J 8.5, Ar-H), 5.40 (1 H, dd, J 15.5, 7.0, 5’-H), 5.33 (1 H, m, 4’-H), 4.41 (1 H, d, J 11.0, 
OCHH), 4.37 (1 H, m, 4-H), 4.32 (1 H, d, J 11.0, OCHH), 4.19 (1 H, m, 5-HH), 4.12 (1 H, dd, J 
9.0, 3.0, 5-HH), 3.73 (3 H, s, OMe), 3.73 (1 H, m, 2’-H), 3.31 (1 H, m, 7’-H), 2.41 (1 H, m, 3’-
HH), 2.27 (1 H, m, 6-H), 2.23 (1 H, m, 6’-H) 2.06 (1 H, app. dt, J 14.0, 7.0, 3’-HH), 1.05 (3 H, d, 
J 7.0, 2’-CH3), 1.00 (3 H, d, J 7.0, 8’-H3), 0.90 (3 H, d, J 7.0, 6’-CH3), 0.83 (3 H, d, J 7.0, 6-CH3), 
0.79 (3 H, d, J 7.0, 6-CH3); δC (125 MHz, CDCl3) 176.6 (C-1’), 159.0 (Ar-C), 153.7 (C-2), 135.7 
(C-5’), 131.2 (Ar-C), 129.1 (Ar-C), 126.7 (C-4’), 113.7 (Ar-C), 78.0 (C-7’), 70.3 (OCH2), 63.1 (C-
5), 58.4 (C-4), 55.3 (OCH3), 41.5 (C-6’), 37.8 (C-2’), 37.1 (C-3’), 28.5 (C-6), 18.0 (6-CH3), 16.1 
(C-8’), 16.0 (2’-CH3), 15.2 (6’-CH3), 14.7 (6-CH3); Found (ESI) 440.2313 [M+Na]+, 











Alkene 71 (150 mg, 0.36 mmol) was dissolved in anhydrous Et2O (5 mL) and cooled to 0°C 
under N2. To this solution was added EtOH (0.32 mL, 0.55 mmol) followed by dropwise 
addition of LiBH4 (0.28 mL, 0.55 mmol). The solution was stirred at 0°C for 1 h, followed by 3 
h at RT. Aq. NaOH (1 M, 3 mL) was added and the reaction mixture extracted with Et2O (3 x 
5 mL). The combined organic extracts were dried (MgSO4) and the solvent removed in vacuo 
to give a pale yellow oil. This was purified by column chromatography (40% EtOAc in petrol) 
to give 85 as a pale yellow oil (92 mg, 88%); νmax (neat)/cm-1 3339 (OH), 2957, 2928, 2857, 
1462, 1374, 1252; [𝛼]𝐷
25=+ 80 (c 1.0, CHCl3); δH (400 MHz, CDCl3) 5.36 (2 H, m, 4-H & 5-H), 
3.65 (1 H, m, 7-H), 3.47 (1 H, m, 1-HH), 3.42 (1 H, m, 1-HH), 2.08 (1 H, m, 6-H), 2.04 (1 H, m, 
3-HH), 1.89 (1 H, m, 3-HH), 1.66 (1 H, m, 2-H), 1.00 (3 H, d, J 6.5, 8-H3), 0.93 (3 H, d, J 6.5, 6-
H3), 0.88 (3 H, d, J 6.5, 2-CH3), 0.85 (9 H, s, SiC(CH3)3), 0.03 (3 H, s, SiCH3), 0.03 (3 H, s, SiCH3); 
δC (100 MHz, CDCl3) 134.6 (C-5), 128.2 (C-4), 72.1 (C-7), 68.2 (C-1), 44.4 (C-6), 36.8 (C-3), 36.1 
(C-2), 26.1 (SiC(CH3)3), 26.0 (SiC(CH3)3), 20.8 (C-8), 16.5 (2-CH3), 16.2 (6-CH3), -4.2 (SiCH3), -
4.7 (SiCH3); Found (ESI): 309.2221 [M+Na]+, (C16H34NaO2Si requires 309.2220). 
(2R,6R,7S,E)-7-((tert-Butyldimethylsilyl)oxy)-2,6-dimethyloct-4-enal 72 
 
Alcohol 85 (140 mg, 0.52 mmol) was dissolved in anhydrous DCM (15 mL) and NaHCO3 was 
added and the reaction cooled to 0 °C. DMP (0.3 M in DCM, 1.8 mL, 0.68 mmol) was added 
dropwise and the reaction mixture stirred at RT for 1.5 h, then quenched by addition of sat. 
aq. Na2S2O3 (10 mL). The reaction mixture was then extracted with DCM (3 x 10 mL), the 
combined organic extracts dried (MgSO4) and the solvent removed in vacuo to give a white 
oily solid. This was purified by column chromatography (5% EtOAc in petrol) to give aldehyde 
72 as a colourless oil (125 mg, 89%); νmax (neat)/cm-1 2957, 2928, 2956, 1727, 1461, 1374, 
1252, 1093, 1029;  [𝛼]𝐷
25=+ 120 (c 1.0, CHCl3);  δH (400 MHz, CDCl3) 9.65 (1 H, d, J 1.5, 1-H), 




5.46 (1 H, ddt, J 15.5, 8.0, 1.0, 4-H), 5.33 (1 H, m, 5-H), 3.67 (1 H, qd, J 6.0, 4.0, 7-H), 2.40 (2 
H, m, 2-H & 3HH), 1.95 (2 H, m, 6-H, 3HH), 1.09 (3 H, d, J 7.0, 2-CH3), 1.02 (3 H, d, J 7.0, 8-H3), 
0.95 (3 H, d, J 7.0, 6-H3), 0.88 (9 H, s, C(CH3)3), 0.03 (3 H, s, SiCH3), 0.03 (3 H, s, SiCH3); δC (100 
MHz, CDCl3) 205.0 (C-1), 135.7 (C-4), 126.0 (C-5), 71.8 (C-7), 46.3 (C-2), 44.3 (C-6), 33.9 (C-3), 
25.9 (SiC(CH3)3), 20.8 (C-8), 18.1 (SiC(CH3)3), 16.2 (6-CH3), 13.1 (2-CH3), -4.3 (SiCH3), -4.8 




Auxiliary 52 (268 mg, 1.32 mmol) was dissolved in anhydrous DCM (10 mL) under N2 and the 
system degassed (3 x 5 mins). The reaction mixture was cooled to 0 °C and TiCl4 (2.64 mL, 
2.64 mmol, 1 M in toluene) was added dropwise. After stirring for 10 mins, the reaction 
mixture was cooled to -40 °C and (-)-sparteine (0.17 mL, 1.32 mmol) was added dropwise 
with vigourous stirring. After stirring for 1 h at -40 °C, the reaction was cooled to -78 °C and 
aldehyde 72 (125 mg, 0.44 mmol) in anhydrous DCM (1 mL) was added. The reaction was 
stirred for a further 45 mins at this temperature before the addition of phosphonate buffer 
solution (ca. 10 mL). The reaction mixture was extracted with DCM (3 x 10 mL), the combined 
organic extracts were dried (MgSO4) and the solvent removed in vacuo to give a bright yellow 
oil. This was purified by column chromatography (10-20% EtOAc in petrol) to give 73 as a 
yellow oil (137 mg, 64%); νmax (neat)/cm-1 2959, 2928, 2856, 1687, 1462, 1371, 1306, 1253, 
1159, 1092, 1033; δH (400 MHz, CDCl3) 5.38 (2 H, m, 6’-H and 7’-H), 5.16 (1 H, ddd, J 8.0, 6.0, 
1.0, 4-H), 4.10-4.00 (1 H, m, 3’-H), 3.69 (1 H, qd, J 6.0, 4.0, 9’-H), 3.60 (1 H, m, 2’-HH), 3.52 (1 
H, dd, J 11.5, 8.0, 5-HH), 3.26-3.12 (1 H, m, 2’-HH), 3.03 (1 H, dd, J 11.5, 1.0, 5-HH), 2.37 (1 H, 
m, 6-H), 2.21 (1 H, m, 5’-HH), 2.14 (1 H, dq, J 11.0, 4.0, 3.5, 8’-H), 1.94 (1 H, m, 4’-H), 1.74-
1.60 (1 H, m, 5’-HH), 1.07 (3 H, d, J 7.0, 6-CH3), 1.02 (3 H, d, J 6.5, 10’-CH3), 0.98 (3 H, d, J 7.0, 
6-CH3), 0.96 (3 H, d, J 7.0, 8’-CH3), 0.91 (3 H, d, J 7.0, 4’-CH3), 0.88 (9 H, s, SiC(CH3)3), 0.03 (6 
H, s, SiCH3 x 2); δH (100 MHz, CDCl3) 203.2 (C-1’), 173.9 (C-2), 134.8 (C-6’), 128.1 (C-7’), 72.1 
(C-9’), 71.6 (C-4), 71.5 (C-3’), 44.4 (C-8’), 42.5 (C-2’), 38.7 (C-5’), 36.7 (C-4’), 31.0 (C-6), 30.8 




(C-5), 26.1 (SiC(CH3)3), 20.7 (10’-CH3), 19.2 (6-CH3), 18.3 (SiC(CH3)3), 18.0 (6-CH3), 16.1 (8’-
CH3), 15.4 (4’-CH3), -4.2 (SiCH3), -4.6 (SiCH3); Found (ESI) 488.2684 [M+Na]+, 
(C24H45NaNO3S2Si requires 488.2683). 
N-acetylcysteamine 35 
 
Cysteamine hydrochloride 86 (1.00 g, 8.80 mmol), KOH (0.49 g, 8.80 mmol) and NaHCO3 (2.22 
g, 26.4 mmol) were dissolved in water (50 mL). Ac2O (0.82 mL, 8.80 mmol) was added 
dropwise and the reaction stirred at RT for 1 h. The pH was adjusted to ca. pH 7 and the 
reaction mixture extracted with EtOAc (3 x 50 mL). The combined organic extracts were dried 
(MgSO4) and the solvent removed in vacuo to give 35 as a colourless oil (1.02 g, 97%); δH (400 
MHz, CDCl3) 6.09 (1 H, br s, NH), 3.41 (2 H, app. q, J 6.5, 3-H2), 2.65 (2 H, dt, J 8.5, 6.5, 4-H2), 
1.99 (3 H, s, 1-CH3), 1.35 (1 H, t, J 8.5, SH); δC (100 MHz, CDCl3) 170.5 (C-1), 42.6 (C-3), 24.6 




Alkene 73 (100 mg, 0.20 mmol) was dissolved in anhydrous DCM (1 mL) and imidazole (40 
mg, 0.60 mmol) and HSNAC (27 mg, 0.23 mmol) were added under N2. The reaction mixture 
was stirred at RT for 2.5 h. The solvent was removed in vacuo and the residue applied directly 
to a silica column containing a layer of CuSO4 impregnated silica. The crude material was 
purified (20-100% EtOAc in petrol) to give 87 as a colourless oil (55 mg, 62%); νmax (neat)/cm-
1 3299 (OH), 2957, 2958, 2929, 2857, 1659 (C=O), 1551, 1462, 1374, 1253, 1097,1031; δH (400 
MHz, CDCl3) 5.85 (1 H, brs, NH), 5.38 (1 H, m, 6-H), 5.34 (1 H, m, 7-H), 4.00-3.90 (1 H, m, 3-
H), 3.65 (1 H, qd, J 6.0, 4.0, 9-H), 3.42 (2 H, app. q, J 6.5, 2’-H2), 3.03 (2 H, app. hept, J 7.5, 
6.5, 4.0, 2-H2), 2.68 (2 H, m, 1’-H2), 2.16 (1 H, m, 5-HH), 2.11 (1 H, m, 8-H), 1.93 (3 H, s, 4’-H3), 
1.90 (1 H, m, 4-H), 1.65-1.58 (1 H, m, 5-HH), 1.00 (3 H, d, J 6.5, 10-H3), 0.95 (3 H, d, J 6.5, 8-




CH3), 0.89 (3 H, d, J 6.5, 4-CH3), 0.85 (9 H, s, SiC(CH3)3), 0.00 (3 H, s, SiCH3), 0.00 (3 H, s, SiCH3); 
δC (100 MHz, CDCl3) 199.9 (C-1), 170.5 (C-3’), 135.0 (C-6), 130.0 (C-7), 72.6 (C-3), 71.6 (C-9), 
48.8 (C-1’), 44.4 (C-8), 39.5 (C-2’), 36.6 (C-4), 36.1 (C-5), 29.0 (C-2), 26.0 (SiC(CH3)3), 23.4 (C-
4’), 20.9 (C-10), 18.3 (SiC(CH3)3), 16.4 (8-CH3), 14.1 (4-CH3), -4.2 (SiCH3), -4.7 (SiCH3); Found 
(ESI) 446.2758 [M+H]+, (C22H43NO4SSi requires 446.2755). 
S-(2-acetamidoethyl) (4R,8R,9S,E)-3,9-dihydroxy-4,8-dimethyldec-6-enethioate 28 
 
To a solution of 87 (50 mg, 0.11 mmol) in pyridine (0.20 mL) and anhydrous THF (2 mL) was 
added HF.pyridine (0.62 mL, 0.24 mmol) under N2. The reaction mixture was stirred at RT for 
5 h.  The reaction was then diluted with Et2O (2 mL), washed with H2O (ca. 3 mL), sat. aq. 
NaCl (ca. 3 mL) and dried (MgSO4). The solvent was removed in vacuo to give a colourless oil 
that was purified by column chromatography (3-6% MeOH in DCM), to give 28 as a colourless 
oil (29 mg, 77%); νmax (neat)/cm-1 3300 (OH), 2966, 2928, 1658 (C=O), 1552, 1439, 1405, 1375, 
1290, 1093, 1047, 1005; δH (400 MHz, CDCl3) 6.02 (1 H, brs, NH), 5.46 (1 H, dt, J 15.0, 7.0, 6-
H), 5.31 (1 H, ddd, J 15.0, 8.5, 3.0, 7-H), 3.98 (1 H, m, 3-H), 3.46 (1 H, app. p, J 6.0, 9-H), 3.38 
(2 H, app. p, J 6.5, 2’-H2), 2.98 (2 H, m, 2-H2), 2.65 (2 H, m, 1’-H2), 2.13 (1 H, m, 5-HH), 2.00 (1 
H, m, 8-H), 1.91 (1 H, m, 4-H), 1.90 (3 H, s, 4’-H3), 1.65 (1 H, m, 5-HH), 1.10 (3 H, d, J 6.5, 10-
H3), 0.92 (3 H, d, J 6.5, 8-CH3), 0.86 (3 H, d, J 6.5, 4-CH3); δC (100 MHz, CDCl3) 199.9 (C-1), 
170.7 (C-3’), 134.4 (C-6), 130.2 (C-7), 71.5 (C-9), 71.3 (C-3), 48.9 (C-1’), 48.2 (C-8), 45.2 (C-4), 
39.4 (C-2’), 35.9 (C-5), 29.1 (C-2), 23.3 (C-4’), 20.5 (C-10), 16.9 (8-CH3), 15.6 (4-CH3); Found 
(ESI) 354.1720 [M+Na]+, (C16H29NNaO4S requires 354.1709). 
D-homoserine 93 
 
D-methionine 89 (1.00 g, 6.70 mmol) was dissolved in H2O (15 mL) and CH3I (1.25 mL, 20.1 
mmol) was added dropwise. The reaction mixture was stirred for 24 h at RT. The solvent was 
removed in vacuo until ca. 10 mL remained and KHCO3 (0.93 g, 6.70 mmol) in H2O (3.50 mL) 




was added dropwise over 1 h to maintain pH 6. The solution was heated to reflux for 10 h, 
after which time the solvent was removed in vacuo. A solution of MeOH:H2O (100:1, 15 mL) 
was added, followed by the dropwise addition of conc. HCl (ca. 2 mL) to adjust the pH to 6. 
The reaction mixture was filtered while it was still hot, and the solvent concentrated to ca. 5 
mL. The resulting colourless solution was crystallised by freezing to give 93 as a white solid 
(630 mg, 79%); lit. [𝛼]𝐷
25=+8.7; [𝛼]𝐷
24=+8.8 (c 5, H2O);  H (400 MHz, D2O) 4.07 (2 H, m, 4-H2), 
2.69 (1 H, t, J 7.5, 2-H), 2.19 (1 H, m, 3-HH), 2.10 (1 H, m, 3-HH). Data in accordance with the 
literature.199 
(S)-2-(2,2-Dimethyl-5-oxo-1,3-dioxolan-4-yl)acetic acid 95 
 
L-Malic acid 94 (5.00 g, 37.3 mmol) was dissolved in 2,2 dimethoxypropane (19 mL, 149.2 
mmol) at RT. PTSA (71 mg, 0.37 mmol) was added and the reaction mixture was stirred for 3 
h. The reaction was quenched by addition of H2O (25 mL) containing NaHCO3 (31 mg) 
followed by extraction with DCM (5 x 25 mL), dried (Na2SO4) and the solvent was removed 
in vacuo. The resulting colourless oil was redissolved in Et2O (10 mL) and hexane (150 mL) 
and half the solvent removed in vacuo. The resulting colourless crystals were filtered to give 
95 (6.20 g, 96%); δH (400 MHz, CDCl3) 4.75 (1 H, dd, J 6.5, 4.0, 4-H), 3.03 (1 H, dd, J 17.0, 4.0, 
1’-HH), 2.88 (1 H, dd, J 17.0, 4.0, 1’-HH), 1.66 (3 H, s, 2-CH3), 1.60 (3 H, s, 2-CH3); δC (100 MHz, 
CDCl3); 174.5 (C-2’), 171.8 (C-5), 111.4 (C-2), 70.4 (C-4), 36.0 (C-1’),26.8 (2-CH3), 25.8 (2-CH3). 
Data in accordance with the literature.200 
(S)-3-(tert-Butyldimethylsilyloxy)dihydrofuran-2(3H)-one 97 
 
Lactone 90 (200 mg, 1.96 mmol) was dissolved in anhydrous DCM (10 mL) under N2. 
Imidazole (200 mg, 2.94 mmol), TBSCl (532 mg, 3.53 mmol) and DMAP (24.0 mg, 0.20 mmol) 
were added and the reaction stirred for 16 h at RT. The reaction was quenched by addition 
of H2O (10 mL) and extracted with DCM (3 x 10 mL). The combined organic extracts were 




dried (MgSO4) and the solvent removed in vacuo to give 97 as a colourless oil (413 mg, 97%); 
νmax (neat)/cm-1 2935, 2864, 1784, 1151, 1021, 998; [𝛼]𝐷
25= -10 (c 1.0, CHCl3); δH (400 MHz, 
CDCl3) 4.38 (2 H, m, 5-HH + 3-H), 4.18 (1 H, tdd, J 9.0, 6.5, 0.5, 5-HH), 2.45 (1 H, dddd, J 12.5, 
7.5, 6.5, 3.5, 4-HH), 2.21 (1 H, dddd, J 12.5, 9.0, 8.5, 8.0, 4-HH), 0.90 (9 H, s, SiC(CH3)3), 0.16 
(3 H, s, SiCH3), 0.14 (3 H, s, SiCH3); δC (100 MHz, CDCl3) 176.0 (C-2), 68.4 (C-3), 64.9 (C-5), 32.5 
(C-4), 25.8 (SiC(CH3)3), 18.4 (SiC(CH3)3), -4.6 (SiCH3), -5.1 (SiCH3); Found (ESI): 239.1077 
[M+Na]+, (C10H20NaO3SiNa requires 239.1074). 
(3S)-3-(tert-Butyldimethylsilyloxy)-2-methyltetrahydrofuran-2-ol 98 
 
Lactone 97 (2.40 g, 11.2 mmol) was dissolved in anhydrous THF (25 mL) at -78 C under N2. 
MeLi (1.6 M in Et2O, 7.69 mL, 12.3 mmol) was added and the reaction mixture was stirred 
for 3 h at -78 C followed by addition of aqueous NH4Cl (15 mL). The reaction mixture was 
extracted with EtOAc (3 x 20 mL), the combined organic extracts were dried (MgSO4) and the 
solvent removed in vacuo to give a pale yellow oil. This was purified by column 
chromatography (20% EtOAc in petrol) to give lactol 98 as a colourless oil (2.1 g, 81%); νmax 
(neat)/cm-1 3434, 2961, 2929, 2864, 1252, 1103, 1088, 1054, 1021, 1005; δH (400 MHz, CDCl3) 
4.03 (1 H, m, 3-H), 4.00 (1 H, m, 5-HH), 3.80 (1 H, m, 5-HH), 2.14 (1 H, m, 4-HH), 1.81 (1 H, m, 
4-HH), 1.39 (3 H, s, CH3), 0.91 (9 H, s, SiC(CH3)3), 0.12 (6 H, s, SiCH3 x 2); δC (100 MHz, CDCl3) 
102.6 (C-2), 76.1 (C-3), 64.7 (C-5), 33.5 (C-4), 25.7 (SiC(CH3)3), 25.1 (CH3), 18.0 (SiC(CH3)3), -
4.7 (SiCH3), -5.1 (SiCH3); Found (ESI): 215.1469 [M+H-H2O]+, (C11H23O2Si requires 215.1462). 
Data reported for the major product. 
(S)-3-(tert-Butyldimethylsilyloxy)-4-methylpent-4-en-1-ol 99 
 
Lactol 98 (112 mg, 0.50 mmol) was dissolved in anhydrous THF (2 mL) and Petasis reagent 
(7.14 mL, 1.5 mmol, 0.21 M) was added under N2. The reaction mixture was stirred in a sealed 
boiling tube at 75 °C for 16 h before being diluted with petrol (10 mL) and filtered through 




celite. The filtrate was washed with 2 N HCl (10 mL) followed by brine (ca. 10 mL) and dried 
(MgSO4). The solvent was removed in vacuo to give an orange oil which was purified by 
column chromatography (20% EtOAc in petrol) to give alcohol 99 as a pale orange oil (67 mg, 
58%); νmax (neat)/cm-1 3430 (OH), 2955, 2930, 2858, 2251, 1471, 1256, 1063; [𝛼]𝐷
25= -12 (c 
0.5, CHCl3); H (400 MHz, CDCl3) 4.98 (1 H, s, 5-HH), 4.84 (1 H, s, 5-HH), 4.29 (1 H, t, J 5.5, 3-
H), 3.73 (2 H, m, 1-H2), 2.36 (1 H, t, J 5.5, OH), 1.79 (2 H, q, J 6.5, 5.5, 2-H2), 1.69 (3 H, s, 4-
CH3), 0.91 (9 H, s, SiC(CH3)3), 0.08 (3 H, s, SiCH3), 0.03 (3 H, s, SiCH3); C (100 MHz, CDCl3) 
147.0 (C-4), 111.2 (C-5), 75.9 (C-3), 60.5 (C-1), 37.7 (C-2), 26.0 (SiC(CH3)3), 18.3 (SiC(CH3)3), 




Alcohol 90 (200 mg, 1.96 mmol) was dissolved in anhydrous DCM (10 mL) and PMBTCA (1.11 
g, 3.92 mmol) and PPTS (50 mg, 0.20 mmol) were added at RT under N2. The reaction was 
stirred for 16 h before addition of solid NaHCO3 (ca. 2.00 g) and petroleum ether (ca. 20 mL). 
The precipitate was filtered, and the filtrate was concentrated in vacuo to give 100 as a 
colourless oil (435 mg, quant.); δH (400 MHz, CDCl3) 7.32 (2 H, d, J 8.5, Ar-H), 6.90 (2 H, d, J 
8.5, Ar-H), 4.87 (1 H, d, J 11.5, OCHH), 4.67 (1 H, d, J 11.5, OCHH), 4.41 (1 H, ddd, J 9.0, 8.0, 
4.5, 5-HH), 4.21 (1 H, ddd, J 9.0, 8.0, 7.0, 5-HH), 4.15 (1 H, t, J 7.5, 3-H), 3.81 (3 H, s, OMe), 
2.43 (1 H, dddd, J 13.0, 7.5, 7.0, 4.5, 4-HH), 2.26 (1 H, dq, J 13.0, 7.5, 4-HH); δC (100 MHz, 
CDCl3) 175.4 (C-2), 159.7 (Ar-C), 130.51 (Ar-C), 129.1 (Ar-C), 114.8 (Ar-C), 72.1 (OCH2), 72.0 
(C-3), 65.7 (C-5), 55.5 (OMe), 30.1 (C-4). Data in accordance with the literature.212 
(3S)-3-(4-Methoxybenzyloxy)-2-methyltetrahydrofuran-2-ol 101 
 
Lactone 100 (435 mg, 1.96 mmol) was dissolved in anhydrous THF (15 mL) at -78 C under 
N2. MeLi (1.6 M in Et2O, 1.35 mL, 2.16 mmol) was added and the reaction mixture was stirred 




for 3 h at -78 C followed by addition of sat. aq. NH4Cl (10 mL). The reaction mixture was 
extracted with EtOAc (3 x 20 mL), the combined organic extracts were dried (MgSO4) and the 
solvent removed in vacuo to give a pale yellow oil. This was purified by column 
chromatography (10% EtOAc in petrol) to give lactol 101 as a colourless oil (320 g, 75%); νmax 
(neat)/cm-1 3434, 2961, 2929, 2864, 1252, 1103, 1088, 1054, 1021, 1005; δH (400 MHz, CDCl3) 
7.27 (2 H, m, Ar-H), 6.90 (2 H, m, Ar-H), 4.58 (1 H, m, OCH2), 4.39 (1 H, m, 5-HH), 4.00 (1 H, 
m, 5-HH), 3.98 (1 H, m, 3-H), 3.81 (3 H, s, OMe), 3.75 (2 H, m, 4-H2), 2.20 (3 H, s, CH3); δC (100 
MHz, CDCl3) 159.7 (Ar-H), 129.4 (Ar-H), 114.1 (Ar-H), 113.8 (Ar-H), 102.4 (C-2), 81.6 (C-3), 
72.2 (OCH2), 59.7 (C-4), 55.2 (OMe), 25.3 (CH3); Found (ESI): 222.1247 [M+H-H2O]+, (C13H18O3 
requires 222.1250). Data reported for the major product. 
(S)-3-(4-Methoxybenzyloxy)-4-methylpent-4-en-1-ol 102 
 
CH3PPh3Br (306 mg, 0.86 mmol) was suspended in anhydrous THF (10 mL) under N2 and 
cooled to -78 C. NaHMDS (1.0 M in THF, 0.86 mL, 0.86 mmol) was added and stirred at this 
temperature for 1 h. Lactol 101 (160 mg, 0.71 mmol) was added and the reaction mixture 
stirred at reflux for 24 h. The reaction mixture was quenched by addition of aqueous NH4Cl 
(10 mL) and allowed to cool before extraction with Et2O (3 x 10 mL). The combined organic 
extracts were dried (MgSO4) and the solvent removed in vacuo to give an orange oil which 
was purified by column chromatography (5% EtOAc in petrol) to give alcohol 102 as a 
colourless oil (48 mg, 28%); [𝛼]𝐷
25= -10 (c 1.0, CHCl3);  νmax (neat)/cm-1 3347 (OH), 3063, 2914, 
2930, 1437, 1182, 1119;  δH (400 MHz, CDCl3) 7.24 (2 H, d, J 8.5, Ar-H), 6.88 (2 H, d, J 8.5, Ar-
H), 4.99 (2 H, s, 5-H2), 4.47 (1 H, d, J 11.5, OCHH), 4.21 (1 H, d, J 11.5, OCHH), 3.97 (1 H, dd, J 
9.0, 4.0, 3-H), 3.81 (3 H, s, OMe), 3.73 (2 H, dd, J 7.0, 4.5, 1-H2), 2.40 (1 H, brs, OH), 1.94 (1 H, 
dddd, J 14.5, 9.0, 7.0, 5.0, 2-HH), 1.73 (3 H, t, J 1.0, 4-CH3), 1.69 (1 H, m, 2-HH); δC (100 MHz, 
CDCl3) 159.4 (Ar-C), 144.4 (Ar-C), 130.4 (Ar-C), 129.6 (C-4), 114.0 (Ar-C), 113.7 (C-5), 82.5 (C-
3), 69.9 (OCH2), 61.4 (C-1), 55.4 (OMe), 36.4 (C-2), 17.1 (CH3); Found (ESI): 259.1296 [M+Na]+, 
(C14H20NaO3 requires 259.1305).  
 
 






Alcohol 99 (1.00 g, 4.34 mmol) and PMBTCA (3.70 g, 13.0 mmol) were dissolved in DCM (30 
mL) under N2. PPTS (108 mg, 0.43 mmol) was added and the reaction mixture stirred at RT 
for 16 h, after which time solid NaHCO3 (ca. 1.00 g) and petroleum ether (50 mL) were added. 
The reaction mixture was filtered and the solvent removed in vacuo to give an orange oil 
which was purified by column chromatography (2% EtOAc in petrol) to give PMB ether 91 as 
a colourless oil (600 mg, 39%); νmax (neat)/cm-1 2955, 2928, 2857, 2253, 1513, 1463, 1248, 
1086; [𝛼]𝐷
25= -11 (c 2.0, CHCl3); H (400 MHz, CDCl3) 7.26 (2 H, d, J 8.5, Ar-H), 6.88 (2 H, d, J 
8.5, Ar-H), 4.87 (1 H, s, 1-H), 4.73 (1 H, s, 1-H), 4.44 (1 H, d, J 11.5, OCHH), 4.38 (1 H, d, J 11.5, 
OCHH), 4.21 (1 H, m, 3-H), 3.81 (3 H, s, OMe), 3.48 (2 H, m, 5-H2), 1.77 (2 H, m, 4-H2), 1.68 (3 
H, s, 2-CH3), 0.88 (9 H, s, SiC(CH3)3), 0.04 (3 H, s, SiCH3), 0.00 (3 H, s, SiCH3); C (100 MHz, 
CDCl3) 159.1 (Ar-C), 147.7 (C-2), 130.7 (Ar-C), 129.3 (Ar-C), 113.7 (Ar-C), 110.6 (C-1), 73.6 (C-
3), 72.7 (OCH2), 66.8 (C-5), 55.3 (OMe), 36.5 (C-4), 25.8 (SiC(CH3)3), 18.2 (SiC(CH3)3), 17.1 (2-




Anhydrous THF (10 mL) was vigorously stirred, to which was added CrCl2 (3.58 g, 29.3 mmol) 
and CHI3 (2.55 g, 6.48 mmol) portionwise over 10 mins at 0 C under N2. Aldehyde 77 (700 
mg, 3.24 mmol) in anhydrous THF (16 mL) was added dropwise. The resulting solution was 
stirred at 0 C for 20 mins, followed by 2 h at RT, before being quenched by addition of 
saturated aqueous Na2S2O3 (30 mL) and stirred for 30 mins. The reaction mixture was 
extracted with Et2O (3 x 25 mL), the combined organic extracts were dried (MgSO4) and the 
solvent removed in vacuo to give a yellow oil. This was purified by column chromatography 
(100% petrol) to give vinyl iodide 108 as a pale yellow oil (350 mg, 32%); νmax (neat)/cm-1 




2955, 2928, 2856, 2462, 1372, 1250; [𝛼]𝐷
25= +17 (c 1.0, CHCl3); H (400 MHz, CDCl3) 6.46 (1 H, 
dd, J 14.5, 8.5, 2-H), 5.97 (1 H, dd, J 14.5, 1.0, 1-H), 3.64 (1 H, qd, J 6.0, 5.0, 4-H), 2.17 (1 H, 
m, 3-H), 1.07 (3 H, d, J 6.0, 5-H3), 0.98 (3 H, d, J 7.0, 3-CH3), 0.89 (9 H, s, Si(CH3)3), -0.04 (6 H, 
s, 2 x SiCH3); C (100 MHz, CDCl3) 149.2 (C-2), 74.9 (C-1), 71.4 (C-4), 48.5 (C-3), 26.0 (SiC(CH3)3), 
21.4 (C-5), 18.2 (SiC(CH3)3), 15.9 (3-CH3), -4.2 (SiCH3), -4.6 (SiCH3); Found (ESI): 363.0608 




To a stirred solution of alkene 91 (431 mg, 1.23 mmol) in degassed anhydrous THF (4 mL) at 
-78 C under N2 was added a solution of 9-BBN in THF (0.5 M, 7.40 mL, 3.70 mmol). The 
resulting solution was stirred at RT for 14 h, before being quenched with degassed H2O (4 
mL) and stirred for 1 h. In a separate flask, vinyl iodide 108 (350 mg, 1.03 mmol) was 
dissolved in degassed DMF (29 mL) and Cs2CO3 (1.20 g, 3.70 mmol), Pd(dppf)Cl2 (183 mg, 
0.25 mmol) and AsPh3 (76.6 mg, 0.25 mmol) were added and the reaction mixture stirred for 
10 mins under N2 at RT. The borane solution was added dropwise to this mixture and the 
reaction stirred at RT for 8 h, before being quenched by addition of H2O (ca. 15 mL). The 
mixture was filtered through celite and extracted with Et2O (3 x 30 mL). The combined 
organic extracts were dried (MgSO4) and the solvent removed in vacuo to give a brown oil. 
This was purified by column chromatography (100% petrol) to give alkene 113 as a colourless 
oil (326 mg, 56%); [𝛼]𝐷
25= -20 (c 0.5, CHCl3); νmax (neat)/cm-1 2957, 2931, 2856, 1248, 1086, 
1067, 1005; H (500 MHz, CDCl3) 7.25 (2 H, d, J 8.5, Ar-H), 6.87 (2 H, d, J 8.5, Ar-H), 5.33 (2 H, 
m, 6-H & 7-H), 4.44 (1 H, d, J 11.5, OCHH), 4.40 (1 H, d, J 11.5, OCHH), 3.80 (3 H, s, OMe), 
3.72 (1 H, m, 3-H), 3.67 (1 H, m, 9-H), 3.51 (1 H, m, 1-HH), 3.48 (1 H, m, 1-HH), 2.10 (1 H, m, 
8-H), 2.00 (1 H, m, 5-HH), 1.78 (1 H, m, 5-HH), 1.69 (2 H, m, 2-H2), 1.63 (1 H, m, 4-H), 1.02 (3 
H, d, J 6.5, 10-H3), 0.94 (3 H, d, J 6.5, 8-CH3), 0.88 (9 H, s, SiC(CH3)3), 0.87 (9 H, s, SiC(CH3)3), 
0.85 (3 H, d J 6.5, 4-CH3), 0.03 (6 H, s, SiCH3 x2), 0.01 (SiCH3 x2); C (125 MHz, CDCl3) 159.2 
(Ar-C), 134.1 (C-7), 130.9 (Ar-C), 129.4 (Ar-C), 128.9 (C-6), 113.9 (Ar-C), 72.7 (OCH2), 72.4 (C-




3), 72.1 (C-9), 67.6 (C-1), 55.4 (OMe), 44.4 (C-8), 39.4 (C-4), 36.5 (C-5), 32.0 (C-2), 26.1 
(SiC(CH3)3), 26.0 (SiC(CH3)3), 20.6 (10-CH3), 18.3 (SiC(CH3)3), 18.2 (SiC(CH3)3), 16.0 (8-CH3), 
14.3 (4-CH3), -4.2 (SiCH3), -4.2 (SiCH3), -4.5 (SiCH3), -4.7 (SiCH3); Found (MALDI): 587.3928 
[M+Na]+, (C32H60NaO4Si2 requires 587.3928). 
(S)-1,3-Bis(tert-butyldimethylsilyloxy)-4-methylpent-4-ene 119 
 
Alcohol 99 (200 mg, 0.77 mmol) was dissolved in anhydrous DCM (5 mL) and TBSCl (142 mg, 
1.16 mmol), imidazole (206 mg, 1.37 mmol) and DMAP (5 mg, 0.08 mmol) were added under 
N2. The reaction mixture was stirred at RT for 16 h before the addition of H2O (5 mL). The 
aqueous layer was extracted with DCM (3 x 10 mL), the combined organic extracts were dried 
(MgSO4), and the solvent removed in vacuo to give a pale yellow oil. This was purified by 
filtration through a pad of silica and washing with EtOAc (ca. 40 mL). The solvent was 
removed in vacuo to give silyl ether 119 as a colourless oil (268 mg, 94%); νmax (neat)/cm-1 
2954, 2929, 2857, 1471, 1361, 1253, 1085; [𝛼]𝐷
25= -14 (c 0.5, CHCl3); H (400 MHz, CDCl3) 4.86 
(1 H, s, 5-HH), 4.75 (1 H, s, 5-HH), 4.21 (1 H, dd, J 7.5, 5.0, 3-H), 3.63 (2 H, m, 1-H2), 1.73-1.64 
(2 H, m, 2-H2), 1.68 (3 H, s, 4-CH3), 0.89 (9 H, s, SiC(CH3)3), 0.89 (9 H, s, SiC(CH3)3), 0.04 (3 H, 
s, SiCH3), 0.04 (6 H, s, SiCH3 x 2), 0.01 (3 H, s, SiCH3); C (100 MHz, CDCl3) 148.0 (C-4), 110.6 
(C-5), 73.6 (C-3), 59.9 (C-1), 39.7 (C-2), 26.1 (SiC(CH3)3), 26.0 (SiC(CH3)3), 18.4 (SiC(CH3)3), 18.4 
(SiC(CH3)3), -4.6 (SiCH3), -5.0 (SiCH3), -5.1 (SiCH3), -5.1 (SiCH3); Found (MALDI): 366.2456 
[M+Na]+, (C18H40NaO2Si2 requires 366.2465). 
(3S,4R,8R,9S,E)-1,3,9-Tris(tert-butyldimethylsilyloxy)-4,8-dimethyldec-6-ene 120 
 
To a stirred solution of alkene 119 (150 mg, 0.40 mmol) in degassed anhydrous THF (1.5 mL) 
at -78 C under N2 was added a solution of 9-BBN in THF (0.5 M, 2.40 mL, 1.20 mmol). The 
resulting solution was stirred at RT for 14 h, before being quenched with degassed H2O (1.5 




mL) and stirred for 1 h. In a separate flask, vinyl iodide 108 (115 mg, 0.34 mmol) was 
dissolved in degassed DMF (9 mL) and Cs2CO3 (397 mg, 1.22 mmol), Pd(dppf)Cl2 (66 mg, 0.09 
mmol) and AsPh3 (26 mg, 0.09 mmol) were added and stirred for 10 mins under N2 at RT. 
The borane solution was added dropwise to this mixture and the reaction stirred at RT for 8 
h, before being quenched by addition of H2O (10 mL). The mixture was filtered through celite 
and extracted with Et2O (3 x 30 mL). The combined organic extracts were dried (MgSO4) and 
the solvent removed in vacuo to give a brown oil. This was purified by column 
chromatography (100% petrol) to give silyl ether 120 as a colourless oil (168 mg, 89%); νmax 
(neat)/cm-1 2955, 2928, 2856, 1471, 1462, 1252, 1088; [𝛼]𝐷
25= -2 (c 1.0, CHCl3); H (400 MHz, 
CDCl3) 5.35 (2 H, m, 6-H + 7-H), 3.73-3.68 (3 H, m, 9-H + 1-H2), 3.63 (1 H, dt, J 10.0, 7.5, 3-H), 
2.13 (1 H, qd, J 6.5, 4.0, 8-H), 2.02 (1 H, ddd, J 11.0, 9.0, 5.5, 5-HH), 1.79 (1 H, m, 5-HH), 1.63 
(1 H, m, 4-H), 1.58 (2 H, m, 2-H2), 1.03 (3 H, d, J 6.5, 10-H3), 0.96 (3 H, d, J 6.5, 8-CH3), 0.90 (9 
H, s, SiC(CH3)3, 0.89 (18 H, s, SiC(CH3)3 x2), 0.86 (3 H, d, J 6.5, 4-CH3), 0.05 (6 H, s, SiCH3 x2), 
0.04 (12 H, s, SiCH3 x4); C (100 MHz, CDCl3) 134.0 (C-7), 129.1 (C-6), 72.2 (C-3), 72.1 (C-9), 
60.7 (C-1), 44.4 (C-8), 39.6 (C-4), 36.4 (C-5), 36.2 (C-2), 26.2 (SiC(CH3)3), 26.1 (SiC(CH3)3), 26.1 
(SiC(CH3)3), 20.6 (C-10), 18.5 (SiC(CH3)3), 18.3 (SiC(CH3)3), 18.3 (SiC(CH3)3), 16.1 (8-CH3), 14.4 
(4-CH3), -4.2 (SiCH3), -4.2 (SiCH3), -4.4 (SiCH3), -4.6 (SiCH3), -5.1 (SiCH3), -5.1 (SiCH3). Found 
(MALDI): 580.4211 [M+Na]+, (C30H66NaO3Si3 requires 580.4217). 
(3S,4R,8R,9S,E)-3,9-Bis(tert-butyldimethylsilyloxy)-4,8-dimethyldec-6-en-1-ol 92 
 
PMB ether 113 (100 mg, 0.18 mmol) was dissolved in DCM (2 mL) and phosphate buffer (2 
mL) at 0 C. DDQ (80 mg, 0.35 mmol) was added and the reaction stirred for 5 h at RT before 
addition of solid NaHCO3 (100 mg). The reaction mixture was concentrated in vacuo and the 
resulting orange residue purified by column chromatography (5% EtOAc in petrol) to give 
alcohol 92 as a colourless oil (41 mg, 50%); νmax (neat)/cm-1 3789, 2953, 2929, 2836, 1251, 
1084;  [𝛼]𝐷
25= -7 (c 1.0, CHCl3); H (400 MHz, CDCl3) 5.33 (2 H, m, 6-H + 7-H), 3.79 (1 H, dt, J 
8.5, 4.0, 3-H), 3.74 (2 H, m, 1-H2), 3.68 (1 H, m, 9-H), 2.16 (1 H, m, OH), 2.13 (1 H, td, J 7.0, 
4.0, 8-H), 2.01 (1 H, m, 5-HH), 1.79 (1 H, ddd, J 13.5, 8.5, 5.5, 5-HH), 1.70 (1 H, m, 4-H), 1.66 
(2 H, m, 2-H2), 1.03 (3 H, d, J 6.5, 10-CH3), 0.96 (3 H, d, J 6.5, 8-CH3), 0.90 (9 H, s, SiC(CH3), 




0.88 (9 H, s, SiC(CH3), 0.86 (3 H, d, J 6.5, 4-CH3), 0.09 (3 H, s, SiCH3), 0.07 (3 H, s, SiCH3), 0.03 
(3 H, s, SiCH3), 0.03 (3 H, s, SiCH3); C (100 MHz, CDCl3) 133.1 (C-7), 128.5 (C-6), 74.7 (C-3), 
72.1 (C-9), 61.1 (C-1), 44.4 (C-8), 39.1 (C-4), 36.9 (C-5), 33.2 (C-2), 26.0 (SiC(CH3)3 x 2), 20.7 
(C-10), 18.3 (SiC(CH3)), 18.2 (SiC(CH3)), 16.2 (8-CH3), 14.0 (4-CH3), -4.2 (SiCH3), -4.2 (SiCH3), -




TBS ether 120 (100 mg, 0.18 mmol) was dissolved in anhydrous MeOH (2 mL) and Py.Br3 
(2.87 mg, 0.009 mmol) was added at 0 C under N2. The reaction mixture was stirred at this 
temperature for 2.5 h before being quenched with sat. aq. NaHCO3 (ca. 5 mL) and extracted 
with EtOAc (3 x 10 mL). The combined organic extracts were dried (MgSO4) and the solvent 
removed in vacuo to give a yellow oil. This was purified by column chromatography (5% 
EtOAc in petrol) to give alcohol 92 as a colourless oil (32 mg, 40%); νmax (neat)/cm-1 3789, 
2953, 2929, 2836, 1251, 1084; [𝛼]𝐷
25= -7 (c 1.0, CHCl3); H (400 MHz, CDCl3) 5.33 (2 H, m, 6-H 
+ 7-H), 3.79 (1 H, dt, J 8.5, 4.0, 3-H), 3.74 (2 H, m, 1-H2), 3.68 (1 H, m, 9-H), 2.16 (1 H, m, OH), 
2.13 (1 H, m, 8-H), 2.01 (1 H, m, 5-HH), 1.79 (1 H, ddd, J 13.5, 8.5, 5.5, 5-HH), 1.70 (1 H, m, 4-
H), 1.66 (2 H, m, 2-H2), 1.03 (3 H, d, J 6.5, 10-H3), 0.96 (3 H, d, J 6.5, 8-CH3), 0.90 (9 H, s, 
SiC(CH3), 0.88 (9 H, s, SiC(CH3), 0.86 (3 H, d, J 6.5, 4-CH3), 0.09 (3 H, s, SiCH3), 0.07 (3 H, s, 
SiCH3), 0.03 (3 H, s, SiCH3), 0.03 (3 H, s, SiCH3); C (100 MHz, CDCl3) 133.1 (C-7), 128.5 (C-6), 
74.7 (C-3), 72.1 (C-9), 61.1 (C-1), 44.4 (C-8), 39.1 (C-4), 36.9 (C-5), 33.2 (C-2), 26.0 (SiC(CH3)3 
x 2), 20.7 (C-10), 18.3 (SiC(CH3)), 18.2 (SiC(CH3)), 16.2 (8-CH3), 14.0 (4-CH3), -4.2 (SiCH3), -4.2 











Silyl ether 120 (300 mg, 0.54 mmol) was dissolved in anhydrous MeOH (6 mL) and Py.Br3 
(17.2 mg, 0.054 mmol) added at 0 °C under N2 and stirred for 4 h at this temperature. The 
reaction was quenched with sat. aq. NaHCO3 (ca. 3 mL) and extracted with EtOAc (5 x 10 mL). 
The combined organic extracts were dried (MgSO4) and the solvent removed in vacuo to give 
a pale orange oil. This was purified column chromatography (15-100% EtOAc in petrol) to 
give 122 as a colourless oil (134 mg, 75%); νmax (neat)/cm-1 3364 (brs), 2957, 2929, 2866, 
1462, 1376, 1253, 1059; [𝛼]𝐷
25= + 6 (c 0.5, CHCl3); H (400 MHz, CDCl3) 5.48 (1 H, dt, J 15.5, 
7.0, 6-H), 5.34 (1 H, dd, J 15.5, 8.0, 7-H), 3.80 (1 H, m, 3-H), 3.74 (2 H, m, 1-H2), 3.52 (1 H, m, 
9-H), 2.07 (2 H, m, 8 H + 5HH), 1.86 (1 H, m, 5-HH), 1.73 (1 H, m, 4-H), 1.64 (2 H, m, 2-H2), 
1.17 (3 H, d, J 6.5, 10-CH3), 1.00 (3 H, d, J 6.5, 8-CH3), 0.88 (9 H, s, SiC(CH3)3), 0.86 (3 H, d, J 
6.5, 4-CH3), 0.09 (SiCH3), 0.07 (SiCH3); C (101 MHz, CDCl3) 133.7 (C-7), 131.1 (C-6), 74.0 (C-
3), 71.4 (C-9), 60.8 (C-1), 45.1 (C-8), 38.9 (C-4), 36.8 (C-5), 33.5 (C-2), 26.0 (SiC(CH3)3), 16.8 




Alcohol 92 (130 mg, 0.29 mmol) was dissolved in anhydrous DCM (10 mL), NaHCO3 (121 mg, 
1.45 mmol) and the reaction mixture was cooled to 0 °C under N2. DMP (1.08 mL, 0.38 mmol) 
was added dropwise and the reaction mixture stirred at RT for 1.5 h, after which time sat. 
aq. Na2S2O3 (ca. 5 mL) was added. The reaction mixture was extracted with DCM (3 x 10 mL), 
the combined organic extracts were dried (MgSO4) and the solvent removed in vacuo to give 
a yellow oily solid. This was triturated with Et2O (ca. 2 mL), filtered and the solvent removed 
in vacuo to give aldehyde 123 as a colourless oil (125 mg, 98%) which was used without 
further purification; νmax (neat)/cm-1 2929, 2857, 1729, 1462, 1375, 1253, 1087;  [𝛼]𝐷
25= +2 (c 




1.0, CHCl3); δH (400 MHz, CDCl3) 9.79 (1 H, dd, J 3.0, 2.0, 1-H), 5.34 (2 H, m, 6-H & 7-H), 4.15 
(1 H, dt, J 8.0, 4.0, 3-H), 3.68 (1 H, qd, J 6.5, 4.0, 9-H), 2.50 (1 H, ddd, J 15.5, 8.0, 3.0, 2-HH), 
2.38 (1 H, ddd, J 15.5, 4.0, 2.0, 2-HH), 2.11 (1 H, m, 8-H), 2.01 (1 H, m, 5-HH), 1.82 (1 H, m, 5-
HH), 1.71 (1 H, m, 4-H), 1.02 (3 H, d, J 6.5, 10-H3), 0.95 (3 H, d, J 6.5, 8-CH3), 0.87 (21 H, m, 2 
x Si(CH3)3 & 4-CH3), 0.03 (12 H, m, 4 x SiCH3); C (125 MHz, CDCl3) 202.8 (C-1), 134.8 (C-7), 
128.1 (C-6), 72.0 (C-9), 71.1 (C-3), 46.5 (C-2), 44.4 (C-8), 39.7 (C-4), 36.6 (C-5), 26.0 (C(CH3)3), 
25.9 (C(CH3)3), 20.8 (C-10), 18.3 (C(CH3)3), 18.2 (C(CH3)3), 16.3 (8-CH3), 14.2 (4-CH3), -4.2 
(SiCH3), -4.3 (SiCH3), -4.5 (SiCH3), -4.7 (SiCH3); Found (ESI): 443.3373 [M+H]+, (C24H51O3Si2 
requires 443.3371). 
(3S,4R,8R,9S,E)-3-(tert-Butyldimethylsilyloxy)-9-hydroxy-4,8-dimethyldec-6-enoic acid 124 
 
Aldehyde 99 (30 mg, 0.07 mmol) was dissolved in anhydrous DMF (0.7 mL) and oxone (20 
mg, 0.07 mmol) was added and stirred at RT for 3 h under N2. HCl (1 M, ca. 1 mL) was added 
and the reaction mixture extracted with EtOAc (3 x 1 mL). The combined organic extracts 
were washed with water (3 x 5 mL), dried (MgSO4) and the solvent removed in vacuo to give 
a pale yellow oil. This was purified by column chromatography (20-100% EtOAc in petrol) to 
give acid 100 as a colourless oil (12.5 mg, 52%) ; νmax (neat)/cm-1 3410 (brs), 2959, 2929, 2866, 
1712, 1462, 1378, 1252, 1080; [𝛼]𝐷
25= +4 (c  1, CHCl3); H (500 MHz, CDCl3) 5.48 (1 H, dt, J 
14.5, 7.0, 6-H), 5.38 (1 H, ddt, J 15.5, 8.5, 1.5, 7-H), 4.09 (1 H, m, 3-H), 3.53 (1 H, p, J 6.0, 9-
H), 2.43 (2 H, d, J 6.0, 2-H2), 2.08 (2 H, m, 8-H, 5-HH), 1.88 (1 H, m, 5-HH), 1.73 (1 H, m, 4-H), 
1.16 (3 H, d, J 6.5, 10-H3), 1.00 (3 H, d, J 6.5, 8-CH3), 0.88 (3 H, d, J 6.5, 4-CH3), 0.87 (9 H, s, 
SiC(CH3)3, 0.07 (SiCH3), 0.06 (3 H, s, SiCH3) C (125 MHz, CDCl3) 176.4 (C-1), 133.9 (C-7), 130.4 
(C-6), 72.2 (C-3), 71.2 (C-9), 44.9 (C-8), 39.0 (C-4), 37.6 (C-2), 36.2 (C-5), 25.8 (SiC(CH3)3), 20.2 
(C-10), 18.0 (SiC(CH3)3), 16.6 (8-CH3), 14.3 (4-CH3), -4.6 (SiCH3), -4.8 (SiCH3); Found (ESI): 








(R)-3-(2,2,5,5-tetramethyl-1,3-dioxane-4-carboxamido)propionic acid 126 
 
Acetone (50 mL) was stirred with molecular sieves for 20 mins before calcium D-
pantothenate 125 (1.0 g, 2.09 mmol) and PTSA (0.96 g, 5.56 mmol) were added under N2. 
The reaction mixture was stirred at RT for 16 h before being filtered through celite and 
washed with acetone (30 mL). The solvent was removed in vacuo to give a white residue 
which was dissolved in EtOAc (20 mL) and washed with brine (20 mL). The organic extract 
was dried (MgSO4) and the solvent removed in vacuo to give a white solid which was 
triturated with n-hexanes (ca. 5 mL) to give 126 as a white solid (444 mg, 82%); [𝛼]𝐷
25= +62.0 
(c 1.0, CHCl3); H (400 MHz, CDCl3) 7.01 (1 H, m, NH), 4.10 (1 H, s, 3-H), 3.70 (1 H, d, J 12.0, 1-
HH), 3.58 (1 H, m, 6-HH), 3.49 (1 H, m, 6-HH), 3.30 (1 H, d, J 12.0, 1-HH), 2.69 (2 H, t, J 6.0, 7-
H2), 1.46 (3 H, s, 9-CH3), 1.43 (3 H, s, 9-CH3), 1.04 (3 H, s, 2-CH3), 0.98 (3 H, s, 2-CH3); C (100 
MHz, CDCl3) 176.5 (C-8), 170.3 (C-4), 99.2 (C-9), 77.1 (C-3), 71.5 (C-1), 34.2 (C-6), 33.9 (C-7), 
33.0 (C-2), 29.5 (9-CH3), 22.1 (2-CH3), 18.9 (2-CH3), 18.8 (9-CH3). Data in accordance with the 
literature. 213 
Pantetheine dimethyl ketal 127 
 
Acid 126 (410 mg, 1.58 mmol) was dissolved in anhydrous THF (8 mL) under N2 and CDI (374 
mg, 2.30 mmol) was added. The reaction mixture was stirred at RT for 30 mins before 
cysteamine HCl (262 mg, 3.40 mmol) was added and the reaction mixture stirred for 16 h. 
The reaction was quenched by addition of sat. aq. NH4Cl (10 mL) and extracted with DCM (3 
x 10 mL). The combined organic extracts were washed with brine (20 mL), dried (MgSO4) and 
the solvent removed in vacuo to give a colourless oil. This was purified by column 
chromatography (100% EtOAc) to give 127 as a white solid (377 mg, 75%); m.p 99-101 °C; 
[𝛼]𝐷
25= +33.4 (c 1.0, MeOH); H (400 MHz, CDCl3) 6.90 (1 H, br s, NH), 6.21 (1 H, br s, NH), 4.08 
(1 H, s, 3-H), 3.70 (1 H, d, J 12.0, 1-HH), 3.57 (2 H, m, 6-H2), 3.47 (2 H, m, 10-H2), 3.27 (1 H, d, 




J 12.0, 1-HH), 2.66 (2 H, q, J 7.0, 11-H2), 2.47 (2 H, t, J 6.0, 7-H2), 1.46 (3 H, s, 12-CH3), 1.42 (3 
H, s, 12-CH3), 1.36 (1 H, t, J 8.5, SH), 1.09 (3 H, s, 2-CH3), 0.97 (3 H, s, 2-CH3); C (100 MHz, 
CDCl3) 171.1 (C-8), 170.2 (C-4), 99.1 (C-12), 77.1 (C-3), 71.4 (C-1), 42.4 (C-10), 36.1 (C-7), 34.8 
(C-6), 32.9 (C-2), 29.5 (12-CH3), 22.1 (2-CH3), 18.9 (2-CH3), 18.7 (12-CH3). Data in accordance 
with the literature. 214 
(3S,4R,8R,9S,E)-3,9-dihydroxy-4,8-dimethyldec-6-enethioate-pantetheine 29 
 
Acid 124 (9.5 mg, 0.03 mmol) was dissolved in anhydrous DCM (0.2 mL) under N2. Protected 
pantetheine 127 (29 mg, 0.09 mmol) and DMAP (0.4 mg, 0.003 mmol) were added. The 
reaction mixture was cooled to 0 °C and EDCI (7.2 mg, 0.038 mmol) was added. The reaction 
was stirred at this temperature for 5 mins followed by RT for 16 h. HCl (1 M, 1 mL) was added 
and the two layers were separated. The aqueous layer was extracted with EtOAc (3 x 1 mL), 
the combined organic extracts dried (MgSO4) and the solvent removed in vacuo to give a 
pale yellow oil (16.5 mg, 0.03 mmol) which was dissolved in THF (0.5 mL). HCl (2 M, 0.25 mL) 
was added and the reaction mixture was stirred at RT for 9 h before addition of sat. aq. 
NaHCO3 (ca. 1 mL) and extraction with EtOAc (3 x 5 mL). The combined organic extracts were 
dried (MgSO4) and the solvent removed in vacuo to give a colourless oil. This was purified by 
column chromatography (5-15% MeOH in DCM) to give 29 as a colourless oil (14.7 mg, 98%); 
νmax (neat)/cm-1 3676 (brs), 3344 (brs), 2972, 2920, 2904, 1708, 1655, 1578, 1451, 1404, 
1252, 1069; [𝛼]𝐷
25= +4 (c 0.5, MeOD);  H (500 MHz, MeOD) 5.46 (2 H, m, 6-H + 7-H), 3.97 (1 
H, ddd, J 9.0, 6.0, 3.0, 3-H), 3.92 (1 H, s, 7’-H), 3.63 (1 H, qd, J 6.0, 5.0, 9-H), 3.47 (2 H, m, 5’-
H2), 3.47 (1 H, m, 9’-HH), 3.40 (1 H, m, 9’-HH), 3.36 (2 H, m, 2’-H2), 3.03 (2 H, t, J 6.5, 1’-H2), 
2.74 (1 H, dd, J 15.0, 3.5, 2-HH), 2.69 (1 H, m, 2-HH), 2.42 (2 H, t, J 6.5, 4’-H2), 2.21 (1 H, m, 5-
HH), 2.16 (1 H, m, 8-H), 1.91 (1 H, m, 5-HH), 1.64 (1 H, m, 4-H), 1.12 (3 H, s, 10-H3), 1.02 (3 H, 




d, J 6.5, 8-CH3), 0.93 (6 H, s, 2 x 8’-CH3), 0.90 (3 H, d, J 6.5, 4-CH3); C (125 MHz, MeOD) 199.4 
(C-1), 176.1 (C-6’), 174.0 (C-3’), 135.3 (C-7), 130.1 (C-6), 77.3 (C-7’), 73.0 (C-3), 72.2 (C-9), 
70.4 (C-9’), 49.1 (C-2), 45.3 (C-8), 40.4 (C-4), 40.0 (C-2’), 36.7 (C-5), 36.4 (C-4’), 36.3 (C-5’), 
29.3 (C-1’), 21.3 (C-8’), 20.9 (8’-CH3 x 2), 20.2 (C-10), 16.6 (8-CH3), 15.6 (4-CH3); Found (ESI): 
513.2572 [M+Na]+,(C23H42N2NaO7S requires 513.2570).  
9-(4-Methoxybenzyloxy)nonan-1-ol 174 
 
To a suspension of NaH (60% in mineral oil, 91 mg, 2.29 mmol) in anhydrous THF/DMSO (1:1) 
(10 mL) was added 1,9 nonanediol (1.00 g, 6.24 mmol) under N2 at 0°C. The mixture was 
stirred at 0 °C for 1 h, after which time TBAI (76.7 mg, 0.21 mmol) and PMBCl (0.28 mL, 2.08 
mmol) were added. The mixture was stirred for 16 h at RT before sat. aq. NH4Cl (15 mL) was 
added. The reaction mixture was extracted with EtOAc (3 x 20 mL), the combined organic 
extracts were dried (MgSO4) and the solvent removed in vacuo to give an orange oil which 
was purified by column chromatography (10% EtOAc in hexane) to give 174 as a colourless 
oil (1.48 g, 85%); δH (400 MHz, CDCl3) 7.28 (2 H, d, J 8.5, Ar-H), 6.90 (2 H, d, J 8.5, Ar-H), 4.45 
(2 H, s, OCH2Bn), 3.83 (3 H, s, OMe), 3.66 (2 H, t, J 6.5, OCH2), 3.45 (2 H, t, J 6.5, OCH2), 1.60 
(4 H, m, 2  x CH2), 1.33 (10 H, m, 5 x CH2 + OH); δC (100 MHz, CDCl3) 159.1 (Ar-C), 130.8 (Ar-
C), 129.2 (Ar-C), 113.7 (Ar-C), 72.5 (OCH2Bn), 70.2 (OCH2), 63.0 (OCH2), 55.3 (OMe), 32.8 
(CH2), 29.8 (CH2), 29.5 (CH2), 29.4 (CH2), 29.4 (CH2), 26.2 (CH2), 25.7 (CH2). Data in accordance 
with the literature.215 
9-(4-Methoxybenzyloxy)nonyl 3-methylbut-2-enoate 176 
 
To a stirred solution of 3-3-dimethylacrylic acid 175 (160 mg, 1.60 mmol), in anhydrous DCM 
(4 mL) was added DMAP (26 mg, 0.21 mmol), alcohol 174 (300 mg, 1.07 mmol) and DCC (330 
mg, 1.60 mmol) at 0°C under N2. The reaction mixture was stirred for 16 h at RT. After this 
time, the reaction mixture was filtered through a pad of celite and the solvent removed in 
vacuo to give a colourless oil which was purified by column chromatography (5% EtOAc in 




hexane) to give 176 as a colourless oil (487 mg, 84%); νmax (neat)/cm-1 2929, 2854, 1723, 
1511, 1152;  δH (400 MHz, CDCl3) 7.19 (2 H, d, J 8.5, Ar-H), 6.80 (2 H, d, J 8.5, Ar-H), 5.60 (1 H, 
s, 2-H), 4.36 (2 H, s, OCH2Bn), 4.00 (2 H, t, J 6.5, OCH2), 3.73 (3 H, s, OMe), 3.36 (2 H, t, J 6.5, 
OCH2), 2.20 (3 H, s, 4-H3), 1.89 (3 H, s, 3-CH3), 1.66 (4 H, m, 2 x CH2), 1.35 (10 H, m, 5 x CH2); 
δc (100 MHz, CDCl3) 166.8 (C-1), 159.1 (Ar-C), 156.4 (C-3), 130.8 (Ar-C), 129.2 (Ar-C), 115.9 
(C-2), 113.7 (Ar-C), 72.5 (OCH2Ar), 72.3 (CH2OPMB), 63.7 (CO2CH2), 55.3 (OMe), 29.7 (CH2), 
29.5 (CH2), 29.4 (CH2), 29.2 (CH2), 28.7 (CH2), 27.4 (C-4), 26.2 (CH2), 26.0 (CH2), 20.2 (2 x 3-
CH3); Found (ESI): 385.2347 [M+Na]+ , (C22H34O4Na requires 385.2345). 
Silyl dienol ether 171 
 
To a stirred solution of DIPA (0.14 mL, 1.02 mmol) in anhydrous THF (5 mL) at -78 C was 
added nBuLi (1.49 M in hexanes, 0.68 mL, 1.02 mmol) dropwise under N2. The reaction 
mixture was stirred at this temperature for 30 mins after which time PMB ether 176 (300 
mg, 0.83 mmol) was added dropwise and stirred for 15 mins followed by the addition of 
TMSCl (0.105 mL, 0.82 mmol). The reaction mixture was stirred for a further 30 mins at this 
temperature and then warmed to RT for an additional 1 h. The reaction was diluted with 
pentane (ca. 3 mL) and the supernatant removed by pipette and concentrated in vacuo. The 
crude oil was redissolved in pentane and filtered. The filtrate was concentrated in vacuo to 
give silyl dienol ether 171 as an orange oil which was used without further purification (420 
mg, 95%); νmax (neat)/cm-1 2929, 2855, 1644, 1517, 1242, 841; δH (400 MHz, CDCl3) 7.26 (2 
H, d, J 8.5, Ar-H), 6.88 (2 H, d, J 8.5, Ar-H), 4.76 (1 H, s, 4-HH), 4.52 (1 H, s, 4-HH), 4.43 (2 H, 
s, OCH2Ar), 4.22 (1 H, s, 2-H), 3.80 (3 H, s, OCH3), 3.71 (2 H, t, J 6.5, CO2CH2), 3.43 (2 H, t, J 
6.5, CH2OPMB), 1.92 (3 H, s, 3-CH3), 1.63 (4 H, m, 2 x CH2), 1.30 (10 H, m, 5 x CH2), 0.24 (9 H, 
s, TMS); δC (100 MHz, CDCl3) 159.1 (Ar-C), 156.7 (C-3), 140.6 (C-1), 130.8 (Ar-C), 129.3 (Ar-C), 
113.7 (Ar-C), 107.0 (C-4), 80.8 (C-2), 72.5 (OCH2Ar), 70.2 (CH2OPMB), 67.8 (CO2CH2), 55.3 
(OCH3), 29.8 (CH2), 29.4 (CH2), 29.3 (CH2), 29.2 (CH2), 28.9 (CH2), 26.2 (CH2), 26.1 (CH2), 23.7 
(3-CH3), 0.5 (Si(CH3)3); Found (ESI): 457.2748 [M+Na]+, (C25H42NaO4Si requires 457.2745). 
 
 






To a stirred solution of 120 (150 mg, 0.27 mmol) in anhydrous THF (2.5 mL) under N2 was 
added TBAF (2.7 mL, 2.7 mmol) and the reaction mixture stirred at RT for 20 h, followed by 
addition of sat. aq. NH4Cl (ca. 5 mL) and extraction with EtOAc (3 x 5 mL). The combined 
organic extracts were dried (MgSO4) and the solvent removed in vacuo to give an orange oil. 
This was purified by column chromatography (50% EtOAc in petrol) to give 121 as a 
colourless oil (66 mg, 74%); νmax (neat)/cm-1 3346 (brs), 2957, 2928, 2857, 1462, 1361, 1252, 
1031; [𝛼]𝐷
25= +4 (c 2.0, CHCl3); H (400 MHz, CDCl3) 5.41 (2 H, m, 7-H + 6-H), 3.85 (2 H, m, 1-
H2), 3.69 (2 H, m, 9-H + 3-H), 2.40 (1 H, brs, OH), 2.37 (1 H, brs, OH), 2.15 (2 H, m,  8-H + 5HH), 
1.96 (1 H, m, 5-HH), 1.70 (2 H, m, 2-H2),  1.64 (1 H, m, 4-H), 1.04 (3 H, d, J 6.5, 10-H3), 0.96 (3 
H, d, J 6.5, 8-CH3), 0.89 (3 H, d, J 6.5, 4-CH3), 0.88 (9 H, s, SiC(CH3)3), 0.04 (6 H, s, 2 x SiCH3); 
C (100 MHz, CDCl3) 134.7 (C-7), 128.5 (C-6), 76.7 (C-3), 72.1 (C-9), 62.5 (C-1), 44.4 (C-8), 39.6 
(C-4), 36.5 (C-5), 34.8 (C-2), 26.0 (SiC(CH3)3), 20.9 (C-10), 18.3 (SiC(CH3)3), 16.4 (8-CH3), 15.5 
(4-CH3), -4.2 (SiCH3), -4.7 (SiCH3); Found (ESI): 353.2476 [M+Na]+, (C18H38NaO3Si requires 
353.2482). 
(3S,4R,8R,9S,E)-9-(tert-butyldimethylsilyloxy)-3-hydroxy-4,8-dimethyldec-6-enal 178  
 
Triol 121 (40 mg, 0.12 mmol) was dissolved in anhydrous DCM (0.5 mL) and TEMPO (3 mg, 
0.02 mmol) was added followed by BAIB (39 mg, 0.12 mmol) under N2. The reaction was 
stirred at RT for 3 h before addition of sat. aq. Na2S2O3 (ca. 1 mL) and extraction with DCM 
(3 x 3 mL). The combined organic extracts were dried (MgSO4) and the solvent removed in 
vacuo to give a pale orange oil. This was purified by column chromatography (15% EtOAc in 
petrol) to give 178 as a colourless oil (1.97 mg, 5%); [𝛼]𝐷
25= +3 (c 1.0, CHCl3);  νmax (neat)/cm-
1 3457 (brs), 2957, 2928, 2856, 1725, 1471, 1373, 1361, 1252, 1031; H (500 MHz, CDCl3) 9.87 
(1 H, s, 1-H), 5.39 (2 H, m, 6-H + 7-H), 4.02 (1 H, dd, J 8.5, 6.0, 3-H), 3.68 (1 H, td, J 6.0, 4.5, 9-




H), 2.60 (2 H, m, 2-H2), 2.19 (1 H, m, 5-HH), 2.12 (1 H, m, 8-H), 1.89 (1 H, m, 5-HH), 1.62 (1 H, 
m, 4-H), 1.03 (3 H, d, J 6.5, 10-H3), 0.96 (3 H, d, J 6.5, 8-CH3), 0.90 (3 H, d, J 6.5, 4-CH3), 0.88 
(9 H, s, SiC(CH3)3), 0.03 (3 H, s, SiCH3), 0.03 (3 H, s, SiCH3); C (125 MHz, CDCl3) 203.1 (C-1), 
135.0 (C-7), 128.0 (C-6), 72.1 (C-9), 70.7 (C-3), 47.6 (C-2), 44.4 (C-8), 38.8 (C-4), 36.2 (C-5), 
26.0 (SiC(CH3)3), 20.9 (C-10), 18.3 (SiC(CH3)3), 16.4 (8-CH3), 15.4 (4-CH3), -4.2 (SiCH3), -4.7 
(SiCH3); Found (ESI): 351.2318 [M+Na]+, (C18H36NaO3Si requires 351.2326).  
Treatment of aldehyde 123 with silyl dienol ether 171 
 
Aldehyde 123 (105 mg, 0.24 mmol) was dissolved in anhydrous DCM:Et2O 9:1 (2 mL) and 
cooled to -78 °C. Silyl dienol ether 171 (206 mg, 0.47 mmol) was added followed by B(C6F5)3 
(123 mg, 0.24 mmol). The reaction was stirred at this temperature for 1 h before 
concentrating in vacuo to give a pale orange oil which was purified by column 
chromatography (10% EtOAc in petrol) to give 183 and 184 as colourless oils, both isolated 
as a 1:1 mixture of diastereomers.  
 
Alcohol 183 was repurified by column chromatography (20% DCM in CHCl3) to give a 
colourless oil (52.1 mg, 27%); νmax (neat)/cm-1 3464, 2952, 2928, 2855, 1715, 1646, 1513, 
1462, 1248, 1146, 1093; H (500 MHz, CDCl3, 1:1 mixture of diastereomers) 7.26 (2 H, d, J 8.5, 
Ar-H), 6.87 (2 H, d, J 8.5, Ar-H), 5.73 (1 H, s, 2-H), 5.33 (2 H, m, 10-H & 11-H), 4.43 (2 H, s, 
OCH2Ar), 4.12 (1 H, m, 7-H), 4.07 (2 H, t, J 6.5, 1’-H2), 3.90 (1 H, m, 5-H), 3.80 (3 H, s, OMe), 
3.67 (1 H, m, 13-H), 3.43 (2 H, t, J 6.5, 9’-H2), 2.30 (1 H, m, 6-HH), 2.23 (1 H, m, 6-HH), 2.20 (3 
H, d, J, 1.0 3-H3), 2.12 (1 H, m, 12-H), 1.85 (1 H, m, 9-HH), 1.73 (2 H, m, 8-H + 9-HH), 1.47 (2 
H, m, 4-H2), 1.28 (14 H, m, CH2 x 7), 1.02 (3 H, d, J 6.5, 14-H3), 0.95 (3 H, d, J 6.5, 12-CH3), 0.90 
(9 H, s, SiC(CH3)3), 0.88 (3 H, d, J 6.5, 8-CH3), 0.88 (9 H, s, SiC(CH3)3), 0.11 (3 H, s, SiCH3), 0.10 
(3 H, s, SiCH3), 0.03 (3 H, s, SiCH3), 0.03 (3 H, s, SiCH3); C (125 MHz, CDCl3) 166.8 (C-1), 159.2 
(Ar-C), 156.4 (C-3), 134.6 (C-11), 131.0 (Ar-C), 129.4 (Ar-C), 128.5 (C-10), 128.2 (Ar-C), 118.2 




(C-2), 118.1 (Ar-C), 113.9 (Ar-C). 76.1 (C-5), 72.7 (OCH2Ar), 71.9 (C-13), 70.4 (C-9’), 66.4 (C-7), 
64.0 (C-1’), 55.4 (OMe), 49.2 (C-6), 44.6 (C-12), 39.5 (C-8), 37.1 (C-9), 36.5 (C-4), 29.6 (CH2), 
26.3 (CH2), 26.1 (SiC(CH3)3), 26.0 (SiC(CH3)3), 20.8 (C-14), 18.1 (SiC(CH3)3), 18.0 SiC(CH3)3), 
16.3 (12-CH3), 13.4 (8-CH3), -4.2 (SiCH3), -4.3 (SiCH3), -4.5 (SiCH3), -4.7 (SiCH3); Found (MALDI): 
827.5659 [M+Na]+,(C46H84NaO7Si2 requires 827.5648). 
 
Silyl ether 184 was repurified by column chromatography (60% DCM in CHCl3) to give a 
colourless oil (73.6 mg, 35%); νmax (neat)/cm-1 2954, 2928, 2855, 1716, 1513, 1462, 1374, 
1248, 1146, 1094; H (500 MHz, CDCl3, 1:1 mixture of diastereomers) 7.26 (2 H, d, J 8.5, Ar-
H), 6.87 (2 H, d, J 8.5, Ar-H), 5.68 (1 H, s, 2-H), 5.36 (2 H, m, 10-H + 11-H), 4.43 (2 H, s, OCH2Ar), 
4.08 (2 H, m, 1’-H2), 3.97 (1 H, m, 5-H), 3.80 (3 H, s, OMe), 3.74 (1 H, m, 7-H), 3.69 (1 H, m, 
13-H), 3.43 (2 H, t, J 6.5, 9’-H2), 2.31 (1 H, m, 6-HH), 2.24 (1 H, m, 6-HH), 2.16 (3 H, d, J 1.0, 3-
CH3), 2.10 (1 H, m, 12-H), 1.95 (1 H, m, 9-HH), 1.80 (1 H, m, 9-HH), 1.64 (1 H, m, 8-H), 1.53 (1 
H, m, 4-HH), 1.43 (1 H, m, 4-HH), 1.03 (3 H, d, J 6.5, 14-H3), 0.95 (3 H, d, J 6.5, 12-CH3), 0.88 
(3 H, d, J 6.5, 8-CH3), 0.88 (18 H, s, 2 x SiC(CH3)3), 0.11 (9 H, s, TMS), 0.06 (3 H, s, SiCH3), 0.05 
(3 H, s, SiCH3), 0.04 (3 H, s, SiCH3), 0.03 (3 H, s, SiCH3); C (125 MHz, CDCl3) 166.8 (C-1), 159.2 
(Ar-C), 156.8 (C-3), 134.0 (C-11), 131.0 (Ar-C), 129.4 (Ar-C), 128.9 (C-10), 118.5 (C-2), 118.3 
(Ar-C), 113.9 (Ar-C), 73.0 (C-7), 72.7 (OCH2Ar), 72.2 (C-13), 70.4 (C-9’), 69.0 (C-5), 63.9 (C-1’), 
55.4 (OMe), 50.3 (C-6), 44.4 (C-12), 40.6 (C-4), 39.1 (C-8), 36.1 (C-9), 29.6 (CH2), 29.4 (CH2), 
28.9 (CH2), 26.3 (CH2), 26.1 (SiC(CH3)3), 26.0 (SiC(CH3)3), 20.7 (C-14), 19.4 (3-CH3), 18.3 
(SiC(CH3)3), 18.2 (SiC(CH3)3), 14.3 (12-CH3), 0.97 (TMS), -4.1 (SiCH3), -4.1 (SiCH3), -4.2 (SiCH3), 
-4.6 (SiCH3); Found (MALDI): 899.6049 [M+Na]+,(C49H92NaO7Si3 requires 899.6043). 
Treatment of silyl ethers 183 and 184 with Py.Br3  
 
Silyl ether 184 (74 mg, 0.08 mmol) was dissolved in anhydrous MeOH (1 mL) under N2 and 
Py.Br3 (8.9 mg, 0.03 mmol) added. The reaction was stirred at RT for 5 h before addition of 




sat. aq. NaHCO3 (ca. 2 mL). The mixture was extracted with Et2O (3 x 3 mL), the combined 
organic extracts were dried (MgSO4) and the solvent removed in vacuo to give a pale orange 
oil which was purified by column chromatography (70% EtOAc in petrol) to give alcohols 185 
and 186 as a colourless oil and a 1:1 mixture of diastereomers (41.4 mg, 85%). 
The above reaction was repeated using alcohol 183 (52 mg, 0.06 mmol) to give alcohols 185 
and 186 as a 1:1 mixture (20.2 mg, 82%). The product from both of these reactions were 
combined and the diastereomers separated by column chromatography (100% EtOAc) to 
give alcohol 186 (35 mg) and alcohol 185 (25 mg).  
para-Methoxybenzyl ether of (S)-des-6-hydroxy-desepoxy mupirocin W4-OH 185  
 
 νmax (neat)/cm-1 3327, 2950, 2929, 2850, 1769, 1642, 1513, 1462, 1245, 1145, 1093; [𝛼]𝐷
25= 
+3 (c 1, CHCl3); ẟH (500 MHz, CDCl3) 7.25 (2 H, d, J 8.5, Ar-H), 6.87 (2 H, d, J 8.5, Ar-H), 5.73 (1 
H, s, 2-H), 5.53 (1 H, dt, J 14.5, 7.0, 11-H), 5.33 (1 H, m, 10-H), 4.42 (2 H, s, OCH2Ar), 4.06 (2 
H, t, J 6.5, 1’-CH2), 4.03 (1 H, m, 5-H), 3.80 (3 H, s, OMe), 3.71 (1 H, m, 7-H), 3.50 (1 H, p, J 6.5, 
13-H), 3.42 (2 H, t, J 6.5, 9’-CH2), 2.31 (1 H, dd, J 13.0, 7.5, 4-HH), 2.26 (1 H, dd, J 13.0, 7.5, 4-
HH), 2.18 (3 H, s, 3-CH3), 2.15 (1 H, m, 9-HH), 2.05 (1 H, m, 12-H), 2.00 (1 H, m, 9-HH), 1.63 (1 
H, m, 8-H), 1.62 (6 H, m, CH2 x 3), 1.50 (1 H, m, 6-HH), 1.49 (1 H, m, 6-HH), 1.29 (8 H, m, CH2 
x 4), 1.16 (3 H, d, J 6.5, 14-H3), 0.98 (3 H, d, J 6.5, 12-CH3), 0.90 (3 H, d, J 6.5, 8-CH3); 166.7 (C-
1), 159.2 (Ar-C), 155.8 (C-3), 134.2 (C-10), 130.9 (Ar-C), 130.7 (C-11), 129.4 (Ar-C), 118.5 (C-
2), 113.9 (Ar-C), 76.6 (C-7), 72.6 (OCH2Ar), 71.3 (C-13), 70.7 (C-5), 70.3 (C-9’), 64.1 (C-1’), 55.4 
(OMe), 49.6 (C-4), 45.2 (C-12), 39.4 (C-8), 39.2 (C-6), 35.8, (C-9), 29.8 (CH2), 29.6 (CH2), 29.5 
(CH2), 29.3 (CH2), 28.8 (CH2), 26.3 (CH2), 26.1 (CH2), 20.4 (C-14), 19.1 (3-CH3), 16.9 (12-CH3), 
15.6 (8-CH3); Found (MALDI): 599.3927 [M+Na]+, (C34H56NaO7 requires 599.3918). 
para-Methoxybenzyl ether of (R)-des-6-hydroxy-desepoxy mupirocin W4-OH 186  
 




 νmax (neat)/cm-1 3327, 2950, 2929, 2850, 1769, 1642, 1513, 1462, 1245, 1145, 1093; [𝛼]𝐷
25= 
+6 (c 0.5, CHCl3); ẟH (500 MHz, CDCl3) 7.25 (2 H, d, J 8.5, Ar-H), 6.87 (2 H, d, J 8.5, Ar-H), 5.73 
(1 H, s, 2-H), 5.54 (1 H, m, 11-H), 5.36 (1 H, dd, J 15.0, 8.5, 10-H), 4.42 (2 H, s, OCH2Ar), 4.15 
(1 H, dp, J 12.0, 4.5, 5-H) 4.08 (2 H, t, J 6.5, 1’-CH2), 3.80 (3 H, s, OMe), 3.76 (1 H, m, 7-H), 
3.50 (1 H, p, J 6.5, 13-H), 3.43 (2 H, t, J 6.5, 9’-CH2), 2.34 (1 H, dd, J 13.5, 8.5, 4-HH), 2.27 (1 
H, dd, J 13.5, 5.0, 4-HH), 2.20 (3 H, s, 3-CH3), 2.17 (1 H, m, 9-HH), 2.07 (1 H, m, 12-H), 2.03 (1 
H, m, 9-HH), 1.63 (1 H, m, 8-H), 1.62 (6 H, m, CH2 x 3), 1.50 (1 H, m, 6-HH), 1.49 (1 H, m, 6-
HH), 1.37-1.26 (8 H, m, CH2 x 4), 1.16 (3 H, d, J 6.5, 14-H3), 0.98 (3 H, d, J 6.5, 12-CH3), 0.88 (3 
H, d, J 6.5, 8-CH3);ẟC (125 MHz, CDCl3) 166.7 (C-1), 159.2 (Ar-C), 156.1 (C-3), 134.1 (C-10), 
130.9 (Ar-C), 130.6 (C-11), 129.4 (Ar-C), 118.4 (C-2), 113.9 (Ar-C), 72.6 (OCH2Ar), 72.4 (C-7), 
71.4 (C-13), 70.3 (C-9’), 66.9 (C-5),  64.1 (C-1’), 55.4 (OMe), 49.1 (C-4), 45.1 (C-12), 39.4 (C-
6), 38.9 (C-8), 36.3, (C-9), 29.9 (CH2), 29.8 (CH2), 29.6 (CH2), 29.5 (CH2), 29.3 (CH2), 28.8 (CH2), 
26.3 (CH2), 26.1 (CH2), 20.6 (C-14), 19.2 (3-CH3), 16.9 (12-CH3), 15.7 (8-CH3); Found (MALDI): 
599.3927 [M+Na]+, (C34H56NaO7 requires 599.3918). 
(S)-Des-6-hydroxy-desepoxy mupirocin W4-OH 161 
 
Alcohol 185 (25 mg, 0.04 mmol) was dissolved in DCM (0.95 mL) and pH 7 buffer (0.05 mL). 
DDQ (10 mg, 0.042 mmol) was added and the reaction mixture was stirred in a sealed vial 
for 4 h, before the reaction was quenched by addition of water (ca. 0.5 mL). The layers were 
separated, and the aqueous layer extracted with Et2O (3 x 1 mL). The combined organic 
extracts were dried (MgSO4) and the solvent removed in vacuo to give an orange oil. This 
was purified by column chromatography (100% EtOAc) to give 161 as a pale yellow oil (10.6 
mg, 58%); νmax (neat)/cm-1 3355, 2950, 2929, 2850, 1713, 1550, 1420, 1273, 1151; [𝛼]𝐷
25= +30 
(c 0.5, CHCl3);  ẟH (500 MHz, CDCl3) 5.75 (1 H, s, 2-H), 5.54 (1 H, m, 10-H), 5.34 (1 H, dd, J 15.5, 
8.5, 11-H), 4.07 (2 H, m, 1’-H2), 4.03 (1 H, m, 5-H), 3.72 (1 H, ddd, J 10.5, 5.5, 2.5, 7-H), 3.62 
(2 H, t, J 6.5, 9’-H2), 3.51 (1 H, p, J 6.5, 13-H), 2.32 (1 H, m, 4-HH), 2.30 (1 H, m, 4-HH), 2.19 (3 
H, s, 3-CH3), 2.14 (1 H, m, 9-HH), 2.07 (1 H, m, 12-H), 2.00 (1 H, m, 9-HH), 1.64 (1 H, m, 8-H), 
1.64-1.48 (8 H, m, 4 x CH2), 1.58 (1 H, m, 6-HH), 1.49 (1 H, m, 6-HH), 1.38-1.26 (10 H, m, 5 x 
CH2), 1.16 (3 H, d, J 6.5, 14-H3), 0.98 (3 H, d, J 6.5, 12-CH3), 0.90 (3 H, d, J 6.5, 8-CH3); ẟC (125 




MHz, CDCl3) 166.7 (C-1), 155.8 (C-3), 134.2 (C-10), 130.7 (C-11), 119.3 (C-2), 76.7 (C-7), 71.3 
(C-13), 70.7 (C-5), 64.0 (C-1’), 63.1 (C-9’), 49.6 (C-4), 45.3 (C-12), 39.4 (C-8), 39.3 (C-6), 35.8 
(CH2), 32.9 (CH2), 29.5 (CH2), 29.3 (CH2), 29.2 (CH2), 28.8 (CH2), 26.0 (CH2), 25.8 (CH2), 20.5 
(C-14), 19.2 (3-CH3), 16.9 (12-CH3), 15.6 (8-CH3); Found (ESI): 479.3339 [M+Na]+, (C26H48NaO6 
requires 479.3343). 
(R)-Des-6-hydroxy-desepoxy mupirocin W4-OH 187 
 
Alcohol 186 (35 mg, 0.06 mmol) was dissolved in DCM (0.95 mL) and pH 7 buffer (0.05 mL). 
DDQ (10 mg, 0.042 mmol) was added and the reaction mixture was stirred in a sealed vial 
for 4 h, before the reaction was quenched by addition of water (ca. 0.5 mL). The layers were 
separated, and the aqueous layer extracted with Et2O (3 x 1 mL). The combined organic 
extracts were dried (MgSO4) and the solvent removed in vacuo to give an orange oil. This 
was purified by column chromatography (100% EtOAc) to give 187 as a pale yellow oil (17.2 
mg, 63%); νmax (neat)/cm-1 3355, 2950, 2929, 2850, 1713, 1550, 1420, 1273, 1151; [𝛼]𝐷
25= +8 
(c 0.5, CHCl3); ẟH (500 MHz, CDCl3) 5.74 (1 H, s, 2-H), 5.55 (1 H, dt, J 15.0, 7.0, 10-H), 5.34 (1 
H, dd, J 15.0, 8.5, 11-H), 4.16 (1 H, m, 5-H), 4.08 (2 H, m, 1’-H2), 3.77 (1 H, ddd, J 9.0, 6.5, 2.5, 
7-H), 3.63 (2 H, t, J 6.5, 9’-H2), 3.51 (1 H, p, J 6.5, 13-H), 2.34 (1 H, m, 4-HH), 2.28 (1 H, dd, J 
13.5, 4.5, 4-HH), 2.19 (3 H, s, 3-CH3), 2.18 (1 H, m, 9-HH), 2.06 (1 H, m, 12-H), 2.04 (1 H, m, 9-
HH), 1.69 (1 H, m, 8-H), 1.66-1.53 (8 H, m, 4 x CH2), 1.58 (1 H, m, 6-HH), 1.49 (1 H, m, 6-HH), 
1.38-1.26 (8 H, m, 4 x CH2), 1.16 (3 H, d, J 6.5, 14-H3), 0.98 (3 H, d, J 6.5, 12-CH3), 0.89 (3 H, 
d, J 6.5, 8-CH3); ẟC (125 MHz, CDCl3) 166.7 (C-1), 156.2 (C-3), 134.1 (C-10), 130.6 (C-11), 118.4 
(C-2), 72.4 (C-7), 71.5 (C-13), 66.9 (C-5), 64.0 (C-1’), 63.1 (C-9’), 49.1 (C-4), 45.2 (C-12), 39.4 
(C-8), 38.9 (C-6), 36.3 (CH2), 32.9 (CH2), 29.5 (CH2), 29.3 (CH2), 29.2 (CH2), 28.7 (CH2), 26.0 
(CH2), 25.8 (CH2), 20.6 (C-14), 19.2 (3-CH3), 16.9 (12-CH3), 15.7 (8-CH3); Found (ESI): 479.3340 








(2S,3S)-Acetonide of (3R,4S,5R)-5-(hydroxymethyl)tetrahydrofuran-2,3,4-triol 205 
 
To a stirred suspension of D-ribose 198 (10.0 g, 66.6 mmol) in acetone (100 mL) was added 
conc. H2SO4 (0.2 mL) and the resulting solution stirred at RT for 2 h. After this time the 
solution was neutralised with solid NaHCO3 (ca. 20 g), filtered and the solvent removed in 
vacuo to give a viscous oil. This was purified by column chromatography (80% EtOAc in 
petrol) to give 205 as a viscous colourless oil (12.2 g, 97%); H (400 MHz, CDCl3) 5.42 (1 H, d, 
J 6.0, 1-H), 4.84 (1 H, dd, J 6.0, 1.0, 4-H), 4.58 (1 H, d, J 6.0, 2-H), 4.41 (1 H, t, J 3.0, 3-H), 3.80-
3.66 (2 H, m, 5-H2), 1.49 ( 3H, s, C(CH3)2), 1.32 (3 H, s, C(CH3)2); C (101 MHz, CDCl3) 112.3 (C-
1) , 103.2 (C(CH3)2), 88.0 (C-3), 87.0 (C-2), 81.8 (C-4), 63.8 (C-5), 26.5 (CH3), 24.9 (CH3). Data 
in accordance with the literature.216 Data reported for the major compound. 
(2S,3S)-Acetonide of (3S,4S)-tetrahydrofuran-2,3,4-triol 206 
 
 
Lactol 205 (12.7 g, 66.7 mmol) was dissolved in MeOH (75 mL) and cooled to 0 °C. NaBH4 
(3.79 g, 100.1 mmol) was added portion wise over 10 mins. The cold bath was removed and 
the reaction stirred at RT for 1 h, after which time the solvent was removed in vacuo to give 
a white foam. To this was added H2O (60 mL) and tBuOH (90 mL) and the foam dissolved by 
sonication. To this stirred solution was added NaIO4 (50.0 g, 240 mmol) portionwise over 10 
mins and the reaction mixture stirred at RT for 4 h, before dilution with DCM (100 mL) and 
neutralisation by solid NaHCO3 (ca. 40 g). This was filtered and the filtrate extracted with 
DCM (3 x 50 mL), dried (MgSO4) and the solvent removed in vacuo to give a colourless oil. 
This was purified by column chromatography (50% EtOAc in petrol) to give 206 as a 
colourless oil (10.2 g, 44%); H (400 MHz, CDCl3)  5.41 (1 H, d, J 2.0, 1-H), 4.83 (1 H, dd, J 6.0, 
3.5, 3-H), 4.57 (1 H, d, J 6.0, 2-H), 4.07 (1 H, dd, J 10.5, 3.5, 4-HH), 4.01 (1 H, d, J 10.5, 4-HH), 
1.46 (3 H, s, C(CH3)2), 1.31 (3 H, s, C(CH3)2); C (101 MHz, CDCl3) 112.4 (C(CH3)2), 102.0 (C-1), 




85.3 (C-2), 80.1 (C-3), 72.1 (C-4), 26.3 (CH3), 24.9 (CH3). Data in accordance with the 
literature.217 Data reported for the major compound. 
(2S,3S)-Acetonide of L-erythrono-1,4-lactone 207 
 
Lactol 206 (10.2 g, 63.7 mmol) was dissolved in CHCl3 (250 mL) and a solution of TEMPO (0.90 
g, 5.73 mmol), NaHCO3 (8.02 g, 95.5 mmol), K2CO3 (1.32 g, 9.56 mmol), TBACl (1.59 g, 5.73 
mmol) in H2O (150 mL) was added followed by NCS (15.3 g, 114.6 mmol). The reaction was 
stirred overnight at RT before the addition of sat.  aq. Na2S2O3 (100 mL). The layers were 
separated, and the aqueous layer extracted with EtOAc (3 x 100 mL), combined and dried 
(MgSO4) and the solvent removed in vacuo to give an orange oil. This was purified by column 
chromatography (30% EtOAc in petrol) to give 207 as a white crystalline solid (4.66 g, 74%). 
M.p. 62-64 °C (lit. 60-62 °C); [𝛼]𝐷
23 +124.0 (c 1.0, CHCl3), lit. [𝛼]𝐷
20 +118.0 (c 1.0, CHCl3); H 
(400 MHz, CDCl3) 4.88 (1H, ddd, J 5.5, 4.0, 0.5, 2-H), 4.74 (1H, d, J 5.5, 3-H), 4.47 (1H, d, J 
11.0, 4-HH), 4.40 (1H, dd, J 11.0, 4.0, 4-HH), 1.49 (3H, s, C(CH3)2), 1.40 (3H, s, C(CH3)2); C (101 
MHz, CDCl3) 174.1 (C-1), 114.2 (C(CH3)2), 75.6 (C-2), 74.8 (C-3), 70.3 (C-4), 26.9 (CH3), 25.8 
(CH3). Data in accordance with the literature.218 
(2S,3S)-Acetonide of 1-methyltetrahydrofuran-1-ol 208 
 
To a stirred solution of lactol 207 (9.32 g, 58.9 mmol) in anhydrous THF (170 mL) was added 
MeLi (40.5 mL, 64.8 mmol) dropwise at -78 °C and the reaction mixture stirred for 3 h at this 
temperature. After this time aq. NH4Cl (100 mL) was added and the mixture extracted with 
EtOAc (3 x 100 mL). The combined organic extracts were dried (MgSO4) and the solvent 
removed in vacuo to give 208 as an orange oil (9.33 g, 91%); H (400 MHz, CDCl3) 4.86 (1H, 
dd, J 6.0, 4.0, 3-H), 4.41 (1H, d, J 6.0, 2-H), 4.01 (1H, dd, J 10.5, 4.0, 4-HH), 3.92 (1H, d, J 10.5, 
4-HH), 2.09 (1H, s, OH), 1.54 (3H, s, 5-CH3), 1.48 (3H, s, C(CH3)2), 1.33 (3H, s, C(CH3)2); C (101 




MHz, CDCl3) 112.6 (C(CH3)2), 106.4 (C-1), 85.1 (C-2), 81.0 (C-3), 71.2 (C-4), 26.5 (C(CH3)2), 25.1 
(C(CH3)2), 22.6 (C-5); Found (ESI): 198.0825 [M+Na]+,(C8H14O4Na requires 198.0818). Data in 
accordance with the literature.219 
(2S,3R)-Acetonide of 4-methylpent-4-en-1-ol 209 
 
To a suspension of methyltriphenylphosphonium bromide (18.5 g, 51.7 mmol) in anhydrous 
THF (150 mL) at −78 °C was added dropwise nBuLi (2.5 M in hexanes, 20.7 mL, 51.7 mmol). 
The reaction was stirred at 0 °C for 30 mins, then cooled to −78 °C. Lactol 208 (3.00 g, 17.2 
mmol) in anhydrous THF (10 mL) was added dropwise, and the reaction was stirred for 1 h, 
then heated to reflux for 24 h. The reaction was cooled to RT and quenched with water (50 
mL) and the phases were separated. The aqueous layer was extracted with EtOAc (3 × 50 
mL), the combined organic extracts washed with brine (30 mL) and dried (MgSO4). The 
solvent was removed in vacuo to give an orange oil which was purified by column 
chromatography (20-30% EtOAc in petrol) to give 209 as a colourless oil (2.60 g, 29%); 
[𝛼]𝐷
23  −91.0 (c 1.0, CHCl3), lit. [𝛼]𝐷
20 −86.0 (c 1.0, CHCl3); H (400 MHz, CDCl3) 5.13 (1 H, m, 
5-HH), 4.96 (1 H, m, 5-HH), 4.61 (1 H, d, J 6.5, 3-H), 4.28 (1 H, ddd, J 8.0, 6.5, 4.5, 2-H), 3.55 – 
3.41 (2 H, m, 1-H2), 1.87 (1 H, s, OH), 1.74 (3 H, m, 6-H3), 1.52 (3 H, q, J 1.0, C(CH3)2), 1.40 (3 
H, q, J 1.0, C(CH3)2); C (101 MHz, CDCl3) 139.7 (C-4), 112.3 (C-5), 108.8 (C(CH3)2), 79.3 (C-3), 
77.8 (C-2), 62.3 (C-1), 27.9 (C(CH3)2), 25.6 (C(CH3)2), 20.3 (C-6). Data are consistent with 
literature.88 
(2S,3R)-Acetonide of 1-(4-methoxybenzyloxy)-4-methylpent-4-ene 199 
 
NaH (60% in mineral oil, 208 mg, 5.21 mmol) was suspended in anhydrous THF (5.5 mL) and 
DMSO (7.5 mL) under N2 at 0 °C. To this was added alcohol 209 (750 mg, 4.74 mmol) in 
anhydrous THF (2 mL). The reaction was stirred at this temperature for 1 h, then PMBCl (0.71 




mL, 5.21 mmol) and TBAI (174 mg, 0.47 mmol) were added. The reaction was allowed to 
slowly warm to RT over 16 h, after which time H2O (10 mL) was added. The reaction mixture 
was extracted with DCM (3 x 15 mL), the combined organic extracts were dried (MgSO4) and 
the solvent removed in vacuo to give a yellow oil. This was purified by column 
chromatography (20% EtOAc in petrol) to give 199 as a colourless oil (860 mg, 62%); νmax 
(neat)/cm-1 2954, 2873, 1616, 1513, 1244;  [𝛼]𝐷
23  −16.9 (c 0.65, CHCl3), lit. [𝛼]𝐷
20 −19.8 (c 
0.65, CHCl3); H (400 MHz, CDCl3) 7.24 (2 H, d, J 9.0, 9-H2), 6.86 (2 H, d, J 9.0, 10-H2), 5.07 (1 
H, m, 5-HH), 4.96 – 4.89 (1 H, m, 5-HH), 4.59 (1 H, d, J 6.5, 3-H), 4.46 (1 H, d, J 11.5, 7-HH), 
4.40 (1 H, d, J 11.5, 7-HH), 4.39 (1 H, td, J 6.5, 5.5, 2-H), 3.80 (3 H, s, OMe), 3.37 (1 H, d, 1.5, 
1-HH), 3.36 (1 H, d, 0.5, 1-HH), 1.75 – 1.69 (3 H, m, 6-H3), 1.49 (3 H, d, J 0.5, C(CH3)2), 1.38 (3 
H, d, J 0.5, C(CH3)2); ); C (101 MHz, CDCl3) 159.3 (C-11), 140.6 (C-4), 130.3 (C-8), 129.5 (C-9), 
113.9 (C-5), 112.3 (C-10), 108.6 (C(CH3)2), 79.9 (C-3), 76.8 (C-2), 73.1 (C-9), 69.5 (C-1), 55.4 





To a stirred solution of alkene 199 (616 mg, 2.11 mmol) in degassed THF (8 mL) at -78 °C was 
added 9-BBN (12.68 mL, 6.24 mmol) under N2. The reaction was stirred at RT for 16 h before 
the addition of degassed H2O (8 mL) and stirred for 1 h. In a separate flask vinyl iodide 108 
(600 mg, 1.76 mmol) was dissolved in degassed DMF (15 mL) and Cs2CO3 (2.07 g, 6.35 mmol), 
Pd(dppf)Cl2 (322 mg, 0.44 mmol) and AsPh3 (135 mg, 0.44 mmol) were added and the 
reaction mixture stirred for 10 mins. The borane solution was then added to this mixture and 
the reaction was stirred at RT for 8 h before the addition of H2O (15 mL). The reaction mixture 
was filtered through Celite and washed with H2O (5 x 15 mL). The organic extract was dried 
(MgSO4) and the solvent removed in vacuo to give a brown oil. This was purified by column 
chromatography (10% EtOAc in petrol) to give 200 as a colourless oil (449 mg, 42%);  [𝛼]𝐷
23  − 
12.0(c 1.0, CHCl3); H (400 MHz, CDCl3) 7.25 (1 H, d, J 8.5, Ar-H), 6.89 (1 H, d, J 8.5, Ar-H), 5.51 




– 5.30 (2 H, m, 7-H + 6-H), 4.49 (2 H, s, 13-H2), 4.20 (1 H, dt, J 7.0, 5.0, 2-H), 3.80 (4 H, m, 
OCH3, 3-H), 3.70 (1 H, qd, J 6.0, 4.0, 9-H), 3.51 (1 H, dd, J 10.0, 5.0, 1-HH), 3.39 (1 H, dd, J 
10.0, 7.0, 1-HH), 2.34 (1 H, m, 5-HH), 2.18 (1 H, m, 8-H), 1.91 (1 H, m, 5-HH), 1.66 (1 H, m, 4-
H), 1.40 (3H, s, C(CH3)2), 1.32 (3H, s, C(CH3)2), 1.04 (3H, d, J 6.5, 10-H3), 0.97 (3H, d, J 7.0, 11-
CH3), 0.88 (9H, s, SiC(CH3)3), 0.86 (3H, dd, J 12.5, 6.5, 12-CH3), 0.02 (6H, s, Si(CH3)3); δC (101 
MHz, CDCl3) 159.2 (Ar-C), 135.1 (C-7), 130.3 (Ar-C), 129.5 (Ar-C), 127.1 (C-6), 113.9 (Ar-C), 
107.9 (C(CH3)2), 81.4 (C-3), 76.6 (C-2), 73.2 (C-13), 72.1 (C-9), 69.2 (C-1), 55.4 (OMe), 44.4 (C-
8), 37.1 (C-5), 32.3 (C-4), 28.5 (C(CH3)2), 26.0 (C(CH3)2), 26.0 (SiC(CH3)3), 20.5 (C-10), 18.3 
(SiC(CH3)3), 16.1 (C-11), 16.0 (C-12), -4.2 (Si(CH3)2), -4.7 (Si(CH3)2); νmax (neat)/cm-1 2960, 
2929, 2856, 1632, 1513, 1369, 1247, 1090; Found (ESI): 530.3359 [M+Na]+,(C29H50O5SiNa 
requires 530.3353).  
(8R,9S)-Acetonide of (2S,3R,7R,4E)-2-(tert-butyldimethylsilyloxy)-3,7-dimethyldec-4-ene 
211 
 
PMB ether 200 (100 mg, 0.20 mmol) was dissolved in DCM (1.5 mL) and pH 7 buffer (0.1 mL) 
added. To this mixture was added DDQ (45 mg, 0.40 mmol) and the reaction stirred at RT for 
3 h before the addition of aq. NaHCO3 (5 mL). The reaction mixture was extracted with DCM 
(3 x 5 mL), the combined organic extracts were dried (MgSO4) and the solvent removed in 
vacuo to give an orange oil. This was purified by column chromatography (10% EtOAc in 
petrol) to give 211 as a colourless oil (34 mg, 44%);  [𝛼]𝐷
23  −26.0 (c 1.0, CHCl3); H (400 MHz, 
CDCl3) 5.52-5.32 (2 H, m, 7-H + 6-H), 4.13 (1 H, q, J 6.0, 9-H), 3.84 (1 H, ddd, J 10.5, 5.5, 2.0, 
3-H), 3.69 (1 H, qd, J 6.0, 4.0, 9-H), 3.64-3.58 (2 H, m, 10-H2), 2.38 (1 H, m, 5-HH), 2.14 (1 H, 
m, 8-H), 1.98-1.87 (2 H, m, 5-HH, OH), 1.70 (1 H, m, 4-H), 1.47 (3 H, s, C(CH3)2), 1.36 (3 H, s, 
C(CH3)2), 1.03 (3 H, d, J 6.0, 10-H3), 0.96 (3 H, d, J 7.0, 11-H3), 0.88 (9 H, s, SiC(CH3)3), 0.87 (3 
H, dd, J 6.5, 12-H3), 0.03 (6 H, s, Si(CH3)2); δC (101 MHz, CDCl3) 135.4 (C-7), 126.7 (C-6), 108.3 
(C(CH3)2), 81.1 (C-3), 77.9 (C-2), 72.1 (C-9), 61.7 (C-1), 44.4 (C-8), 37.1 (C-5), 32.0 (C-4), 28.7 
(C(CH3)2), 26.0 (C(CH3)2), 26.0 (SiC(CH3)3), 20.8 (C-10), 18.3 (SiC(CH3)3), 15.8 (C-11), 15.8 (C-




12), -4.2 (Si(CH3)2), -4.7 (Si(CH3)2); νmax (neat)/cm-1 3443 (br), 2955, 2929, 2856, 1461, 1370 , 
1250, 1063, 1032; Found (ESI): 410.2784 [M+Na]+,(C21H42O4SiNa requires 410.2778). 
General Procedure for Biotransformations 
Agar was prepared and the plates streaked with E.coli BL21 containing the plasmid for mupW 
and mupZ expression. This plate was incubated overnight at 37 oC. Auto-induction media 
(200 mL) was prepared and autoclaved for 3 h. A single colony was selected and added to 
the auto-induction media, to which were added carbenicillin (100 µl) and kanamycin (100 µl) 
to eliminate any bacteria which did not contain the desired plasmid. The cultures were then 
incubated for 16 h at 37 oC and shaken at 200 rpm. The culture was separated into three 
equal portions, one as a negative control (enzymes boiled at 95 oC for 10 mins and with 
substrate) and to two were added substrate. In addition, pH 7.3 buffer (2 mL) and glucose 
(50 µl) were added. The reaction mixtures were shaken at 200 rpm for 16 h at 30 oC. After 
this time an aliquot of the reaction mixture (1 mL) was centrifuged and the supernatant was 
suspended in MeCN. The mixture was vortexed and the organic layer concentrated under a 
stream of N2. The resulting product was analysed by HP-LC. 
General Procedure for Bacterial Growth 
 
LB agar was inoculated with Tetracycline (5 µg/mL) and the plate streaked with 
Pseudomonas fluorescens ΔmupA-pJH2. The plate was incubated overnight at 37 oC and a 
single colony was selected. This was added to a seed culture which had been made from 1% 
Tryptone, 0.5% yeast extract, and 0.5% NaCl. This was shaken overnight at 200 rpm and 30 
oC. Fermentation culture (2.13 L) was prepared by the addition of Tryptone (25 g), Yeast 
extract (12.5 g) and NaCl (12.5 g) in water (2.13 L). Into 24 flasks was added 85 mL of this 
mixture and autoclaved overnight. A solution of glucose was made by dissolving glucose (100 
g) in water (100 mL) and making up to 250 mL. This was autoclaved overnight. To the 
fermentation culture was added the seed culture (5 mL), glucose solution (10 mL) and IPTG 
(5 µL). This mixture was shaken at 200 rpm and 22 oC for 50 h. After this time the combined 
fermentation mixtures were centrifuged and the supernatant extract with EtOAc.  





H (700 MHz, CD3OD) 5.74 (1 H, s, 2-H), 5.58 (1 H, dt, J 15.0, 7.5, 10-H), 5.50 (1 H, dd, J 15.0, 
7.5, 11-H), 4.09 (2 H, t, J 6.5, OCH2), 3.96 (1 H, dddd, J 11.0, 8.0, 5.0, 3.0, 5-H), 3.76 (1 H, t, J 
3.5, 7-H), 3.64 (1 H, p, J 6.0, 13-H), 3.56 (2 H, t, J 6.5, OCH2), 3.54 (1 H, d, J 11.5, 16-HH), 3.41 
(1 H, d, J 11.5, 16-HH), 2.38 (2 H, m, 9-H2), 2.36 (1 H, m, 4-HH), 2.27 (1 H, dd, J 14.0, 5.0, 4-
HH), 2.20 (1 H, m, 12-H), 2.18 (3 H, s, 3-CH3), 1.72 (1 H, dt, J 14.0, 3.5, 6-HH), 1.67 (1 H, m, 6-
HH), 1.67 (2 H, m, CH2), 1.55 (2 H, m, CH2), 1.36 (10 H, m, 5 x CH2), 1.13 (3 H, d, J 6.5, 14-H3), 
1.02 (3 H, d, J 6.5, 12-CH3); C (175 MHz, CD3OD) 168.3 (C-1), 158.2 (C-3), 137.4 (C-11), 126.1 
(C-10), 118.5 (C-2), 72.1 (C-13), 71.2 (C-5), 71.1 (C-7), 70.4 (C-16), 70.0 (C-8), 64.9 (OCH2), 
63.0 (OCH2), 47.2 (C-4), 45.5 (C-12), 39.8 (C-9), 37.0 (C-6), 33.7 (CH2), 30.6 (CH2), 30.5 (CH2), 
30.3 (CH2), 29.8 (CH2), 27.1 (CH2), 26.9 (CH2), 20.3 (C-14), 19.2 (3-CH3), 16.5 (12-CH3); Found 
(ESI): 471.32 [M+H]+,(C26H47O7 requires 471.3244). 
 
H (700 MHz, CD3OD) 5.74 (1 H, s, 2-H), 5.58 (1 H, dt, J 15.0, 7.5, 10-H), 5.50 (1 H, dd, J 15.0, 
7.5, 11-H), 4.09 (2 H, t, J 6.5, OCH2), 3.96 (1 H, dddd, J 11.0, 8.0, 5.0, 3.0, 5-H), 3.75 (1 H, t, J 
3.5, 7-H), 3.63 (1 H, p, J 6.0, 13-H), 3.54 (1 H, d, J 11.5, 16-HH), 3.41 (1 H, d, J 11.5, 16-HH), 
2.38 (2 H, m, 9-H2), 2.36 (1 H, m, 4-HH), 2.27 (1 H, dd, J 14.0, 5.0, 4-HH), 2.22 (2 H, m, 
CH2CO2H), 2.19 (1 H, m, 12-H), 2.18 (3 H, s, 3-CH3), 1.71 (1 H, dt, J 14.0, 3.5, 6-HH), 1.67 (1 H, 
m, 6-HH), 1.65 (2 H, m, CH2), 1.61 (2 H, m, CH2), 1.36 (8 H, m, 4 x CH2), 1.12 (3 H, d, J 6.5, 14-
H3), 1.02 (3 H, d, J 6.5, 12-CH3); C (175 MHz, CD3OD) 180.1 (CO2H), 165.5 (C-1), 158.1 (C-3), 
137.4 (C-11), 126.1 (C-10), 118.5 (C-2), 72.1 (C-13), 71.2 (C-5), 71.1 (C-7), 70.4 (C-16), 70.1 (C-
8), 64.9 (OCH2), 47.2 (C-4), 45.0 (C-12), 39.8 (C-9), 37.5 (CH2COOH), 36.9 (C-6), 33.7 (OCH2), 




30.5 (CH2), 30.4 (CH2), 30.3 (CH2), 29.8 (CH2), 27.1 (CH2), 27.1 (CH2), 20.2 (C-14), 19.2 (3-CH3), 
16.5 (12-CH3); Found (ESI): 485.30 [M+H]+,(C26H45O8 requires 485.3036). 
 
H (700 MHz, CD3OD) 5.76 (1 H, s, 2-H), 5.45 (1 H, dt, J 15.5, 7.0, 10-H), 5.40 (1 H, dd, J 15.5, 
7.5, 11-H), 4.09 (2 H, t, J 6.5, OCH2), 4.04 (1 H, tt, J 8.5, 5.0, 5-H), 3.63 (2 H, m, 13-H + 7-H), 
2.39 (1 H, dd, J 13.5, 4.5, 4-HH), 2.26 (2 H, m, CH2CO2H), 2.24 (1 H, m, 4-HH), 2.20 (3 H, s, 3-
CH3), 2.18 (2 H, m, 12-H + 9-HH), 1.89 (1 H, dt, J 14.5, 7.5, 9-HH), 1.65 (2 H, m, CH2), 1.63 (1 
H, m, 6-HH), 1.60 (2 H, m, CH2), 1.57 (1 H, m, 8-H), 1.55 (1 H, m, 6-HH), 1.35 (8 H, m, 4 x CH2), 
1.30 (2 H, m, CH2), 1.11 (3 H, d, J 6.5, 14-H3), 1.00 (3 H, d, J 6.5, 12-CH3), 0.91 (3 H, d, J 6.5, 8-
CH3); C (175 MHz, CD3OD) 179.4 (CO2H), 168.3 (C-1), 158.5 (C-3), 135.0 (C-10), 130.5 (C-11), 
118.8 (C-2), 74.9 (C-7), 72.2 (C-13), 69.9 (C-5), 64.8 (OCH2), 49.6 (C-4), 45.3 (C-12), 40.7 (C-6), 
40.6 (C-8), 36.6 (CH2CO2H), 36.6 (C-9), 30.4 (CH2), 30.3 (CH2), 29.8 (CH2), 27.1 (CH2), 27.1 
(CH2),  26.7 (CH2), 20.2 (C-14), 19.3 (3-CH3), 16.6 (12-CH3), 15.5 (8-CH3); Found (ESI): 471.32 
[M+H]+,(C26H47O7 requires 471.3277). 
 
H (700 MHz, CD3OD) 5.75 (1 H, s, 2-H), 5.47 (1 H, dt, J 15.5, 6.5, 10-H), 5.43 (1 H, dd, J 15.5, 
7.5, 11-H), 4.09 (3 H, t, J 6.5, OCH2 + 5-H), 3.71 (1 H, ddd, J 10.0, 5.5, 2.0, 7-H), 3.63 (1 H, p, J 
6.0, 13-H), 2.32 (2 H, m, 4-H2), 2.25 (3 H, m, CH2CO2H + 9-HH), 2.21 (3 H, s, 3-CH3), 2.16 (1 H, 
td, J 7.0, 5.0, 12-H), 1.89 (1 H, dt, J 14.0, 8.0, 9-HH), 1.66 (2 H, m, CH2), 1.62 (1 H, ddd, J 14.5, 
9.5, 2.0, 6-HH), 1.60 (2 H, m, CH2), 1.57 (1 H, m, 8-H), 1.47 (1 H, ddd, J 14.0, 10.0, 2.5, 6-HH), 
1.35 (8 H, m, 4 x CH2), 1.30 (2 H, m, CH2), 1.11 (3 H, d, J 6.5, 14-H3), 1.00 (3 H, d, J 6.5, 12-
CH3), 0.91 (3 H, d, J 6.5, 8-CH3); C (175 MHz, CD3OD) 179.7 (CO2H), 168.4 (C-1), 158.7 (C-3), 
134.9 (C-10), 130.6 (C-11), 118.6 (C-2), 72.5 (C-7), 72.2 (C-13), 67.4 (C-5), 64.8 (OCH2), 50.6 




(C-4), 45.3 (C-12), 41.8 (C-6), 41.0 (C-8), 36.9 (CH2CO2H), 36.9 (C-9), 30.4 (CH2), 30.3 (CH2), 
30.2 (CH2), 29.8 (CH2), 27.1 (CH2), 26.6 (CH2), 20.2 (C-14), 19.2 (3-CH3), 16.6 (12-CH3), 15.6 (8-
CH3); Found (ESI): 471.32 [M+H]+,(C26H47O7 requires 471.3277). 
 
H (700 MHz, CD3OD) 5.73 (1 H, s, 2-H), 5.47 (1 H, m, 10-H), 5.46 (1 H, m, 11-H), 5.08 (1 H, s, 
8-HH), 4.84 (1 H, s, 8-HH), 4.31 (1 H, dd, J 9.5, 3.0, 7-H), 4.07 (2 H, t, J 6.5, OCH2), 4.05 (1 H, 
m, 5-H), 3.62 (1 H, m, 13-H), 2.81 (1 H, dd, J 16.0, 5.5, 9-HH), 2.73 (1 H, dd, J 16.0, 5.5, 9-HH), 
2.35 (1 H, m, 4-HH), 2.30 (1 H, m, 4-HH), 2.18 (3 H, s, 3-CH3), 2.16 (1 H, m, 12-H), 2.16 (2 H, t, 
J 6.5, CH2COOH), 2.06 (2 H, m, CH2), 2.02 (2 H, m, CH2), 1.61 (1 H, m, 6-HH), 1.60 (2 H, m, 
CH2), 1.56 (1 H, m, 6-HH), 1.60 (2 H, m, CH2), 1.32 (4 H, m, 2 x CH2), 1.10 (3 H, d, J 6.5, 14-
CH3), 1.01 (3 H, d, J 6.5, 12-CH3); Found (ESI): 469.31 [M+H]+,(C26H47O7 requires 469.3121). 
 
H (700 MHz, CD3OD) 5.75 (1 H, s, 2-H), 5.49 (2 H, m, 10-H + 11-H), 4.40 (1 H, dt, J 14.5, 6.0, 
5-H), 4.21 (1 H, dd, J 6.0, 3.0, 5-H), 4.07 (2 H, t, J 6.5, OCH2), 3.65 (1 H, m, 15-HH), 3.63 (1 H, 
m, 15-HH), 3.61 (1 H, m, 13-H), 2.41 (1 H, dd, J 13.5, 7.0, 4-HH), 2.35 (1 H, dd, J 13.5, 5.5, 4-
HH), 2.25 (2 H, m, 9-H2), 2.24 (2 H, m, CH2COOH), 2.19 (3 H, s, 3-CH3), 2.17 (1 H, m, 12-H), 
1.97 (1 H, ddd, J 13.0, 5.5, 3.0, 6-HH), 1.87 (1 H, m, 6-HH), 1.66 (2 H, m, CH2), 1.60 (2 H, m, 
CH2), 1.37 (2 H, m, CH2), 1.32 (6 H, m, 3 x CH2), 1.11 (3 H, d, J 6.5, 14-CH3), 1.01 (3 H, d, J 6.5, 
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CHAPTER 6: Appendix 

















































D-homoserine 93  
 




















(S)-2-(2,2-Dimethyl-5-oxo-1,3-dioxolan-4-yl)acetic acid 95 
 
 











Methyl (2S,3S)-3-hydroxy-2-methylbutanoate 74 
 
 











































































































































































 (S)-3-(tert-Butyldimethylsilyloxy)-4-methylpent-4-en-1-ol 99 
 
 


















































































(3S,4R,8R,9S,E)-3-(tert-Butyldimethylsilyloxy)-9-hydroxy-4,8-dimethyldec-6-enoic acid 124 
 
 



































9-(4-Methoxybenzyloxy)nonyl 3-methylbut-2-enoate 176 
 
 




Silyl dienol ether 171 
 
 



























para-Methoxybenzyl ether of (S)-des-6-hydroxy-desepoxy Mupirocin W4-OH 185 
 
 




para-Methoxybenzyl ether of (R)-des-6-hydroxy-desepoxy Mupirocin W4-OH 186 
 
 




(S)-Des-6-hydroxy-desepoxy mupirocin W4-OH 161 
 
 




(R)-Des-6-hydroxy-desepoxy mupirocin W4-OH 187 
 
 




(2S,3S)-Acetonide of (3R,4S,5R)-5-(hydroxymethyl)tetrahydrofuran-2,3,4-triol 205  
 
 




(2S,3S)-Acetonide of (3S,4S)-tetrahydrofuran-2,3,4-triol 206 
 
 




(2S,3S)-Acetonide of L-erythrono-1,4-lactone 207 
 
 




















(2S,3R)-Acetonide of 1-(4-methoxybenzyloxy)-4-methylpent-4-ene 199 
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